RM
301.45
.A66
1993
Dec
Suppl

CUMULATIVE SUPPLEMENT 12

JAN'93-DEC'93



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

RM301.45 .A66 1993 Dec Suppl

Approved drug products with therapeutic equivalence

C:355661 M:174736 O:12937927

SUBSCRIBE NOW!

Available in March 1994

New 14th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION
1994

Library Use Only

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Division of Blood and Blood Products List
- Discontinued Drug Product List
- USP Monograph Title Additions or Changes
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Biopharmaceutic Guidance Availability
- ANDA Suitability Petitions
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

Cumulative Supplement 12

DECEMBER 1993

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

CUMULATIVE SUPPLEMENT 12

DECEMBER 1993

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 13th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line containing overstruck print. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the " ∂ " symbol to designate their non-marketed status. All products having a " ∂ " symbol in the 12th Cumulative Supplement of the 13th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 14th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant; or when an applicant changes its name; or when an applicant name is changed to meet internal publication standards. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
AH ROBINS CO (ROBINS)	AH ROBINS CO (ROBINS AH)
ALLERGAN HERBERT SKIN CARE DIV ALLERGAN INC (ALLERGAN HERBERT)	ALLERGAN HERBERT DIV ALLERGAN INC (ALLERGAN)
ANAQUEST DIV BOC INC (ANAQUEST)	ANAQUEST INC (ANAQUEST) **then changed to** OHMEDA PHARMACEUTICAL PRODUCTS DIVISION INC (OHMEDA PHARM)
ANAQUEST INC (ANAQUEST)	OHMEDA PHARMACEUTICAL PRODUCTS DIVISION INC (OHMEDA PHARM)
ASTRA PHARMACEUTICAL PRODUCTS INC (ASTRA)	ASTRA USA INC (ASTRA)
BAKER CUMMINS PHARMACEUTICALS INC (BAKER CUMMINS)	BAKER NORTON PHARMACEUTICALS INC (BAKER NORTON)
BENEDICT NUCLEAR PHARMACEUTICALS INC (BENEDICT)	NORTH AMERICAN CHEMICAL CORPORATION (NORTH AM CHEM)
BOLAR PHARMACEUTICAL CO INC (BOLAR)	CIRCA PHARMACEUTICALS INC (CIRCA)
CIS US INC (CIS)	CIS US INC (CIS) **formerly** (CIS US)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CUTTER BIOLOGICAL DIV MILES LABORATORIES INC (CUTTER)	MILES LABORATORIES INC (MILES LABS)
DANBURY PHARMACAL INC (DANBURY)	DANBURY PHARMACAL INC (DANBURY PHARMA)
FUJISAWA PHARMACEUTICAL CO (FUJISAWA)	FUJISAWA USA INC (FUJISAWA)
GENSIA PHARMACEUTICAL INC (GENSIA)	GENSIA INC (GENSIA)
HERBERT LABORATORIES DIV SMITH KLINE AND FRENCH CO (HERBERT)	ALLERGAN HERBERT DIV ALLERGAN INC (ALLERGAN HERBERT)
ICI PHARMACEUTICALS GROUP DIV ICI AMERICAS (ICI)	ZENECA PHARMACEUTICALS GROUP DIV ZENECA INC (ZENECA) **formerly** ZENECA PHARMACEUTICALS GROUP
KABIVITRUM INC (KABIVITRUM)	KABI PHARMACIA INC (KABI)
LEMMON CO (LEMMON)	LEMMON CO SUB TEVA PHARMACEUTICALS (LEMMON)
LYPHOMED DIV FUJISAWA USA INC (LYPHOMED)	FUJISAWA USA INC (FUJISAWA)
OWEN GALDERMA LABORATORIES INC (OWEN GALDERMA)	GALDERMA LABORATORIES INC (GALDERMA)
PIONEER PHARMACEUTICALS INC (PIONEER PHARMS)	PIONEER PHARMACEUTICALS CO INC (PIONEER PHARMS)
ROXANE LABORATORIES INC (ROXANE)	ROXANE LABORATORIES INC (ROXANE) **formerly** (ROXANE LABS)
RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE DIV MCNEILAB (JOHNSON RW)	RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE DIV ORTHO PHARMACEUTICAL CORP (JOHNSON RW)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
SCHIAPPARELLI SEARLE (SCHIAPPARELLI SEARLE)	SCS PHARMACEUTICALS (SCS PHARMS)
SCHWARZ PHARMA KERMERS URBAN (SCHWARZ PHARMA)	SCHWARZ PHARMA DIV KREMERS URBAN CO (SCHWARZ PHARMA)
SOMERSET PHARMACEUTICALS INC (SOMERSET)	SOMERSET PHARMACEUTICALS INC (SOMERSET PHARMS)
STERLING DRUG INC (STERLING)	STERLING WINTHROP INC (STERLING WINTHROP)

1.4 USP MONOGRAPH TITLE ADDITIONS OR CHANGES

The U.S. Pharmacopeia (USP) periodically makes additions to or changes in monograph titles. Some of these additions or changes may affect dosage form terms listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (ADP). Instead of making the change in each affected product, the Cumulative Supplement (CS) will list applicable monograph title and dosage form additions or changes in this section. These will appear as soon as the modified USP monograph title is official. It is possible for these additions or changes to be listed in this section before all applicant holders have made labeling modifications.

The monograph title additions or changes shown below will remain in this section in each succeeding supplement of this edition. Once the next edition of the ADP is published, the products affected by the title additions or changes will be displayed with the new dosage form in the appropriate drug list. As notification to the reader, these monograph title additions or changes will also be listed in a special section of the ADP.

USP MONOGRAPH TITLE ADDITIONS OR CHANGES

FORMER USP MONOGRAPH TITLE (FORMER ADP DOSAGE FORM; ROUTE)	NEW USP MONOGRAPH TITLE (NEW ADP DOSAGE FORM; ROUTE)

THERE WERE NO USP MONOGRAPH TITLE ADDITIONS OR CHANGES DURING THE MONTH OF DECEMBER 1993.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1992) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1992	JUN 1993	SEP 1993	DEC 1993
DRUG PRODUCTS LISTED	9488	9194	9142	9140
SINGLE SOURCE	2245 (23.7%)	2119 (23.0%)	2151 (23.5%)	2144 (23.5%)
MULTISOURCE	7243 (76.3%)	7075 (77.0%)	6991 (76.5%)	6996 (76.5%)
THERAPEUTICALLY EQUIVALENT	6516 (68.6%)	6357 (69.1%)	6276 (68.7%)	6292 (68.8%)
NOT THERAPEUTICALLY EQUIVALENT	577 (6.1%)	555 (6.1%)	532 (5.8%)	527 (5.8%)
EXCEPTIONS[1]	150 (1.6%)	163 (1.8%)	183 (2.0%)	177 (1.9%)
NEW MOLECULAR ENTITIES APPROVED	--	2	9	15
NUMBER OF APPLICANTS	477	508	515	526

[1]Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

/AB/	/HALLARD/	/325MG;50MG;40MG/	/N87628/001/ /OCT/01,/1986/
AB	ROBERTS HAUCK	325MG;50MG;40MG	N87628 001 OCT 01, 1986

TABLET; ORAL

/ESGIC/

/AB/	/FOREST/PHARMS/	/325MG;50MG;40MG/	/N89660/001/ /DEC/23,/1988/
	∂ FOREST PHARMS	325MG;50MG;40MG	N89660 001 DEC 23, 1988

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

COMPAL

AA	PURDUE FREDERICK	356.4MG;30MG;16MG	N88584 001 MAR 04, 1986
/AA/	/SOLVAY/	/356.4MG;30MG;16MG/	/N88584/001/ /MAR/04,/1986/

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

∂ LEMMON	300MG;30MG	N88324 001 DEC 29, 1983

/ACETAMINOPHEN/W//CODEINE/#3/

/LEMMON/	/300MG;30MG/	/N88324/001/ /DEC/29,/1983/

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	PENNEX PHARMS	120MG/5ML;12MG/5ML	N87006 001
/AA/	/PHARM/BASICS/	/120MG/5ML;12MG/5ML/	/N87006/001/

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

/AA/	/PHARMAFAIR/	/300MG;30MG/	/N87762/001/ /DEC/10,/1982/
AA	PHARMERAL	300MG;30MG	N87762 001 DEC 10, 1982

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ALLAY

/AA/	/LUCHEM/	/500MG;5MG/	/N89907/001/ /JAN/13,/1989/
AA	NORTON HN	500MG;5MG	N89907 001 JAN 13, 1989

/BANCAP HC/

/AA/	/FOREST/PHARMS/	/500MG;5MG/	/N87961/001/ /MAR/17,/1983/
	∂ FOREST PHARMS	500MG;5MG	N87961 001 MAR 17, 1983

TABLET; ORAL

ANEXSIA

AA	BOEHRINGER MANNHEIM	500MG;5MG	N89160 001 APR 23, 1987
/AA/	/SKCP/	/500MG;5MG/	/N89160/001/ /APR/23,/1987/

ANEXSIA 7.5/650

AA	BOEHRINGER MANNHEIM	650MG;7.5MG	N89725 001 SEP 30, 1987
/AA/	/SKCP/	/650MG;7.5MG/	/N89725/001/ /SEP/30,/1987/

/DURADYNE DHC/

/AA/	/FOREST/PHARMS/	/500MG;5MG/	/N87809/001/ /MAR/17,/1983/
	∂ FOREST PHARMS	500MG;5MG	N87809 001 MAR 17, 1983

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

/AA/	/LUCHEM/	/500MG;5MG/	/N89696/001/ /APR/21,/1988/
AA	NORTON HN	500MG;5MG	N89696 001 APR 21, 1988

/NORCET/

/AA/	/ABANA/	/500MG;5MG/	/N88871/001/ /MAY/15,/1986/
	∂ ABANA	500MG;5MG	N88871 001 MAY 15, 1986

/TYCOLET/

/AA/	/JOHNSON/RW/	/500MG;5MG/	/N89385/001/ /AUG/27,/1986/
	∂ JOHNSON RW	500MG;5MG	N89385 001 AUG 27, 1986

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB	HALSEY	325MG;50MG	N72105 001	MAY 13, 1988
AB		650MG;100MG	N72106 001	MAY 13, 1988
	∂ HALSEY	325MG;50MG	N72105 001	MAY 13, 1988
	∂	650MG;100MG	N72106 001	MAY 13, 1988

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	QUAD	EQ 500MG/VIAL	N89619 001	JAN 13, 1988
	∂ QUAD	EQ 500MG/VIAL	N89619 001	JAN 13, 1988

DIAMOX

AP	LEDERLE	EQ 500MG/VIAL	N09388 001	DEC 05, 1990
	LEDERLE	EQ 500MG/VIAL	N09388 001	DEC 05, 1990

ACETYLCHOLINE CHLORIDE

POWDER FOR RECONSTITUTION; OPHTHALMIC

MIOCHOL-E

+	IOLAB	20MG/VIAL	N20213 001	SEP 22, 1993

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ZOVIRAX

+	BURROUGHS WELLCOME	EQ 1GM BASE/VIAL	N18603 002	JUN 29, 1989
	∂	EQ 250MG BASE/VIAL	N18603 003	AUG 30, 1983

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	COPLEY	EQ 0.083% BASE	N73495 001	MAY 28, 1993

SYRUP; ORAL

ALBUTEROL SULFATE

AA	WATSON LABS	EQ 2MG BASE/5ML	N73165 001	APR 29, 1993

TABLET; ORAL

ALBUTEROL SULFATE

AB	NOVOPHARM	EQ 2MG BASE	N72779 001	JUN 25, 1993
AB		EQ 4MG BASE	N72780 001	JUN 25, 1993

TABLET, EXTENDED RELEASE; ORAL

PROVENTIL

BC	SCHERING	EQ 4MG BASE	N19383 001	JUL 13, 1987

VOLMAX

BC	GLAXO	EQ 4MG BASE	N19604 002	DEC 23, 1992
+		EQ 8MG BASE	N19604 001	DEC 23, 1992
BC +	MURO	EQ 4MG BASE	N19604 002	DEC 23, 1992
+		EQ 8MG BASE	N19604 001	DEC 23, 1992

ALPRAZOLAM

CONCENTRATE; ORAL

ALPRAZOLAM

	ROXANE	1MG/ML	N74312 001	OCT 31, 1993

SOLUTION; ORAL

ALPRAZOLAM

	ROXANE	0.5MG/5ML	N74314 001	OCT 31, 1993

		SOLUTION; ORAL		
		ALPRAZOLAM		
		ROXANE	0.5MG/5ML	N74314 001 OCT 31, 1993

ALPRAZOLAM

TABLET; ORAL
ALPRAZOLAM

AB	ALPHAPHARM	0.25MG		N74046 001 OCT 19, 1993
AB		0.5MG		N74046 002 OCT 19, 1993
AB		1MG		N74046 003 OCT 19, 1993
AB	LEDERLE	0.25MG		N74174 001 OCT 19, 1993
AB		0.5MG		N74174 002 OCT 19, 1993
AB		1MG		N74174 003 OCT 19, 1993
AB		2MG		N74174 004 OCT 19, 1993
AB	PUREPAC	0.25MG		N74342 001 OCT 31, 1993
AB		0.5MG		N74342 002 OCT 31, 1993
AB		1MG		N74342 003 OCT 31, 1993
AB		2MG		N74342 004 OCT 31, 1993
AB	ROXANE	0.25MG		N74199 001 OCT 19, 1993
AB		0.5MG		N74199 002 OCT 19, 1993
AB		1MG		N74199 003 OCT 19, 1993

XANAX

AB	UPJOHN	0.25MG		N18276 001
AB		0.5MG		N18276 002
AB	+	1MG		N18276 003
AB		2MG		N18276 004 NOV 27, 1985

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HCL

/AB/	/CIRCA/	/100MG/		/N71382/001/ /JAN/21,/1987/
	∂ CIRCA	100MG		N71382 001 JAN 21, 1987

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL
AMANTADINE HCL

AA	MIKART	50MG/5ML		N74028 001 JUN 28, 1993
	/TABLET;/ORAL/			
	/SYMMETREL/			
	/+//DUPONT/	/100MG/		/N18101/001/
	∂ DUPONT	100MG		N18101 001

AMDINOCILLIN

	/INJECTABLE;/INJECTION/			
	/COACTIN/			
	/ROCHE/	/250MG/VIAL/		/N50565/001/ /DEC/21,/1984/
		/500MG/VIAL/		/N50565/002/ /DEC/21,/1984/
		/1GM/VIAL/		/N50565/003/ /DEC/21,/1984/
	∂ ROCHE	250MG/VIAL		N50565 001 DEC 21, 1984
	∂	500MG/VIAL		N50565 002 DEC 21, 1984
	∂	1GM/VIAL		N50565 003 DEC 21, 1984

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN

AP	DUPONT MERCK	EQ 50MG BASE/ML		N63350 001 JUL 30, 1993
AP		EQ 250MG BASE/ML		N63350 002 JUL 30, 1993
AP	GENSIA	EQ 50MG BASE/ML		N64045 001 SEP 28, 1993
AP		EQ 250MG BASE/ML		N64045 002 SEP 28, 1993

AMIKIN

/AP/	/BRISTOL/	/EQ 250MG BASE/ML/		/N50495/002/
AP	+ BRISTOL	EQ 250MG BASE/ML		N50495 002

AMIKACIN SULFATE

INJECTABLE; INJECTION

/AMIKIN/IN/SODIUM/CHLORIDE/0.9%/IN/PLASTIC/CONTAINER/		/N50618/002/	> DLT >
/BRISTOL/	/EQ/5MG/BASE/ML/	/NOV/30,/1987/	> DLT >
	/EQ/10MG/BASE/ML/	/N50618/001/	> DLT >
		/NOV/30,/1987/	> ADD >
∂ BRISTOL	EQ 5MG BASE/ML	N50618 002 NOV 30, 1987	> ADD >
∂	EQ 10MG BASE/ML	N50618 001 NOV 30, 1987	

AMINO ACIDS

INJECTABLE; INJECTION

NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER

BAXTER	15%	N20107 001 FEB 05, 1993
/NOVAMINE/8.5%/ /KABIVITRUM/	/8.5%/	/N17957/002/ /AUG/09,/1982/
∂ KABIVITRUM	8.5%	N17957 002 AUG 09, 1982

TRAVASOL 10% IN PLASTIC CONTAINER

BAXTER	10%	N18931 003 AUG 23, 1984
	/10%/	/N18931/004/ /APR/27,/1988/
/TRAVASOL/10%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/ /BAXTER/	/10%/	/N18931/003/ /AUG/23,/1984/

TRAVASOL 5.5% IN PLASTIC CONTAINER

BAXTER	5.5%	N18931 001 AUG 23, 1984
/TRAVASOL/5.5%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/ /BAXTER/	/5.5%/	/N18931/001/ /AUG/23,/1984/

TRAVASOL 8.5% IN PLASTIC CONTAINER

BAXTER	8.5%	N18931 002 AUG 23, 1984
/TRAVASOL/8.5%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/ /BAXTER/	/8.5%/	/N18931/002/ /AUG/23,/1984/

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

/INJECTABLE;/INJECTION/ /VEINAMINE/8%/ /KABIVITRUM/	/8%;61MG/100ML;211MG/100ML;/ /56MG/100ML;388MG/100ML/	/N17957/001/
∂ KABI	8%;61MG/100ML;211MG/100ML; 56MG/100ML;388MG/100ML	N17957 001

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

/AMINOSYN/II/7%/W/ELECTROLYTES/ /ABBOTT/	/7%;102MG/100ML;45MG/100ML;/ /522MG/100ML;410MG/100ML/	/N19437/006/ /APR/03,/1986/
∂ ABBOTT	7%;102MG/100ML;45MG/100ML; 522MG/100ML;410MG/100ML	N19437 006 APR 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

/AMINOSYN/II/3.5%/W/ /ABBOTT/	/3.5%;30MG/100ML;97MG/100ML;/ /120MG/100ML;49MG/100ML/	/N19437/007/ /APR/03,/1986/
∂ ABBOTT	3.5%;30MG/100ML;97MG/100ML; 120MG/100ML;49MG/100ML	N19437 007 APR 03, 1986

AMINOCAPROIC ACID

INJECTABLE; INJECTION

	AMICAR		
AP	+ IMMUNEX	250MG/ML	N15229 002
/AP/	/LEDERLE/	/250MG/ML/	/N15229/002/
	AMINOCAPROIC ACID		
/AP/	/LYPHOMED/	/250MG/ML/	/N70522/001/ /JUN/17,/1986/
∂ LYPHOMED		250MG/ML	N70522 001 JUN 17, 1986

SYRUP; ORAL

AMICAR		
IMMUNEX	1.25GM/5ML	N15230 002

AMINOCAPROIC ACID

SYRUP; ORAL

AMICAR		
/LEDERLE/	/1.25GM/5ML/	/N15236/002/

TABLET; ORAL

AMICAR		
+ IMMUNEX	500MG	N15197 001
/+//LEDERLE/	/500MG/	/N15197/001/

AMINOPHYLLINE

/ENEMA;/RECTAL/

/SOMOPHYLLIN/		
/FISONS/	/300MG/5ML/	/N18232/001/
		/APR/02;/1982/
∂ FISONS	300MG/5ML	N18232 001
		APR 02, 1982

INJECTABLE; INJECTION

AMINOPHYLLINE			
/AP/ /BRISTOL/	/25MG/ML/	/N87431/001/	
AP FUJISAWA	25MG/ML	N88407 001	
		JAN 25, 1984	
∂	25MG/ML	N87431 001	
/AP/ /LYPHOMED/	/25MG/ML/	/N86407/001/	
		/JAN/25;/1984/	

SOLUTION; ORAL

AMINOPHYLLINE		
∂ PENNEX PHARMS	105MG/5ML	N88156 001
		DEC 05, 1983
/AA/ /PHARM/BASICS/	/105MG/5ML/	/N88156/001/
		/DEC/05;/1983/
/SOMOPHYLLIN/		
/AA/ /FISONS/	/105MG/5ML/	/N86466/001/
∂ FISONS	105MG/5ML	N86466 001
/SOMOPHYLLIN-DF/		
/AA/ /FISONS/	/105MG/5ML/	/N87045/001/
∂ FISONS	105MG/5ML	N87045 001

TABLET; ORAL

/AMINOPHYLLIN/		
/AB//+//SEARLE/	/100MG/	/N02386/002/
/AB//+/	/200MG/	/N02386/003/
∂ SEARLE	100MG	N02386 002
∂	200MG	N02386 003

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE			
/AB/ /ROXANE/	/100MG/	/N87500/001/	
		/FEB/09;/1982/	
AB + ROXANE	100MG	N87500 001	
		FEB 09, 1982	
/AB/	/200MG/	/N87501/001/	
		/FEB/09;/1982/	
AB +	200MG	N87501 001	
		FEB 09, 1982	

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ELAVIL			
/AP/ /MSD/	/10MG/ML/	/N12704/001/	
AP ZENECA	10MG/ML	N12704 001	

TABLET; ORAL

AMITRIPTYLINE HCL			
> DLT >/AB/ /CHELSEA/	/10MG/	/N85816/001/	
> DLT >/AB/	/25MG/	/N85817/001/	
> DLT >/AB/	/50MG/	/N85815/001/	
> DLT >/AB/	/75MG/	/N85819/001/	
> DLT >/AB/	/100MG/	/N85820/001/	
> ADD > ∂ CHELSEA	10MG	N85816 001	
> ADD > ∂	25MG	N85817 001	
> ADD > ∂	50MG	N85815 001	
> ADD > ∂	75MG	N85819 001	
> ADD > ∂	100MG	N85820 001	
ELAVIL			
/AB/ /MSD/	/10MG/	/N12703/001/	
/AB//+/	/25MG/	/N12703/003/	
/AB/	/50MG/	/N12703/004/	
/AB/	/75MG/	/N12703/005/	
/AB/	/100MG/	/N12703/006/	
/AB/	/150MG/	/N12703/007/	
AB ZENECA	10MG	N12703 001	
AB +	25MG	N12703 003	
AB	50MG	N12703 004	
AB	75MG	N12703 005	
AB	100MG	N12703 006	
AB	150MG	N12703 007	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HCL

/AB/	/PAR/	/10MG;2MG/	/N70565/001/	/SEP/11,/1986/
/AB/		/10MG;4MG/	/N70620/001/	/SEP/11,/1986/
/AB/		/25MG;2MG/	/N70621/001/	/SEP/11,/1986/
/AB/		/25MG;4MG/	/N70595/001/	/SEP/11,/1986/
/AB/		/50MG;4MG/	/N70574/001/	/SEP/11,/1986/
	ə PAR	10MG;2MG	N70565 001	SEP 11, 1986
	ə	10MG;4MG	N70620 001	SEP 11, 1986
	ə	25MG;2MG	N70621 001	SEP 11, 1986
	ə	25MG;4MG	N70595 001	SEP 11, 1986
	ə	50MG;4MG	N70574 001	SEP 11, 1986

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

/AMMONIUM CHLORIDE/

/AP/	/ABBOTT/	/5MEQ/ML/	/N83130/001/
	ə ABBOTT	5MEQ/ML	N83130 001

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

/AP/	/ABBOTT/	/5MEQ/ML/	/N88366/001/
	+ ABBOTT	5MEQ/ML	N88366 001

/JUN/13,/1984/

JUN 13, 1984

AMOXICILLIN

CAPSULE; ORAL

/POLYMOX/

/AB/	/BRISTOL/	/250MG/	/N61885/001/	
/AB/		/500MG/	/N61885/002/	

/TRIMOX/

/AB/	/SQUIBB/	/250MG/	/N62096/001/	
/AB/		/250MG/	/N62152/001/	
/AB/		/500MG/	/N62096/002/	
/AB/		/500MG/	/N62152/002/	

AMOXICILLIN

CAPSULE; ORAL

TRIMOX

AB	APOTHECON	250MG	N61885 001
AB		500MG	N61885 002
	ə APOTHECON	250MG	N62098 001
	ə	250MG	N62152 001
	ə	500MG	N62098 002
	ə	500MG	N62152 002

POWDER FOR RECONSTITUTION; ORAL

AMOXICILLIN

AB	CLONMEL	125MG/5ML	N62927 001
			NOV 25, 1988
AB		250MG/5ML	N62927 002
			NOV 25, 1988
/BX/		/125MG/5ML/	/N62927/001/
			/NOV/25,/1988/
/BX/		/250MG/5ML/	/N62927/002/
			/NOV/25,/1988/

/POLYMOX/

/AB/	/BRISTOL/	/125MG/5ML/	/N61886/002/
/AB/		/50MG/ML/	/N61886/001/
/AB/		/250MG/5ML/	/N61886/003/
/AB/	/BRISTOL/MYERS/	/125MG/5ML/	/N62885/001/
			/MAR/08,/1988/
/AB/		/250MG/5ML/	/N62885/002/
			/MAR/08,/1988/

/TRIMOX/

/AB/	/SQUIBB/	/125MG/5ML/	/N62099/001/
/AB/		/125MG/5ML/	/N62154/001/
/AB/		/250MG/5ML/	/N62099/002/
/AB/		/250MG/5ML/	/N62154/002/

TRIMOX

AB	APOTHECON	125MG/5ML	N61886 002
AB		125MG/5ML	N62885 001
			MAR 08, 1988
AB		50MG/ML	N61886 001
AB		250MG/5ML	N61886 003
AB		250MG/5ML	N62885 002
			MAR 08, 1988
	ə APOTHECON	125MG/5ML	N62099 001
	ə	125MG/5ML	N62154 001
	ə	250MG/5ML	N62099 002
	ə	250MG/5ML	N62154 002

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

/CAPSULE;/ORAL/
/DELCOBESE/
/LEMMON/

	/1.25MG;1.25MG;1.25MG;/ /1.25MG/	/N83564/001/
	/2.5MG;2.5MG;2.5MG;2.5MG/	/N83564/002/
	/3.75MG;3.75MG;3.75MG;/ /3.75MG/	/N83564/003/
	/5MG;5MG;5MG;5MG/	/N83564/004/
@ LEMMON	1.25MG;1.25MG;1.25MG; 1.25MG	N83564 001
@	2.5MG;2.5MG;2.5MG;2.5MG	N83564 002
@	3.75MG;3.75MG;3.75MG; 3.75MG	N83564 003
@	5MG;5MG;5MG;5MG	N83564 004

/TABLET;/ORAL/
/DELCOBESE/
/LEMMON/

	/1.25MG;1.25MG;1.25MG;/ /1.25MG/	/N83563/004/
	/2.5MG;2.5MG;2.5MG;2.5MG/	/N83563/003/
	/3.75MG;3.75MG;3.75MG;/ /3.75MG/	/N83563/002/
	/5MG;5MG;5MG;5MG/	/N83563/001/
@ LEMMON	1.25MG;1.25MG;1.25MG; 1.25MG	N83563 004
@	2.5MG;2.5MG;2.5MG;2.5MG	N83563 003
@	3.75MG;3.75MG;3.75MG; 3.75MG	N83563 002
@	5MG;5MG;5MG;5MG	N83563 001

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

/CAPSULE;/EXTENDED/RELEASE;/ORAL/
/BIPHETAMINE/12.5/
/FISONS/

	/EQ/6.25MG/BASE;/ /EQ/6.25MG/BASE/	/N10093/007/
@ FISONS	EQ 6.25MG BASE; EQ 6.25MG BASE	N10093 007

/BIPHETAMINE/20/
/+//FISONS/

	/EQ/10MG/BASE;/ /EQ/10MG/BASE/	/N10093/003/
@ FISONS	EQ 10MG BASE; EQ 10MG BASE	N10093 003

AMPHOTERICIN B

CREAM; TOPICAL
FUNGIZONE
+ APOTHECON 3% N50314 001
/SQUIBB/ /3%/ /N50314/001/

INJECTABLE; INJECTION
FUNGIZONE
AP + APOTHECON 50MG/VIAL N60517 001
/AP/ /SQUIBB/ /50MG/VIAL/ /N60517/001/

LOTION; TOPICAL
FUNGIZONE
+ APOTHECON 3% N60570 001
/SQUIBB/ /3%/ /N60570/001/

OINTMENT; TOPICAL
FUNGIZONE
+ APOTHECON 3% N50313 001
/SQUIBB/ /3%/ /N50313/001/

AMPICILLIN SODIUM

INJECTABLE; INJECTION
AMPICILLIN SODIUM

AP	HANFORD	EQ 125MG BASE/VIAL	N63143 001 APR 15, 1993
AP		EQ 250MG BASE/VIAL	N63145 001 APR 15, 1993
AP		EQ 500MG BASE/VIAL	N63146 001 APR 15, 1993
AP		EQ 500MG BASE/VIAL	N63147 001 APR 15, 1993
AP		EQ 1GM BASE/VIAL	N62772 001 APR 15, 1993
AP		EQ 1GM BASE/VIAL	N63139 001 APR 15, 1993
AP		EQ 2GM BASE/VIAL	N63140 001 APR 15, 1993
AP		EQ 2GM BASE/VIAL	N63141 001 APR 15, 1993
AP		EQ 10GM BASE/VIAL	N63142 001 APR 15, 1993
AP	IBI	EQ 125MG BASE/VIAL	N62797 001 JUL 12, 1993
AP		EQ 2GM BASE/VIAL	N62797 002 JUL 12, 1993

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

/AP/	/LILLY/	/EQ 500MG BASE/VIAL/	/N62565/001/ /APR/04,/1985/	
/AP/		/EQ 1GM BASE/VIAL/	/N62565/002/ /APR/04,/1985/	
/AP/		/EQ 2GM BASE/VIAL/	/N62565/003/ /JUN/24,/1986/	
	ə LILLY	EQ 500MG BASE/VIAL	N62565 001 APR 04, 1985	
	ə	EQ 1GM BASE/VIAL	N62565 002 APR 04, 1985	
	ə	EQ 2GM BASE/VIAL	N62565 003 JUN 24, 1986	
	PENBRITIN-S /WYETH/AYERST/ ə WYETH AYERST /POLYCILLIN-N/	/EQ 4GM BASE/VIAL/ EQ 4GM BASE/VIAL	/N50072/006/ N50072 006	
/AP/ /AP/	/BRISTOL/	/EQ 125MG BASE/VIAL/ /EQ 125MG BASE/VIAL/	/N61395/001/ /N62860/001/ /FEB/05,/1988/	
/AP/ /AP/		/EQ 250MG BASE/VIAL/ /EQ 250MG BASE/VIAL/	/N61395/002/ /N62860/002/ /FEB/05,/1988/	
/AP/ /AP/		/EQ 500MG BASE/VIAL/ /EQ 500MG BASE/VIAL/	/N61395/003/ /N62860/003/ /FEB/05,/1988/	
/AP/ /AP/		/EQ 1GM BASE/VIAL/ /EQ 1GM BASE/VIAL/	/N61395/004/ /N62738/001/ /FEB/19,/1987/	
/AP/		/EQ 1GM BASE/VIAL/	/N62860/004/ /FEB/05,/1988/	
/AP/ /AP/		/EQ 2GM BASE/VIAL/ /EQ 2GM BASE/VIAL/	/N61395/005/ /N62738/002/ /FEB/19,/1987/	
/AP/		/EQ 2GM BASE/VIAL/	/N62860/005/ /FEB/05,/1988/	
/AP/		/EQ 10GM BASE/VIAL/	/N61395/006/	

AMPICILLIN SODIUM

INJECTABLE; INJECTION

PRINCIPEN

AP	APOTHECON	EQ 125MG BASE/VIAL	N61395 001
AP		EQ 125MG BASE/VIAL	N62860 001 FEB 05, 1988
AP		EQ 250MG BASE/VIAL	N61395 002
AP		EQ 250MG BASE/VIAL	N62860 002 FEB 05, 1988
AP		EQ 500MG BASE/VIAL	N61395 003
AP		EQ 500MG BASE/VIAL	N62860 003 FEB 05, 1988
AP		EQ 1GM BASE/VIAL	N61395 004
AP		EQ 1GM BASE/VIAL	N62738 001 FEB 19, 1987
AP		EQ 1GM BASE/VIAL	N62860 004 FEB 05, 1988
AP		EQ 2GM BASE/VIAL	N61395 005
AP		EQ 2GM BASE/VIAL	N62738 002 FEB 19, 1987
AP		EQ 2GM BASE/VIAL	N62860 005 FEB 05, 1988
AP +		EQ 10GM BASE/VIAL	N61395 006

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN

/PFIZER/	/EQ 500MG BASE/VIAL;/ /EQ 250MG BASE/VIAL/	/N50608/003/ /DEC/31,/1986/	
ə PFIZER	EQ 500MG BASE/VIAL; EQ 250MG BASE/VIAL	N50608 003 DEC 31, 1986	

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

/POLYCILLIN/

/AB//+//BRISTOL/	/EQ 250MG BASE/	/N61392/001/	
/AB/	/EQ 500MG BASE/	/N61392/002/	
/AB/ /BRISTOL/MYERS/	/EQ 250MG BASE/	/N62888/001/ /MAR/04,/1988/	
/AB//+/	/EQ 500MG BASE/	/N62888/002/ /MAR/04,/1988/	

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

PRINCIPEN

AB	+ APOTHECON	EQ 250MG BASE	N61392 001	
AB		EQ 250MG BASE	N62888 001	
			MAR 04, 1988	
AB		EQ 500MG BASE	N61392 002	
AB	+	EQ 500MG BASE	N62888 002	
			MAR 04, 1988	

/PRINCIPEN '250'/

/AB/	/SQUIBB/	/EQ 250MG BASE/	/N50056/001/	
/AB/		/EQ 250MG BASE/	/N62157/002/	
	ə APOTHECON	EQ 250MG BASE	N50056 001	
	ə	EQ 250MG BASE	N62157 002	

/PRINCIPEN '500'/

/AB/	/SQUIBB/	/EQ 500MG BASE/	/N50056/002/	
/AB/		/EQ 500MG BASE/	/N62157/001/	
	ə APOTHECON	EQ 500MG BASE	N50056 002	
	ə	EQ 500MG BASE	N62157 001	

TOTACILLIN

/AB/	/SMITHKLINE/BEECHAM/	/EQ 250MG BASE/	/N60060/001/	
/AB/		/EQ 500MG BASE/	/N60060/002/	
	ə SMITHKLINE BEECHAM	EQ 250MG BASE	N60060 001	
	ə	EQ 500MG BASE	N60060 002	

POWDER FOR RECONSTITUTION; ORAL

/POLYCILLIN/

/AB/	/BRISTOL/	/EQ 125MG BASE/5ML/	/N61394/002/	
/AB/		/EQ 250MG BASE/5ML/	/N61394/003/	
		/EQ 100MG BASE/ML/	/N61394/001/	

PRINCIPEN

AB	APOTHECON	EQ 125MG BASE/5ML	N61394 002	
AB		EQ 250MG BASE/5ML	N61394 003	
AB		EQ 100MG BASE/ML	N61394 001	

/PRINCIPEN '125'/

/AB/	/SQUIBB/	/EQ 125MG BASE/5ML/	/N60127/002/	
/AB/		/EQ 125MG BASE/5ML/	/N62151/001/	
	ə APOTHECON	EQ 125MG BASE/5ML	N60127 002	
	ə	EQ 125MG BASE/5ML	N62151 001	

/PRINCIPEN '250'/

/AB/	/SQUIBB/	/EQ 250MG BASE/5ML/	/N60127/001/	
/AB/		/EQ 250MG BASE/5ML/	/N62151/002/	
	ə APOTHECON	EQ 250MG BASE/5ML	N60127 001	
	ə	EQ 250MG BASE/5ML	N62151 002	

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

/CAPSULE;ORAL/

/PRINCIPEN/W//PROBENECID/

/+//SQUIBB/		/EQ 389MG/BASE;111MG/	/N50488/001/	
		/EQ 389MG/BASE;111MG/	/N62150/001/	
	ə APOTHECON	EQ 389MG BASE;111MG	N50488 001	
	ə	EQ 389MG BASE;111MG	N62150 001	

POWDER FOR RECONSTITUTION; ORAL

POLYCILLIN-PRB

AB	+ APOTHECON	EQ 3.5GM BASE/BOT; 1GM/BOT	N61898 001	
/AB//+//BRISTOL/		/EQ 3.5GM BASE/BOT;/ 1GM/BOT/	/N61898/001/	

ANISOTROPINE METHYLBROMIDE

/TABLET;ORAL/

/VALPIN/50/

/DUPONT/	/50MG/	/N13428/001/	
ə DUPONT	50MG	N13428 001	

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

IOPIDINE

+ ALCON	EQ 0.5% BASE	N20258 001	
		JUL 30, 1993	

> ADD > **APROTININ BOVINE**

> ADD > INJECTABLE; INJECTION

> ADD > TRASYLOL

> ADD > + MILES	10,000KIU/ML	N20304 001	
> ADD >		DEC 29, 1993	

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

/INJECTABLE;/INJECTION/
/M.V.I.-12/LYOPHILIZED/
/ASTRA/ /100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL/ /15MG/VIAL;5UGM/VIAL;0.4MG/VIAL;/ /40MG/VIAL;4MG/VIAL;3.6MG/VIAL;/ /3MG/VIAL;1MG/VIAL;/ /10MG/VIAL/ /N18933/002/ /AUG/08,/1985/

∂	ASTRA	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL 15MG/VIAL;5UGM/VIAL;0.4MG/VIAL; 40MG/VIAL;4MG/VIAL;3.6MG/VIAL; 3MG/VIAL;1MG/VIAL; 10MG/VIAL	N18933 002 AUG 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
M.V.C. 9+3

AP	FUJISAWA	10MG/ML;0.006MG/ML;0.5UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML; 0.4MG/ML;0.36MG/ML;0.3MG/ML; 330 UNITS/ML;1 IU/ML	N18440 002 AUG 08, 1985
/AP/	/LYPHOMED/	/10MG/ML;0.006MG/ML;0.5UGM/ML;/ /1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;/ /0.4MG/ML;0.36MG/ML;0.3MG/ML;/ /330 UNITS/ML;1 IU/ML/	/N18440/002/ /AUG/08,/1985/

> ADD > ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC
> ADD > ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE;
> ADD > PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE;
> ADD > VITAMIN E

> ADD > INJECTABLE; INJECTION
> ADD > KABIVITE PED F + M KIT
> ADD > KABI 80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;
> ADD > 400IU/10ML;0.14MG/VIAL;17MG/VIAL;
> ADD > 5MG/VIAL;0.2MG/10ML;1MG/VIAL;
> ADD > 1.4MG/VIAL;1.2MG/VIAL;
> ADD > EQ 2300 UNITS BASE/10ML;
> ADD > 7IU/10ML N20176 003
> ADD > DEC 29, 1993

ASPIRIN; BUTALBITAL

TABLET; ORAL
AXOTAL
/+//ADRIA/ /650MG;50MG/ /N88305/001/ /OCT/13,/1983/

+	SAVAGE	650MG;50MG	N88305 001 OCT 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL
BUTALBITAL W/ ASPIRIN & CAFFEINE
/AB/ /PHARMAFAIR/ /325MG;50MG;40MG/ /N87048/002/ /DEC/09,/1983/

AB	PHARMERAL	325MG;50MG;40MG	N87048 002 DEC 09, 1983

BUTALBITAL, ASPIRIN AND CAFFEINE
> DLT >/AB/ /CHELSEA/ /325MG;50MG;40MG/ /N86237/002/ /MAR/23,/1984/
> DLT >
> ADD > ∂ CHELSEA 325MG;50MG;40MG N86237 002 MAR 23, 1984
> ADD >

ASPIRIN; PROPOXYPHENE NAPSYLATE

/TABLET;/ORAL/
/DARVON-N/W//ASA/
/+//LILLY/ /325MG;100MG/ /N16863/001/

∂	LILLY	325MG;100MG	N16863 001

ATENOLOL

TABLET; ORAL
ATENOLOL

AB	MUTUAL PHARM	50MG	N73475 001 MAR 30, 1993
AB		100MG	N73476 001 MAR 30, 1993
AB	NOVOPHARM	50MG	N73315 001 MAY 28, 1993
AB		100MG	N73316 001 MAY 28, 1993

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB	MUTUAL PHARM	50MG;25MG	N73581 001 APR 29, 1993
AB		100MG;25MG	N73582 001 APR 29, 1993
AB	MYLAN	50MG;25MG	N74203 001 OCT 31, 1993
AB		100MG;25MG	N74203 002 OCT 31, 1993

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HCL AND ATROPINE SULFATE

/AA/	/PHARMAFAIR/	/0.025MG;2.5MG/	/N85035/001/
AA	PHARMERAL	0.025MG;2.5MG	N85035 001

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

/AZATHIOPRINE/

/AP/	/QUAD/	/EQ 100MG BASE/VIAL/	/N71056/001/ JUN/08,/1988/
	∂ QUAD	EQ 100MG BASE/VIAL	N71056 001 JUN 08, 1988

IMURAN

/AP/	/BURROUGHS/WELLCOME/	/EQ 100MG BASE/VIAL/	/N17391/001/
	BURROUGHS WELLCOME	EQ 100MG BASE/VIAL	N17391 001

AZLOCILLIN SODIUM

INJECTABLE; INJECTION

AZLIN

	/MILES/	/EQ/2GM/BASE/VIAL/	/N62388/001/ /SEP/08,/1982/
	∂ MILES	EQ 2GM BASE/VIAL	N62388 001 SEP 08, 1982
	∂	/EQ/2GM/BASE/VIAL/	/N62417/001/ /OCT/12,/1982/
		EQ 2GM BASE/VIAL	N62417 001 OCT 12, 1982
	∂	/EQ/4GM/BASE/VIAL/	/N62388/003/ /SEP/08,/1982/
		EQ 4GM BASE/VIAL	N62388 003 SEP 08, 1982
	∂	/EQ/4GM/BASE/VIAL/	/N62417/003/ /OCT/12,/1982/
		EQ 4GM BASE/VIAL	N62417 003 OCT 12, 1982

AZTREONAM

INJECTABLE; INJECTION

AZACTAM IN PLASTIC CONTAINER

	/SQUIBB/	/10MG/ML/	/N50632/003/ /MAY/24,/1989/
	∂ SQUIBB	10MG/ML	N50632 003 MAY 24, 1989

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

>DLT>	/OINTMENT;OPHTHALMIC/		
>DLT>	/MYCITRACIN/		
>DLT>	/UPJOHN/	/500/UNITS/GM;EQ/3.5MG/BASE/GM;/ /10,000/UNITS/GM/	/N61048/001/
>DLT>	∂ UPJOHN	500 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N61048 001
>ADD>			
>ADD>			

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CORTISPORIN

/AT/	/BURROUGHS/WELLCOME/	/400 UNITS/GM;1%;EQ 3.5MG BASE/GM;/ /10,000 UNITS/GM/	/N50416/002/
	+ BURROUGHS WELLCOME	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N50416 002

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

/ZINC BACITRACIN;NEOMYCIN SULFATE;POLYMYXIN B SULFATE/			
/HYDROCORTISONE/			
/AT/ /PHARMAFAIR/	/400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM/		/N62389/001/ /JUL/02,/1982/
ə PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM		N62389 001 JUL 02, 1982

OINTMENT; TOPICAL

CORTISPORIN			
/AT/ /BURROUGHS/WELLCOME/	/400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM/		/N50168/002/ /MAY/04,/1984/
+ BURROUGHS WELLCOME	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM		N50168 002 MAY 04, 1984
/NEOMYCIN B POLYMYXIN B SULFATES B BACITRACIN ZINC B/			
/HYDROCORTISONE/			
/AT/ /PHARMAFAIR/	/400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM/		/N62381/001/ /SEP/06,/1985/
ə PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM		N62381 001 SEP 06, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

/BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE/			
/AT/ /PHARMAFAIR/	/400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM/		/N62386/001/ /SEP/09,/1982/
ə PHARMAFAIR	400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM		N62386 001 SEP 09, 1982

BACITRACIN-NEOMYCIN-POLYMYXIN

/PHARMADERM/	/400/UNITS/GM;EQ/3.5MG/BASE/GM; /5,000/UNITS/GM/		/N62167/001/
ə PHARMADERM	400 UNITS/GM;EQ 3.5MG BASE/GM; 5,000 UNITS/GM		N62167 001

BACLOFEN

>DLT>	/INJECTABLE;/INJECTION/		
>DLT>	/LIORESAL/		
>DLT>	/MEDTRONIC/	/0.5MG/ML/	/N20075/001/ /JUN/17,/1992/
>DLT>		/2MG/ML/	/N20075/002/ /JUN/17,/1992/
>ADD>	INJECTABLE; INTRATHECAL		
>ADD>	LIORESAL		
>ADD>	MEDTRONIC	0.5MG/ML	N20075 001 JUN 17, 1992
>ADD>		2MG/ML	N20075 002 JUN 17, 1992

BENTIROMIDE

SOLUTION; ORAL

CHYMEX			
/ADRIA/	/500MG/7.5ML/		/N18366/001/ /DEC/29,/1983/
SAVAGE	500MG/7.5ML		N18366 001 DEC 29, 1983

BENTONITE; SULFUR

/POWDER;/TOPICAL/			
/BENSULFOID/			
/POYTHRESS/	/66.64%;33.32%/		/N02918/001/
ə POYTHRESS	66.64%;33.32%		N02918 001

BENZONATATE

CAPSULE; ORAL

	BENZONATATE		
AA	PHARMACAPS	100MG	N81297 001 JAN 29, 1993
	TESSALON		
AA	FOREST LABS	100MG	N11210 001

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DIDREX			
/UPJOHN/	/25MG/		/N12427/003/
ə UPJOHN	25MG		N12427 003

BENZTHIAZIDE

TABLET; ORAL

	AQUATAG		
BP	SOLVAY	50MG	N16001 002
	∂ SOLVAY	50MG	
	EXNA		
BP ‡	ROBINS AH	50MG	N12489 001
	+ ROBINS AH	50MG	

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

	BEPADIN		
AB	WALLACE	200MG	N19001 001 DEC 28, 1990
AB		300MG	N19001 002 DEC 28, 1990
AB		400MG	N19001 003 DEC 28, 1990
	∂ WALLACE	200MG	
	∂	300MG	
	∂	400MG	
	VASCOR		
AB	JOHNSON RW	200MG	N19002 001 DEC 28, 1990
AB		300MG	N19002 002 DEC 28, 1990
AB ‡		400MG	N19002 003 DEC 28, 1990
	+ JOHNSON RW	400MG	
		200MG	
		300MG	

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

	BETAMETHASONE DIPROPIONATE		
AB	PHARMADERM	EQ 0.05% BASE	N19136 001 JUN 26, 1984
	∂ PHARMADERM	EQ 0.05% BASE	

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

	BETAMETHASONE DIPROPIONATE		
AB	PHARMADERM	EQ 0.05% BASE	N70274 001 AUG 12, 1985
	∂ PHARMADERM	EQ 0.05% BASE	

OINTMENT; TOPICAL

	BETAMETHASONE DIPROPIONATE		
AB	PHARMADERM	EQ 0.05% BASE	N19140 001 SEP 04, 1984
	∂ PHARMADERM	EQ 0.05% BASE	

BETAMETHASONE VALERATE

CREAM; TOPICAL

	BETAMETHASONE VALERATE		
AB	PHARMADERM	EQ 0.1% BASE	N18860 002 AUG 31, 1983
	∂ PHARMADERM	EQ 0.1% BASE	

LOTION; TOPICAL

	BETAMETHASONE VALERATE		
AB	PHARMADERM	EQ 0.1% BASE	N18870 001 AUG 31, 1983
	∂ PHARMADERM	EQ 0.1% BASE	

OINTMENT; TOPICAL

	BETAMETHASONE VALERATE		
AB	NMC	EQ 0.1% BASE	N70051 001 OCT 10, 1984
	BETAMETHASONE VALERATE		
AB	PHARMADERM	EQ 0.1% BASE	N18864 001 AUG 31, 1983
	∂ PHARMADERM	EQ 0.1% BASE	
	VALNAC		
AB	NMC	EQ 0.1% BASE	N70051 001 OCT 10, 1984

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ZIAC
+ LEDERLE — 10MG;6.25MG — N20186 002 MAR 26, 1993
2.5MG;6.25MG — N20186 003 MAR 26, 1993
5MG;6.25MG — N20186 001 MAR 26, 1993

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE
/AP/ /ASTRA/ — /50MG/ML/ — /N71152/001/ /AUG/10,/1987/
@ ASTRA — 50MG/ML — N71152 001 AUG 10, 1987

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL
MYBAHCIL
AA PENNEX PHARMS — 12.5MG/5ML;10MG/5ML — N88626 001 OCT 12, 1984
/AA/ /PHARM/BASICS/ — /12.5MG/5ML;10MG/5ML/ — /N88626/001/ /OCT/12,/1984/

BROMPHENIRAMINE MALEATE

TABLET; ORAL
BROMPHENIRAMINE MALEATE
/AA/ /ANABOLIC/ — /4MG/ — /N86187/001/
@ ANABOLIC — 4MG — N86187 001
/AA/ /NEWTRON/ — /4MG/ — /N86987/001/
@ NEWTRON — 4MG — N86987 001
AA NYLOS TRADING — 4MG — N85592 001
/AA/ /TABLICAPS/ — /4MG/ — /N85592/001/
/AA/ /ZENITH/ — /4MG/ — /N84351/001/
@ ZENITH — 4MG — N84351 001

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL
MYPHETANE DC
AA PENNEX PHARMS — 2MG/5ML;10MG/5ML; 12.5MG/5ML — N88904 001 FEB 21, 1985
/AA/ /PHARM/BASICS/ — /2MG/5ML;10MG/5ML; /12.5MG/5ML/ — /N88904/001/ /FEB/21,/1985/

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL
MYPHETANE DX
AA PENNEX PHARMS — 2MG/5ML;10MG/5ML; 30MG/5ML — N88811 001 JUN 07, 1985
/AA/ /PHARM/BASICS/ — /2MG/5ML;10MG/5ML; /30MG/5ML/ — /N88811/001/ /JUN/07,/1985/

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL
BIPHETAP
@ PENNEX PHARMS — 4MG/5ML;25MG/5ML — N88687 001 SEP 26, 1984
/@/PHARM/BASICS/ — /4MG/5ML;25MG/5ML/ — /N88687/001/ /SEP/26,/1984/

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
BUSPAR
>DLT> /#//BRISTOL/ — /10MG/ — /N18731/002/ /SEP/29,/1986/
>DLT> /5MG/ — /N18731/001/ /SEP/29,/1986/
>ADD> + BRISTOL MYERS SQUIBB 10MG — N18731 002 SEP 29, 1986
>ADD> 5MG — N18731 001 SEP 29, 1986

BUTABARBITAL SODIUM

ELIXIR; ORAL
BUTABARBITAL SODIUM
∂ PENNEX PHARMS 30MG/5ML N85383 001
/AA/ /PHARM/BASICS/ /30MG/5ML/ /N85383/001/

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
STADOL
+ APOTHECON 1MG/ML N17857 001
+ 2MG/ML N17857 002
/BRISTOL/ /1MG/ML/ /N17857/001/
/2MG/ML/ /N17857/002/

CALCIFEDIOL, ANHYDROUS

CAPSULE; ORAL
CALDEROL
+ ORGANON 0.05MG N18312 002
0.02MG N18312 001
/#/UPJOHN/ /0.05MG/ /N18312/002/
/0.02MG/ /N18312/001/

> ADD > CALCIPOTRIENE

> ADD > OINTMENT; TOPICAL
> ADD > DOVONEX
> ADD > + BRISTOL MYERS SQUIBB 0.005% N20273 001
> ADD > DEC 29, 1993

CALCITONIN, SALMON

INJECTABLE; INJECTION
CALCIMAR
/AP/ /RHONE/POULENC/RORER/ /200 IU/ML/ /N17769/001/
AP + RHONE POULENC RORER 200 IU/ML N17769 001
MIACALCIN
/SANDOZ/ /100/IU/ML/ /N17808/001/
/JUL/03/1986/
∂ SANDOZ 100 IU/ML N17808 001
JUL 03, 1986

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION
ENDOSOL EXTRA
AT ALLERGAN 0.154MG/ML;0.92MG/ML;0.184MG/ML;
0.2MG/ML;0.38MG/ML;2.1MG/ML;
7.14MG/ML;0.42MG/ML N20079 001
NOV 27, 1991

ENDOSOL PLUS
/AT/ /ALLERGAN/ /0.154MG/ML;0.92MG/ML;0.184MG/ML;/
/0.2MG/ML;0.38MG/ML;2.1MG/ML;/
/7.14MG/ML;0.42MG/ML/ /N20079/001/
/NOV/27/1991/

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER
MCGAW 37MG/100ML;5GM/100ML;31MG/100ML;
120MG/100ML;330MG/100ML;
88MG/100ML N19864 001
JUN 10, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION
> ADD > ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
> ADD > MCGAW 35MG/100ML;5GM/100ML;30MG/100ML;
> ADD > 74MG/100ML;640MG/100ML;500MG/100ML;
> ADD > 74MG/100ML N19867 001
> ADD > DEC 20, 1993

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION
CALCIUM GLUCEPTATE
/AP/ /ABBOTT/ /EQ 90MG CALCIUM/5ML/ /N80001/001/
+ ABBOTT EQ 90MG CALCIUM/5ML N80001 001
/AP/ /LILLY/ /EQ 90MG CALCIUM/5ML/ /N06470/001/
∂ LILLY EQ 90MG CALCIUM/5ML N06470 001
/AP/ /LYPHOMED/ /EQ 90MG CALCIUM/5ML/ /N89573/001/
/APR/30/1987/
∂ LYPHOMED EQ 90MG CALCIUM/5ML N89573 001
APR 30, 1987

CARBACHOL

INJECTABLE; INJECTION

	CARBACHOL			
AP	PHARMAFAIR	0.01%	N70292 001	MAY 21, 1986

MIOSTAT

AP	ALCON	0.01%	N16968 001	

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN

AP	ROERIG	EQ 1GM BASE/VIAL	N50306 001	
AP		EQ 2GM BASE/VIAL	N50306 004	
AP		EQ 5GM BASE/VIAL	N50306 002	
AP		EQ 10GM BASE/VIAL	N50306 006	

PYOPEN

AP	SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N50298 001	
AP		EQ 2GM BASE/VIAL	N50298 002	
AP		EQ 5GM BASE/VIAL	N50298 003	
AP		EQ 10GM BASE/VIAL	N50298 006	
AP		EQ 20GM BASE/VIAL	N50298 007	

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

AB	PUREPAC	10MG;100MG	N74260 001	SEP 03, 1993
AB		25MG;100MG	N74260 002	SEP 03, 1993
AB		25MG;250MG	N74260 003	SEP 03, 1993

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

AB	WATSON LABS	10MG;100MG	N73381 001	SEP 28, 1993
AB		25MG;100MG	N73382 001	SEP 28, 1993
AB		25MG;250MG	N73383 001	SEP 28, 1993

CARBINOXAMINE MALEATE

TABLET; ORAL

CLISTIN

	JOHNSON RW	4MG	N08915 001	

CARISOPRODOL

CAPSULE; ORAL

SOMA

	WALLACE	250MG	N11792 003	

TABLET; ORAL

CARISOPRODOL

AA	PIONEER PHARMS	350MG	N89390 001	OCT 13, 1988

BELA

AA	SCHERING	350MG	N12155 001	

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OPTIPRESS

	BURROUGHS WELLCOME	1%	N19972 001	MAY 23, 1990
	OTSUKA	1%		

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
DURICEF
AB + BRISTOL MYERS SQUIBB EQ 500MG BASE N50512 001
/AB/+/MEAD JOHNSON/ /EQ 500MG BASE/ /N50512/001/

POWDER FOR RECONSTITUTION; ORAL
DURICEF
AB + BRISTOL MYERS SQUIBB EQ 125MG BASE/5ML N50527 002
AB + EQ 250MG BASE/5ML N50527 003
AB + EQ 500MG BASE/5ML N50527 001
/AB/+/MEAD JOHNSON/ /EQ 125MG BASE/5ML/ /N50527/002/
/AB/+/ /EQ 250MG BASE/5ML/ /N50527/003/
/AB/+/ /EQ 500MG BASE/5ML/ /N50527/001/

TABLET; ORAL
DURICEF
AB + BRISTOL MYERS SQUIBB EQ 1GM BASE N50528 001
/AB/+/MEAD JOHNSON/ /EQ 1GM BASE/ /N50528/001/

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION
MANDOL
+ LILLY EQ 10GM BASE/VIAL N50504 004

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM
/AP/ /BEN/VENUE/ /EQ 250MG BASE/VIAL/ /N62894/001/ /JUL/21,/1988/
/AP/ /EQ 500MG BASE/VIAL/ /N62894/002/ /JUL/21,/1988/
/AP/ /EQ 1GM BASE/VIAL/ /N62894/003/ /JUL/21,/1988/
/AP/ /EQ 5GM BASE/VIAL/ /N62894/004/ /JUL/21,/1988/
/AP/ /EQ 10GM BASE/VIAL/ /N62894/005/ /JUL/21,/1988/
∂ BEN VENUE EQ 250MG BASE/VIAL N62894 001 JUL 21, 1988
∂ EQ 500MG BASE/VIAL N62894 002 JUL 21, 1988
∂ EQ 1GM BASE/VIAL N62894 003 JUL 21, 1988
∂ EQ 5GM BASE/VIAL N62894 004 JUL 21, 1988
∂ EQ 10GM BASE/VIAL N62894 005 JUL 21, 1988
AP SMITHKLINE BEECHAM EQ 1GM BASE/VIAL N64033 001 OCT 31, 1993

CEFMENOXIME HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/CEFMAX/
/TAP/ /EQ/500MG/BASE/VIAL/ /N50571/001/ /DEC/30,/1987/
/EQ/1GM/BASE/VIAL/ /N50571/002/ /DEC/30,/1987/
/EQ/2GM/BASE/VIAL/ /N50571/003/ /DEC/30,/1987/
∂ TAP EQ 500MG BASE/VIAL N50571 001 DEC 30, 1987
∂ EQ 1GM BASE/VIAL N50571 002 DEC 30, 1987
∂ EQ 2GM BASE/VIAL N50571 003 DEC 30, 1987

CEFONICID SODIUM

INJECTABLE; INJECTION
MONOCID
SMITHKLINE BEECHAM — EQ 1GM BASE/VIAL — N63295 001 JUL 26, 1993
/EQ/2GM/BASE/VIAL/ — /N50579/003/ /MAY/23,/1984/
∂ — EQ 2GM BASE/VIAL — N50579 003 MAY 23, 1984

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CLAFORAN
HOECHST ROUSSEL — EQ 500MG BASE/VIAL — N50547 001

CEFOTETAN DISODIUM

INJECTABLE; INJECTION
CEFOTAN
/AP/ /STUART/ — /EQ 1GM BASE/VIAL/ — /N50588/001/ /DEC/27,/1985/
/AP/ — /EQ 2GM BASE/VIAL/ — /N50588/002/ /DEC/27,/1985/
/AP/ /ZENECA/ — /EQ 1GM BASE/VIAL/ — /N63293/001/ /APR/29,/1993/
/AP/ — /EQ 2GM BASE/VIAL/ — /N63293/002/ /APR/29,/1993/
+ ZENECA — EQ 1GM BASE/VIAL — N50588 001 DEC 27, 1985
+ — EQ 2GM BASE/VIAL — N50588 002 DEC 27, 1985
— EQ 1GM BASE/VIAL — N63293 001 APR 29, 1993
— EQ 2GM BASE/VIAL — N63293 002 APR 29, 1993

CEFOTAN IN PLASTIC CONTAINER
+ ZENECA — EQ 20MG BASE/ML — N50694 002 JUL 30, 1993
+ — EQ 40MG BASE/ML — N50694 001 JUL 30, 1993

CEFOTIAM HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/CEFADON/
/TAKEDA/ — /EQ/1GM/BASE/VIAL/ — /N50601/001/ /DEC/30,/1988/

CEFOTIAM HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/CEFADON/
∂ TAKEDA — EQ 1GM BASE/VIAL — N50601 001 DEC 30, 1988

CEFOXITIN SODIUM

INJECTABLE; INJECTION
MEFOXIN IN PLASTIC CONTAINER
MERCK — EQ 20MG BASE/ML — N63182 001 JAN 25, 1993
— EQ 40MG BASE/ML — N63182 002 JAN 25, 1993

CEFPIRAMIDE SODIUM

/INJECTABLE;/INJECTION/
/CEFPIRAMIDE/SODIUM/
/WYETH/AYERST/ — /EQ/1GM/BASE/VIAL/ — /N50633/002/ /JAN/31,/1989/
— /EQ/2GM/BASE/VIAL/ — /N50633/003/ /JAN/31,/1989/
— /EQ/10GM/BASE/VIAL/ — /N50633/005/ /JAN/31,/1989/
∂ WYETH AYERST — EQ 1GM BASE/VIAL — N50633 002 JAN 31, 1989
∂ — EQ 2GM BASE/VIAL — N50633 003 JAN 31, 1989
∂ — EQ 10GM BASE/VIAL — N50633 005 JAN 31, 1989

CEFTAZIDIME

INJECTABLE; INJECTION
TAZICEF
AP SMITHKLINE BEECHAM — 1GM/VIAL — N64032 001 OCT 31, 1993
AP — 2GM/VIAL — N64032 002 OCT 31, 1993

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

AP	BAXTER	EQ 10MG BASE/ML	N63221 001 APR 29, 1993
AP		EQ 20MG BASE/ML	N63221 002 APR 29, 1993
AP		EQ 40MG BASE/ML	N63221 003 APR 29, 1993

FORTAZ IN PLASTIC CONTAINER

AP	GLAXO	EQ 10MG BASE/ML	N50634 001 APR 28, 1989
AP		EQ 20MG BASE/ML	N50634 002 APR 28, 1989
AP		EQ 40MG BASE/ML	N50634 003 APR 28, 1989

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

	FUJISAWA	EQ 500MG BASE/VIAL	N50560 001 SEP 15, 1983
		EQ 10GM BASE/VIAL	N50560 005 MAR 19, 1993

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

ROCEPHIN

	ROCHE	EQ 250MG BASE/VIAL	N63239 001 AUG 13, 1993
		EQ 500MG BASE/VIAL	N63239 002 AUG 13, 1993
		EQ 1GM BASE/VIAL	N63239 003 AUG 13, 1993

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

/A/	/ROCHE/	/EQ 10MG BASE/ML/	/N50624 001/ /FEB 11, 1987/
∂	ROCHE	EQ 10MG BASE/ML	N50624 001 FEB 11, 1987

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME

AP	MARSAM	EQ 750MG BASE/VIAL	N64035 001 FEB 26, 1993
AP		EQ 1.5GM BASE/VIAL	N64035 002 FEB 26, 1993
AP		EQ 7.5GM BASE/VIAL	N64036 001 FEB 26, 1993

KEFUROX

AP	LILLY	EQ 7.5GM BASE/VIAL	N62591 003 DEC 17, 1987

ZINACEF

AP	GLAXO	EQ 7.5GM BASE/VIAL	N50558 004 OCT 23, 1986

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

CALCIBIND

/A/	/MISSION PHARMA/	/2.5GM/PACKET/	/N18757 002/ /DEC 28, 1982/
∂	MISSION PHARMA	2.5GM/PACKET	N18757 002 DEC 28, 1982

CEPHALEXIN

CAPSULE; ORAL

CEFAHEX

AB	APOTHECON	EQ 250MG BASE	N63063 001 SEP 29, 1989
AB		EQ 500MG BASE	N63063 002 SEP 29, 1989
/AB/	/BRISTOL MYERS/	/EQ 250MG BASE/	/N63063 001/ /SEP 29, 1989/
/AB/		/EQ 500MG BASE/	/N63063 002/ /SEP 29, 1989/

CEPHALEXIN

AB	APOTHECON	EQ 250MG BASE	N62973 001 NOV 08, 1988
AB		EQ 500MG BASE	N62974 001 NOV 23, 1988
/AB/	/SQUIBB MARK/	/EQ 250MG BASE/	/N62973 001/ /NOV 08, 1988/
/AB/		/EQ 500MG BASE/	/N62974 001/ /NOV 23, 1988/

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION
CEPHALOTHIN SODIUM

/AP/	/ABBOTT/	/EQ 1GM BASE/VIAL/	/N62548/001/ /SEP/11,/1985/
/AP/		/EQ 2GM BASE/VIAL/	/N62548/002/ /SEP/11,/1985/
	@ ABBOTT	EQ 1GM BASE/VIAL	N62548 001 SEP 11, 1985
	@	EQ 2GM BASE/VIAL	N62548 002 SEP 11, 1985

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION
CEFADYL

	@ APOTHECON	EQ 500MG BASE/VIAL	N50446 005
		EQ 500MG BASE/VIAL	N62961 001 SEP 20, 1988
	@	EQ 1GM BASE/VIAL	N50446 001
		EQ 1GM BASE/VIAL	N61769 001
		EQ 1GM BASE/VIAL	N62724 001 DEC 23, 1986
		EQ 1GM BASE/VIAL	N62961 002 SEP 20, 1988
	@	EQ 2GM BASE/VIAL	N50446 002
		EQ 2GM BASE/VIAL	N61769 002
		EQ 2GM BASE/VIAL	N62724 002 DEC 23, 1986
		EQ 2GM BASE/VIAL	N62961 003 SEP 20, 1988
	@	EQ 4GM BASE/VIAL	N50446 003
		EQ 4GM BASE/VIAL	N61769 003
		EQ 4GM BASE/VIAL	N62961 004 SEP 20, 1988
	@	EQ 20GM BASE/VIAL	N50446 004
/AP/	/BRISTOL/	/EQ 500MG BASE/VIAL/	/N50446/005/
/AP/		/EQ 1GM BASE/VIAL/	/N50446/001/
/AP/		/EQ 1GM BASE/VIAL/	/N61769/001/
/AP/		/EQ 1GM BASE/VIAL/	/N62724/001/ /DEC/23,/1986/
/AP/		/EQ 2GM BASE/VIAL/	/N50446/002/
/AP/		/EQ 2GM BASE/VIAL/	/N61769/002/
/AP/		/EQ 2GM BASE/VIAL/	/N62724/002/ /DEC/23,/1986/
/AP/		/EQ 4GM BASE/VIAL/	/N50446/003/
/AP/		/EQ 4GM BASE/VIAL/	/N61769/003/
		/EQ/20GM/BASE/VIAL/	/N50446/004/

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION
CEFADYL

/AP/	/BRISTOL/MYERS/	/EQ 500MG BASE/VIAL/	/N62961/001/ /SEP/20,/1988/
/AP/		/EQ 1GM BASE/VIAL/	/N62961/002/ /SEP/20,/1988/
/AP/		/EQ 2GM BASE/VIAL/	/N62961/003/ /SEP/20,/1988/
/AP/		/EQ 4GM BASE/VIAL/	/N62961/004/ /SEP/20,/1988/

/CEPHAPIRIN SODIUM/

/AP/	/LYPHOMED/	/EQ 500MG BASE/VIAL/	/N62723/001/ /NOV/17,/1986/
/AP/		/EQ 1GM BASE/VIAL/	/N62723/002/ /NOV/17,/1986/
/AP/		/EQ 2GM BASE/VIAL/	/N62723/003/ /NOV/17,/1986/
/AP/		/EQ 4GM BASE/VIAL/	/N62723/004/ /NOV/17,/1986/
	@ LYPHOMED	EQ 500MG BASE/VIAL	N62723 001 NOV 17, 1986
	@	EQ 1GM BASE/VIAL	N62723 002 NOV 17, 1986
	@	EQ 2GM BASE/VIAL	N62723 003 NOV 17, 1986
	@	EQ 4GM BASE/VIAL	N62723 004 NOV 17, 1986

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION
MYCHEL-S

	@ ANGUS	EQ 1GM BASE/VIAL	N60132 001
/@/	/RACHELLE/	/EQ/1GM/BASE/VIAL/	/N60132/001/

CHLORDIAZEPOXIDE

/CAPSULE;/EXTENDED/RELEASE;/ORAL/
/LIBRELEASE/

/+//ROCHE/		/30MG/	/N17813/001/ /SEP/12,/1983/
	@ ROCHE	30MG	N17813 001 SEP 12, 1983

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL

/AB/	/PIONEER/PHARMS/	/25MG/	/N89558/001/	
			/JUL/15,/1988/	
	∂ PIONEER PHARMS	25MG	N89558 001	
			JUL 15, 1988	

LIBRIUM

/AB/	/ROCHE/	/5MG/	/N12249/002/	
/AB/		/10MG/	/N12249/001/	
/AB/		/25MG/	/N12249/003/	
/AB/		/25MG/	/N85475/001/	
AB	+ ROCHE	25MG	N85475 001	
	∂	5MG	N12249 002	
	∂	10MG	N12249 001	
	∂	25MG	N12249 003	

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

/AB/	/MSD/	/150MG;250MG/	/N16016/001/	
	MSD	150MG;250MG	N16016 001	

ALDOCLOR-250

/AB/	/MSD/	/250MG;250MG/	/N16016/002/	
	+ MSD	250MG;250MG	N16016 002	

/METHYLDOPA AND CHLOROTHIAZIDE/

/AB/	/PAR/	/150MG;250MG/	/N70783/001/	
			/NOV/06,/1987/	
/AB/		/250MG;250MG/	/N70654/001/	
			/NOV/06,/1987/	
	∂ PAR	150MG;250MG	N70783 001	
			NOV 06, 1987	
	∂	250MG;250MG	N70654 001	
			NOV 06, 1987	

CHLOROTRIANISENE

CAPSULE; ORAL

TACE

/MERRELL/DOW/	/72MG/	/N16235/001/	
∂ MERRELL DOW	72MG	N16235 001	

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION

CHLOR-TRIMETON

/AP/	/SCHERING/	/10MG/ML/	/N088826/001/	
/⌀/		/100MG/ML/	/N088794/001/	

> ADD >	AP + SCHERING PLOUGH	10MG/ML	N08826 001	
> ADD >	∂	100MG/ML	N08794 001	

CHLORPHENIRAMINE MALEATE

/AP/	/BEL/MAR/	/10MG/ML/	/N080821/001/	
	∂ BEL MAR	10MG/ML	N80821 001	
/AP/	/STERIS/	/100MG/ML/	/N086095/001/	
	STERIS	100MG/ML	N86095 001	

/PYRIDAMAL 100/

/AP/	/BEL/MAR/	/100MG/ML/	/N083733/001/	
	∂ BEL MAR	100MG/ML	N83733 001	

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

/AA/	/NEWTRON/	/4MG/	/N086519/001/	
	∂ NEWTRON	4MG	N86519 001	
	/⌀/PHARMAFAIR/	/4MG/	/N083753/001/	
	∂ PHARMERAL	4MG	N83753 001	

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HCL

	∂ PENNEX PHARMS	30MG/ML	N87032 001	
			JUL 08, 1982	
	∂	100MG/ML	N87053 001	
/AA/	/PHARM/BASICS/	/30MG/ML/	/N87032/001/	
			/JUL/08,/1982/	
/AA/		/100MG/ML/	/N87053/001/	

INJECTABLE; INJECTION

CHLORPROMAZINE HCL

/AP/	/LYPHOMED/	/25MG/ML/	/N84911/001/	
	∂ LYPHOMED	25MG/ML	N84911 001	

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

> DLT > /AB/	/CHELSEA/	/100MG/	/N086865/001/	
> DLT >			/SEP/24,/1984/	
> ADD >	∂ CHELSEA	100MG	N86865 001	
> ADD >			SEP 24, 1984	

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

/AB/	/ABBOTT/	/50MG/	/N87384/001/		
	∂ ABBOTT	50MG	N87384 001		
>DLT >/AB/	/CHELSEA/	/50MG/	/N87082/001/		
>ADD >	∂ CHELSEA	50MG	N87082 001		
/AB/	/PHARM/BASICS/	/50MG/	/N89052/001/ /JUN/01,/1987/		
	∂ PHARM BASICS	50MG	N89052 001 JUN 01, 1987		

CHLORTHALIDONE; METOPROLOL TARTRATE

/CAPSULE;/ORAL/
/LOPRESSIDONE/

/+/	/CIBA/	/25MG;200MG/	/N19451/002/ /DEC/31,/1987/		
		/25MG;100MG/	/N19451/001/ /DEC/31,/1987/		
	∂ CIBA	25MG;100MG	N19451 001 DEC 31, 1987		
	∂	25MG;200MG	N19451 002 DEC 31, 1987	>ADD > >ADD >	

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

>ADD > AA	OHM	250MG	N81298 001 DEC 29, 1993		
>ADD > AA >ADD >		500MG	N81299 001 DEC 29, 1993		
/AA/	/PIONEER/PHARMS/	/250MG/	/N89592/001/ /JAN/06,/1989/		
/AA/		/500MG/	/N89948/001/ /JAN/06,/1989/		
	∂ PIONEER PHARMS	250MG	N89592 001 JAN 06, 1989		
	∂	500MG	N89948 001 JAN 06, 1989	>ADD > >ADD > >ADD > >ADD > >ADD >	

CHYMOPAPAIN

INJECTABLE; INJECTION
CHYMODIACTIN

/BOOTS/	/10,000/UNITS/VIAL/	/N18663/001/ /NOV/10,/1982/	
∂ BOOTS	10,000 UNITS/VIAL	N18663 001 NOV 10, 1982	

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC
CATARASE

+ IOLAB	300 UNITS/VIAL /150/UNITS/VIAL/	N16938 001 /N18121/001/
∂	150 UNITS/VIAL /300/UNITS/VIAL/	N18121 001 /N16938/001/

CISAPRIDE MONOHYDRATE

TABLET; ORAL
PROPULSID

>ADD > >ADD >	+ JANSSEN	EQ 20MG BASE	N20210 002 DEC 23, 1993	
		EQ 10MG BASE	N20210 001 JUL 29, 1993	
>DLT > >DLT >	/∂/	/EQ/20MG/BASE/	/N20210/002/ /JUL/29,/1993/	

CLADRIBINE

INJECTABLE; INJECTION
LEUSTATIN

+ JOHNSON RW	1MG/ML	N20229 001 FEB 26, 1993	

CLARITHROMYCIN

GRANULE, FOR RECONSTITUTION; ORAL
BIAXIN

>ADD > >ADD > >ADD > >ADD > >ADD > >ADD >	+ ABBOTT	250MG/5ML	N50698 002 DEC 23, 1993
		125MG/5ML	N50698 001 DEC 23, 1993

CLARITHROMYCIN

TABLET; ORAL
BIAXIN

>ADD>	ABBOTT	250MG	N50697 001	
>ADD>			DEC 23, 1993	
>ADD>		500MG	N50697 002	
>ADD>			DEC 23, 1993	

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA	BARRE	EQ 0.5MG BASE/5ML	N74075 001	
			OCT 31, 1993	

TABLET; ORAL
CLEMASTINE FUMARATE

AB	GENEVA	2.68MG	N73459 001	
			OCT 31, 1993	

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLEOCIN

AB	+ UPJOHN	EQ 75MG BASE	N50162 001	
/AB///	/EQ 75MG BASE/	/N61809/001/		
AB	+	EQ 150MG BASE	N50162 002	
/AB///	/EQ 150MG BASE/	/N61809/002/		
	∂	EQ 75MG BASE	N61809 001	
	∂	EQ 150MG BASE	N61809 002	

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLEOCIN PHOSPHATE

AP	+ UPJOHN	EQ 150MG BASE/ML	N50441 001	
	CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER			
	+ UPJOHN	EQ 18MG BASE/ML	N50639 003	
			APR 10, 1991	

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

/AP/	/LYPHOMED/	/EQ 12MG BASE/ML/	/N50636/001/	
			/DEC/22,/1989/	
	∂ LYPHOMED	EQ 12MG BASE/ML	N50636 001	
			DEC 22, 1989	

CLOFIBRATE

CAPSULE; ORAL
CLOFIBRATE

>DLT>/AB/	/CHELSEA/	/500MG/	/N71603/001/	
>DLT>			/SEP/18,/1987/	
>ADD>	∂ CHELSEA	500MG	N71603 001	
>ADD>			SEP 18, 1987	

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL

/AB/	/BIOCRAFT/	/0.1MG/	/N70747/001/	
			/MAR/26,/1986/	
/AB/		/0.2MG/	/N70702/001/	
			/MAR/26,/1986/	
/AB/		/0.3MG/	/N70659/001/	
			/MAR/26,/1986/	
	∂ BIOCRAFT	0.1MG	N70747 001	
			JUL 08, 1986	
	∂	0.2MG	N70702 001	
			JUL 08, 1986	
	∂	0.3MG	N70659 001	
			JUL 08, 1986	
/AB/	/PAR/	/0.1MG/	/N70461/001/	
			/NOV/22,/1985/	
/AB/		/0.2MG/	/N70460/001/	
			/NOV/22,/1985/	
/AB/		/0.3MG/	/N70459/001/	
			/NOV/22,/1985/	
	∂ PAR	0.1MG	N70461 001	
			JUL 08, 1986	
	∂	0.2MG	N70460 001	
			JUL 08, 1986	
	∂	0.3MG	N70459 001	
			JUL 08, 1986	

CLOTRIMAZOLE

CREAM; TOPICAL
CLOTRIMAZOLE

AB	TARO	1%	N72640 001
			AUG 31, 1993

LOTRIMIN

/BT/+//SCHERING/		/1%/	/N17619/001/
AB	+ SCHERING PLOUGH	1%	N17619 001

CLOTRIMAZOLE

/CREAM;/VAGINAL/
GYNE-LOTRIMIN
/BT/ /SCHERING/ /1%/ /N18052/001/
MYCELEX-G
/BT/ /MILES/ /1%/ /N18230/001/

/TABLET;/VAGINAL/
GYNE-LOTRIMIN
/BT/ /SCHERING/ /100MG/ /N17717/001/
MYCELEX-G
/BT/ /MILES/ /100MG/ /N18182/001/

CLOXACILLIN SODIUM

CAPSULE; ORAL
TEGOPEN
AB + APOTHECON EQ 250MG BASE N61452 001
AB + EQ 500MG BASE N61452 002
/AB//+//BRISTOL/ /EQ 250MG BASE/ /N61452/001/
/AB//+/ /EQ 500MG BASE/ /N61452/002/

POWDER FOR RECONSTITUTION; ORAL
CLOXACILLIN SODIUM
>DLT >/AA/ /NOVOPHARM/ /EQ 125MG BASE/5ML/ /N62978/001/
>DLT > /APR/06/1989/
>ADD > ∂ NOVOPHARM EQ 125MG BASE/5ML N62978 001
>ADD > APR 06, 1989
TEGOPEN
AA APOTHECON EQ 125MG BASE/5ML N61453 001
/AA/ /BRISTOL/ /EQ 125MG BASE/5ML/ /N61453/001/

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE VC W/ CODEINE
∂ PENNEX PHARMS 10MG/5ML;5MG/5ML; 6.25MG/5ML N88896 001
JAN 04, 1985
/AA/ /PHARM/BASICS/ /10MG/5ML;5MG/5ML;/ /6.25MG/5ML/ /N88896/001/ /JAN/04/1985/

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE W/ CODEINE
/AA/ /PENNEX/PHARMS/ /10MG/5ML;6.25MG/5ML/ /N88875/001/ /DEC/17/1984/
∂ PENNEX PHARMS 10MG/5ML;6.25MG/5ML N88875 001
DEC 17, 1984

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE
AA PENNEX PHARMS 10MG/5ML;30MG/5ML; 1.25MG/5ML N88833 001
NOV 16, 1984
/AA/ /PHARM/BASICS/ /10MG/5ML;30MG/5ML;/ /1.25MG/5ML/ /N88833/001/ /NOV/16/1984/

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL
>DLT > /COLESTID/
>DLT > /+//UPJOHN/ /5GM/PACKET/ /N17563/001/
>DLT > /5GM/SCOOPFUL/ /N17563/002/
>ADD > FLAVORED COLESTID
>ADD > + UPJOHN 5GM/PACKET N17563 001
>ADD > UPJOHN 5GM/SCOOPFUL N17563 002

CORTICOTROPIN

INJECTABLE; INJECTION
ACTH
>DLT >/AP/ /PARKE/DAVIS/ /25 UNITS/VIAL/ /N08317/002/
>ADD > ∂ PARKE DAVIS 25 UNITS/VIAL N08317 002
ACTHAR
/AP/ /ARMOUR/ /40 UNITS/VIAL/ /N07504/003/
>DLT >/AP/ /RHONE/POULENC/RORER/ /25 UNITS/VIAL/ /N07504/002/
AP RHONE POULENC RORER 40 UNITS/VIAL N07504 003
>ADD > 25 UNITS/VIAL N07504 002
H.P. ACTHAR GEL
/BC/ /ARMOUR/ /40/UNITS/ML/ /N08372/006/
/BC/+/ /80/UNITS/ML/ /N08372/008/
BC RHONE POULENC RORER 40 UNITS/ML N08372 006
BC + 80 UNITS/ML N08372 008

CORTICOTROPIN

INJECTABLE; INJECTION
/PURIFIED/CORTROPHIN/GEL/

/BC/	/ORGANON/	/40/UNITS/ML/	/N08975/001/
/BC/		/80/UNITS/ML/	/N08975/002/
	ə ORGANON	40 UNITS/ML	N08975 001
	ə	80 UNITS/ML	N08975 002

CORTICOTROPIN-ZINC HYDROXIDE

/INJECTABLE;/INJECTION/
/CORTROPHIN-ZINC/

/+//ORGANON/	/40/UNITS/ML/	/N09854/001/
ə ORGANON	40 UNITS/ML	N09854 001

CORTISONE ACETATE

TABLET; ORAL
CORTISONE ACETATE

/BP/	/HEATHER/	/25MG/	/N85736/001/
	ə HEATHER	25MG	N85736 001

CROMOLYN SODIUM

/SOLUTION;/NASAL/
/NASALCROM/

/FISONS/	/4%/	/N18306/001/ MAR/18;/1983/

SPRAY, METERED; NASAL
NASALCROM

+ FISONS	5.2MG/INH	N18306 001 MAR 18, 1983

CYANOCOBALAMIN

INJECTABLE; INJECTION
CYANOCOBALAMIN

/AP/	/DELL/	/0.03MG/ML/	/N80689/001/
	DELL	0.03MG/ML	N80689 001
/AP/	/FUJISAWA/	/1MG/ML/	/N83075/001/
	ə FUJISAWA	1MG/ML	N83075 001

CYANOCOBALAMIN

INJECTABLE; INJECTION
/RUBIVITE/

/AP/	/BEL/MAR/	/0.03MG/ML/	/N10791/004/
/AP/		/0.1MG/ML/	/N10791/002/
/AP/		/1MG/ML/	/N10791/003/
		/0.05MG/ML/	/N10791/001/
		/0.12MG/ML/	/N10791/005/
	ə BEL MAR	0.03MG/ML	N10791 004
	ə	0.05MG/ML	N10791 001
	ə	0.1MG/ML	N10791 002
	ə	0.12MG/ML	N10791 005
	ə	1MG/ML	N10791 003

CYCLACILLIN

/POWDER/FOR/RECONSTITUTION;/ORAL/
/CYCLAPEN-W/

/+//WYETH/AYERST/		/500MG/5ML/	/N50508/003/
		/125MG/5ML/	/N50508/001/
		/250MG/5ML/	/N50508/002/
	ə WYETH AYERST	125MG/5ML	N50508 001
	ə	250MG/5ML	N50508 002
	ə	500MG/5ML	N50508 003

CYCLIZINE LACTATE

/INJECTABLE;/INJECTION/
/MARezine/

	/BURROUGHS/WELLCOME/	/50MG/ML/	/N09495/001/
	ə BURROUGHS WELLCOME	50MG/ML	N09495 001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL

AB	INVAMED	10MG	N73683 001 FEB 26, 1993

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
NEOSAR

AP	ADRIA	100MG/VIAL	N40015 001 APR 29, 1993
AP		200MG/VIAL	N40015 002 APR 29, 1993
AP		500MG/VIAL	N40015 003 APR 29, 1993
AP		1GM/VIAL	N40015 004 APR 29, 1993
AP		2GM/VIAL	N40015 005 APR 29, 1993

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL
CYPROHEPTADINE HCL

	∂ PENNEX PHARMS	2MG/5ML	N87001 001 NOV 04, 1982
/AA/	/PHARM/BASICS/	/2MG/5ML/	/N87001/001/ /NOV/04,/1982/

TABLET; ORAL
CYPROHEPTADINE HCL

/AA/	/MYLAN/	/4MG/	/N86678/001/
	∂ MYLAN	4MG	N86678 001

DESIPRAMINE HYDROCHLORIDE

/CAPSULE;/ORAL/
/PERTOFRANE/

/+/	/RHONE/POULENC/RORER/	/50MG/	/N13621/002/
		/25MG/	/N13621/001/
	∂ RHONE POULENC RORER	25MG	N13621 001
	∂	50MG	N13621 002

DESLANOSIDE

/INJECTABLE;/INJECTION/
/CEDILANID-D/

	/SANDOZ/	/0.2MG/ML/	/N09282/002/
	∂ SANDOZ	0.2MG/ML	N09282 002

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DDAVP

	RHONE POULENC RORER	0.01MG/INH	N17922 002 FEB 06, 1989

DESOXYCORTICOSTERONE PIVALATE

/INJECTABLE;/INJECTION/
/PERCORTEN/

	/CIBA/	/25MG/ML/	/N08822/001/
	∂ CIBA	25MG/ML	N08822 001

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE

AA	BARRE	0.5MG/5ML	N88997 001 OCT 10, 1986
/AA/	/NASKA/	/0.5MG/5ML/	/N88997/001/ /OCT/10,/1986/

MYMETHASONE

AA	PENNEX PHARMS	0.5MG/5ML	N88254 001 JUL 27, 1983
/AA/	/PHARM/BASICS/	/0.5MG/5ML/	/N88254/001/ /JUL/27,/1983/

SOLUTION; ORAL
DEXAMETHASONE

	/∂/ROXANE/	/0.5MG/5ML/	/N88248/001/ /SEP/01,/1983/
	ROXANE	0.5MG/5ML	N88248 001 SEP 01, 1983

TABLET; ORAL
DECADRON

AB	MSD	0.5MG	N11664 001
AB	+	0.75MG	N11664 002
AB		1.5MG	N11664 003
AB		4MG	N11664 005
/BP/		/0.5MG/	/N11664/001/
/BP/	/+/	/0.75MG/	/N11664/002/
/BP/		/1.5MG/	/N11664/003/
/BP/		/4MG/	/N11664/005/

DEXAMETHASONE

TABLET; ORAL
DEXAMETHASONE

AB	ROXANE	0.5MG	N84611 001
AB		0.75MG	N84613 001
AB		1.5MG	N84610 001
AB		4MG	N84612 001
/BP/		/0.5MG/	/N84611/001/
/BP/		/0.75MG/	/N84613/001/
/BP/		/1.5MG/	/N84610/001/
/BP/		/4MG/	/N84612/001/

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
/DEXASPORIN/

/AT/	/PHARMAFAIR/	/0.1%;EQ 3.5MG BASE/GM;/ /10,000 UNITS/GM/	/N62411/001/ /MAY/16,/1983/
	ə PHARMAFAIR	0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N62411 001 MAY 16, 1983

SUSPENSION/DROPS; OPHTHALMIC
/DEXASPORIN/

/AT/	/PHARMAFAIR/	/0.1%;EQ 3.5MG BASE/ML;/ /10,000 UNITS/ML/	/N62428/001/ /MAY/18,/1983/
	ə PHARMAFAIR	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62428 001 MAY 18, 1983

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

/AP/	/BEL/MAR/	/EQ 4MG PHOSPHATE/ML/	/N84752/001/
	ə BEL MAR	EQ 4MG PHOSPHATE/ML	N84752 001
/AP/	/BRISTOL/	/EQ 4MG PHOSPHATE/ML/	/N87065/001/
	ə FUJISAWA	EQ 4MG PHOSPHATE/ML	N87065 001
/AP/	/WYETH/AYERST/	/EQ 4MG PHOSPHATE/ML/	/N85641/001/
	ə WYETH AYERST	EQ 4MG PHOSPHATE/ML	N85641 001
	HEXADROL		
	/ORGANON/	/EQ/20MG/PHOSPHATE/ML/	/N14694/004/
	ə ORGANON	EQ 20MG PHOSPHATE/ML	N14694 004

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL
MYLARAMINE

AA	PENNEX PHARMS	2MG/5ML	N88251 001 MAR 23, 1984
/AA/	/PHARM/BASICS/	/2MG/5ML/	/N88251/001/ /MAR/23,/1984/

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
/DEXAMPEX/

/AA/	/LEMMON/	/5MG/	/N83735/001/
/AA/		/10MG/	/N83735/002/
	ə LEMMON	5MG	N83735 001
	ə	10MG	N83735 002
	/FERNDEX/		
/AA/	/FERNDALE/	/5MG/	/N84001/001/
	ə FERNDALE	5MG	N84001 001

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
/PROMETHAZINE HCL/DEXTROMETHORPHAN/

/AA/	/PHARM/BASICS/	/15MG/5ML;6.25MG/5ML/	/N88864/001/ /JAN/04,/1985/
	ə PENNEX PHARMS	15MG/5ML;6.25MG/5ML	N88864 001 JAN 04, 1985

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 50% IN PLASTIC CONTAINER

/AP/	/ABBOTT/	/500MG/ML/	/N19445/001/ /JUN/03,/1986/
	ə ABBOTT	500MG/ML	N19445 001 JUN 03, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

MCGAW	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML	N19873 001 JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER			
	MCGAW	5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML	N19844 001	JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

	ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	MCGAW	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N19843 001	AUG 09, 1993

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER			
	MCGAW	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001	JUN 10, 1993

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

	/HYPAQUE-M 75%/			
	/STERLING/	/50%;25%/	/N10220/003/	
	∂ STERLING	50%;25%	N10220 003	
	/HYPAQUE-M 90%/			
	/STERLING/	/60%;30%/	/N10220/002/	
	∂ STERLING	60%;30%	N10220 002	

DIATRIZOATE SODIUM

	/SOLUTION;URETERAL/			
	/HYPAQUE/SODIUM/20%/			
	/STERLING/	/20%/	/N09561/002/	
	∂ STERLING	20%	N09561 002	

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

AP	MARSAM	5MG/ML	N72370 001	JAN 29, 1993
AP		5MG/ML	N72371 001	JAN 29, 1993
AP		5MG/ML	N72397 001	JAN 29, 1993

VALIUM

/AP/	/ROCHE/	/5MG/ML/	/N16087/001/	
AP	+ ROCHE	5MG/ML	N16087 001	

INJECTABLE; INTRAVENOUS

DIZAC

	+ KABI	5MG/ML	N19287 001	JUN 18, 1993

TABLET; ORAL

DIAZEPAM

	∂ FERNDALE	2MG	N70903 001	APR 01, 1987
	∂	5MG	N70904 001	APR 01, 1987
	∂	10MG	N70905 001	APR 01, 1987
/AB/	/PHARM/BASICS/	/2MG/	/N70903/001/	/APR/01;/1987/
/AB/		/5MG/	/N70904/001/	/APR/01;/1987/
/AB/		/10MG/	/N70905/001/	/APR/01;/1987/
/AB/	/ZENITH/	/2MG/	/N70360/001/	/SEP/04;/1985/
/AB/		/5MG/	/N70361/001/	/SEP/04;/1985/
	∂ ZENITH	2MG	N70360 001	SEP 04, 1985
	∂	5MG	N70361 001	SEP 04, 1985

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

	+ BAKER NORTON	50MG	N17425 001	
/+//MEDCL/MKTS/		/50MG/	/N17425/001/	

/SOLUTION;/URETERAL/
/HYPAQUE/SODIUM/20%/
/STERLING/ /20%/ /N09561/002/
∂ STERLING 20% N09561 002

DIAZOXIDE

CAPSULE; ORAL
PROGLYCEM
+ BAKER NORTON 50MG N17425 001
/+//MEDCL/MKTG/ /50MG/ /N17425/001/

DIAZOXIDE

INJECTABLE; INJECTION
/DIAZOXIDE/
/AP/ /QUAD/ /15MG/ML/ /N71908/001/
/JAN/26,/1988/
∂ QUAD 15MG/ML N71908 001
JAN 26, 1988

HYPERSTAT
/AP/ /SCHERING/ /15MG/ML/ /N16996/001/
SCHERING 15MG/ML N16996 001

SUSPENSION; ORAL
PROGLYCEM
+ BAKER NORTON 50MG/ML N17453 001
/+//MEDCL/MKTG/ /50MG/ML/ /N17453/001/

DICLOFENAC POTASSIUM

TABLET; ORAL
CATAFLAM
+ GEIGY 50MG N20142 002
NOV 24, 1993
25MG N20142 001
NOV 24, 1993

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
VOLTAREN
/CIBA/ /0.1%/ /N20037/001/
/MAR/28,/1991/
CIBA VISION 0.1% N20037 001
MAR 28, 1991

DICLOXACILLIN SODIUM

CAPSULE; ORAL
DYCILL
/AB/ /SMITHKLINE/BEECHAM/ /EQ 250MG BASE/ /N60254/002/
/AB/ /EQ 500MG BASE/ /N60254/003/
∂ SMITHKLINE BEECHAM EQ 250MG BASE N60254 002
∂ EQ 500MG BASE N60254 003
DYNAPEN
AB APOTHECON EQ 125MG BASE N61454 002
AB EQ 250MG BASE N61454 001
/AB/ /BRISTOL/ /EQ 125MG BASE/ /N61454/002/
/AB/ /EQ 250MG BASE/ /N61454/001/

DICLOXACILLIN SODIUM

POWDER FOR RECONSTITUTION; ORAL
DYNAPEN
AB APOTHECON EQ 62.5MG BASE/5ML N61455 001
/AB/ /BRISTOL/ /EQ 62.5MG BASE/5ML/ /N61455/001/

DICUMAROL

TABLET; ORAL
DICUMAROL
/+//ABBOTT/ /50MG/ /N05545/004/
∂ ABBOTT 50MG N05545 004

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL
DICYCLOMINE HCL
/AB/ /PIONEER/PHARMS/ /10MG/ /N89361/001/
/JAN/10,/1989/
∂ PIONEER PHARMS 10MG N89361 001
JAN 10, 1989

TABLET; ORAL
DICYCLOMINE HCL
/AB/ /PIONEER/PHARMS/ /20MG/ /N88585/001/
/AUG/20,/1986/
∂ PIONEER PHARMS 20MG N88585 001
AUG 20, 1986

DIETHYLSTILBESTROL

/INJECTABLE;/INJECTION/
/STILBESTROL/
/SQUIBB/ /0.2MG/ML/ /N04056/003/
/0.5MG/ML/ /N04056/004/
/1MG/ML/ /N04056/005/
/5MG/ML/ /N04056/006/
∂ SQUIBB 0.2MG/ML N04056 003
∂ 0.5MG/ML N04056 004
∂ 1MG/ML N04056 005
∂ 5MG/ML N04056 006

/SUPPOSITORY;/VAGINAL/
/STILBESTROL/
/+//SQUIBB/ /0.1MG/ /N04056/001/
/+/ /0.5MG/ /N04056/002/

DIETHYLSTILBESTROL

/SUPPOSITORY;VAGINAL/
/STILBESTROL/

	∂ SQUIBB	0.1MG	N04056 001
	∂	0.5MG	N04056 002

TABLET, DELAYED RELEASE; ORAL
STILBETIN

/BE/	/SQUIBB/	/0.1MG/	/N04056/011/
	∂ SQUIBB	0.1MG	N04056 011

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM CD

> ADD >	BC +	CARDERM	120MG	N20062 001
> ADD >				AUG 10, 1992
	BC +		180MG	N20062 002
				DEC 27, 1991
	BC +		240MG	N20062 003
				DEC 27, 1991
> DLT >	/+/		/120MG/	/N20062/001/
> DLT >				/AUG/10,/1992/
	+		300MG	N20062 004
				DEC 27, 1991
	/BC/+/	/MARION/MERRELL/DOW/	/180MG/	/N20062/002/
				/DEC/27,/1991/
	/BC/+/		/240MG/	/N20062/003/
				/DEC/27,/1991/
	/+/		/300MG/	/N20062/004/
				/DEC/27,/1991/

CARDIZEM SR

AB	+	MARION MERRELL DOW	60MG	N19471 001
				JAN 23, 1989
AB	+		90MG	N19471 002
				JAN 23, 1989
AB	+		120MG	N19471 003
				JAN 23, 1989

DILACOR XR

> ADD >	BC	RHONE POULENC RORER	120MG	N20092 001
				MAY 29, 1992
> ADD >				
> DLT >	/+/		/120MG/	/N20092/001/
> DLT >				/MAY/29,/1992/

DILTIAZEM HCL

AB	PROGRAPHARM	60MG	N74079 001
			NOV 30, 1993
AB		90MG	N74079 002
			NOV 30, 1993
AB		120MG	N74079 003
			NOV 30, 1993

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL
DILTIAZEM HCL

AB	APOTHECON	30MG	N74051 001
			MAR 31, 1993
AB		60MG	N74051 002
			MAR 31, 1993
AB		90MG	N74051 003
			MAR 31, 1993
AB		120MG	N74051 004
			MAR 31, 1993

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

/AA/	/LEMMON/	/25MG/	/N85874/001/
/AA/		/50MG/	/N85874/002/
	∂ LEMMON	25MG	N85874 001
	∂	50MG	N85874 002

INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL

/AP/	/BEL/MAR/	/10MG/ML/	/N80822/001/
	∂ BEL MAR	10MG/ML	N80822 001
/AP/	/FUJISAWA/	/10MG/ML/	/N87066/001/
	∂ FUJISAWA	10MG/ML	N87066 001

DIPHENYLPYRALINE HYDROCHLORIDE

/CAPSULE;EXTENDED RELEASE;ORAL/
/HISPRIL/

/+/	/SMITHKLINE/BEECHAM/	/5MG/	/N11945/001/
	∂ SMITHKLINE BEECHAM	5MG	N11945 001

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
DISOPYRAMIDE PHOSPHATE

/AB/	/KV/	/EQ 100MG BASE/	/N71929/001/
			/AUG/19,/1988/
B*	KV	EQ 100MG BASE	N71929 001
			AUG 19, 1988

DIVALPROEX SODIUM

/TABLET;DELAYED RELEASE;ORAL/
/DEPAKOTE/CP/
/ABBOTT/ /EQ 250MG BASE/ /N19794/001/ /JUL/11;/1990/
/EQ 500MG BASE/ /N19794/002/ /JUL/11;/1990/

	∂ ABBOTT	EQ 250MG BASE	N19794 001 JUL 11, 1990
	∂	EQ 500MG BASE	N19794 002 JUL 11, 1990

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HCL

AP	ABBOTT	EQ 12.5MG BASE/ML	N74086 001 NOV 29, 1993
AP	GENSIA	EQ 12.5MG BASE/ML	N74206 001 OCT 19, 1993
AP	STERIS	EQ 12.5MG BASE/ML	N74114 001 NOV 30, 1993

DOBUTAMINE HCL IN DEXTROSE 5%

AP +	ABBOTT	EQ 50MG BASE/100ML	N20269 001 OCT 19, 1993
AP +		EQ 100MG BASE/100ML	N20269 002 OCT 19, 1993
AP +		EQ 200MG BASE/100ML	N20269 003 OCT 19, 1993

DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	ABBOTT	EQ 50MG BASE/100ML	N20201 003 OCT 19, 1993
AP		EQ 100MG BASE/100ML	N20201 002 OCT 19, 1993
AP		EQ 200MG BASE/100ML	N20201 001 OCT 19, 1993
AP +	BAXTER	EQ 50MG BASE/100ML	N20255 001 OCT 19, 1993
AP +		EQ 100MG BASE/100ML	N20255 003 OCT 19, 1993
AP +		EQ 200MG BASE/100ML	N20255 004 OCT 19, 1993
+		EQ 400MG BASE/100ML	N20255 005 OCT 19, 1993

DOBUTREX

AP +	LILLY	EQ 12.5MG BASE/ML	N17820 002

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

/AP/ /ASTRA/ /40MG/ML/ /N70087/001/ /OCT/23;/1985/
/AP/ /80MG/ML/ /N70089/001/ /OCT/23;/1985/
/AP/ /80MG/ML/ /N70090/001/ /OCT/23;/1985/
/AP/ /160MG/ML/ /N70093/001/ /OCT/23;/1985/
/AP/ /160MG/ML/ /N70094/001/ /OCT/23;/1985/
/AP/ /BRISTOL/ /40MG/ML/ /N18549/001/ /MAR/11;/1983/
/AP/ /LYPHOMED/ /40MG/ML/ /N70012/001/ /JUN/12;/1985/

	∂ ASTRA	40MG/ML	N70087 001 OCT 23, 1985
	∂	80MG/ML	N70089 001 OCT 23, 1985
	∂	80MG/ML	N70090 001 OCT 23, 1985
	∂	160MG/ML	N70093 001 OCT 23, 1985
	∂	160MG/ML	N70094 001 OCT 23, 1985
	∂ FUJISAWA	40MG/ML	N18549 001 MAR 11, 1983
	∂ LYPHOMED	40MG/ML	N70012 001 JUN 12, 1985

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

>DLT> /ADAPIN/
>DLT>/AB/ /FISONS/ /EQ 10MG BASE/ /N16987/001/
>DLT>/AB/ /EQ 25MG BASE/ /N16987/002/
>DLT>/AB/ /EQ 50MG BASE/ /N16987/003/
>DLT>/AB/ /EQ 75MG BASE/ /N16987/006/
>DLT>/AB/ /EQ 100MG BASE/ /N16987/004/
>DLT>/AB/ /EQ 150MG BASE/ /N16987/007/ /APR/13;/1987/

>DLT>			
>ADD>	DOXEPIN HCL		
>ADD>	∂ FISONS	EQ 10MG BASE	N16987 001
>ADD>	∂	EQ 25MG BASE	N16987 002
>ADD>	∂	EQ 50MG BASE	N16987 003
>ADD>	∂	EQ 75MG BASE	N16987 006
>ADD>	∂	EQ 100MG BASE	N16987 004
>ADD>	∂	EQ 150MG BASE	N16987 007 APR 13, 1987
>ADD>			

DOXEPIN HYDROCHLORIDE

CONCENTRATE; ORAL
DOXEPIN HCL

AA	PENNEX PHARMS	EQ 10MG BASE/ML	N71918 001 JUL 20, 1988
/AA/	/PHARM/BASICS/	/EQ 10MG BASE/ML/	/N71918/001/ /JUL/20,/1988/

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE MONOHYDRATE

/+//MEDICOPHARMA/		/EQ/100MG/BASE/	/N50641/001/ /DEC/29,/1989/
+	VINTAGE	EQ 100MG BASE	N50641 001 DEC 29, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE

/AB/	/PAR/	/EQ 50MG BASE/	/N62434/001/ /OCT/19,/1984/
/AB/		/EQ 100MG BASE/	/N62442/001/ /DEC/22,/1983/
	∂ PAR	EQ 50MG BASE	N62434 001 OCT 19, 1984
	∂	EQ 100MG BASE	N62442 001 DEC 22, 1983

TABLET; ORAL
DOXY-TABS

	∂ RACHELLE	EQ 50MG BASE	N62269 003

DOXYCYCLINE HYCLATE

/AB/	/HEATHER/	/EQ 100MG BASE/	/N62462/001/ /MAY/11,/1983/
	∂ HEATHER	EQ 100MG BASE	N62462 001 MAY 11, 1983

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

/AP/	/QUAD/	/2.5MG/ML/	/N71941/001/ /AUG/17,/1988/
	∂ QUAD	2.5MG/ML	N71941 001 AUG 17, 1988

DROPERIDOL

INJECTABLE; INJECTION
DROPERIDOL

/AP/	/SMITH/NEPHEW/SOLOPAK/	/2.5MG/ML/	/N71754/001/ /SEP/06,/1988/
/AP/		/2.5MG/ML/	/N71755/001/ /SEP/06,/1988/
AP	SOLOPAK	2.5MG/ML	N71754 001 SEP 06, 1988
AP		2.5MG/ML	N71755 001 SEP 06, 1988

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION
FENTANYL CITRATE AND DROPERIDOL

/AP/	/ASTRA/	/2.5MG/ML; EQ 0.05MG BASE/ML/	/N72028/001/ /APR/13,/1989/
	∂ ASTRA	2.5MG/ML; EQ 0.05MG BASE/ML	N72028 001 APR 13, 1989

EDETATE DISODIUM

INJECTABLE; INJECTION
/DISODIUM EDETATE/

/AP/	/STERIS/	/150MG/ML/	/N84356/001/
	∂ STERIS	150MG/ML	N84356 001

EFLORNITHINE HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/ORNIDYL/

	/MERRELL/DOW/	/200MG/ML/	/N19879/002/ /NOV/28,/1990/
	∂ MERRELL DOW	200MG/ML	N19879 002 NOV 28, 1990

ENCAINIDE HYDROCHLORIDE

/CAPSULE;/ORAL/
/ENKAID/
/+//BRISTOL/ /50MG/ /N18981/004/ /DEC/24,/1986/
/25MG/ /N18981/002/ /DEC/24,/1986/
/35MG/ /N18981/003/ /DEC/24,/1986/

∂ BRISTOL	25MG	N18981 002 DEC 24, 1986
∂	35MG	N18981 003 DEC 24, 1986
∂	50MG	N18981 004 DEC 24, 1986

ENOXACIN

TABLET; ORAL
PENETREX
/+//PARKE/DAVIS/ /400MG/ /N19616/005/ /DEC/31,/1991/
/200MG/ /N19616/004/ /DEC/31,/1991/

+ RHONE POULENC RORER	400MG	N19616 005 DEC 31, 1991
	200MG	N19616 004 DEC 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; INJECTION
LOVENOX

RHONE POULENC RORER	30MG/0.3ML	N20164 001 MAR 29, 1993

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL AND EPINEPHRINE

AP	STERLING WINTHROP	0.01MG/ML;2%	N40057 002 FEB 26, 1993
AP		0.02MG/ML;2%	N40057 001 FEB 26, 1993

LIDOCAINE HCL W/ EPINEPHRINE
/AP/ /BEL/MAR/ /0.01MG/ML;1%/ /N60620/001/
/AP/ /0.01MG/ML;2%/ /N80757/001/

∂ BEL MAR	0.01MG/ML;1%	N80820 001
∂	0.01MG/ML;2%	N80757 001

EPINEPHRINE; PROCAINE HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/PROCAINE/HCL/W//EPINEPHRINE/
/BEL/MAR/ /0.02MG/ML;1%/ /N60758/001/
/0.02MG/ML;2%/ /N60759/001/

∂ BEL MAR	0.02MG/ML;1%	N80758 001
∂	0.02MG/ML;2%	N80759 001

ERGOLOID MESYLATES

TABLET; ORAL
HYDERGINE
/SANDOZ/ /0.5MG/ /N17993/003/

∂ SANDOZ	0.5MG	N17993 003

TABLET; SUBLINGUAL
HYDROGENATED ERGOT ALKALOIDS
/AA/ /ZENITH/ /0.5MG/ /N87186/001/

∂ ZENITH	0.5MG	N87186 001

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL
ERGOMAR
/AA/ /FISONS/ /2MG/ /N87693/001/ /FEB/24,/1983/

AA LOTUS	2MG	N87693 001 FEB 24, 1983

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
/ERYC/SPRINKLES/
/+//FAULDING/ /125MG/ /N50593/001/ /JUL/22,/1985/

∂ FAULDING	125MG	N50593 001 JUL 22, 1985

GEL; TOPICAL
ERYGEL
/AT/ /HERBERT/ /2%/ /N50617/001/ /OCT/21,/1987/

AT + HERBERT	2%	N50617 001 OCT 21, 1987

ERYTHROMYCIN

AT STIEFEL	2%	N63211 001 JAN 29, 1993

ERYTHROMYCIN

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

/AT/	/PHARMADERM/	/5MG/GM/	/N62446/001/	/SEP/26,/1983/
	∂ PHARMADERM	5MG/GM	N62446 001	SEP 26, 1983
/AT/	/PHARMAFAIR/	/5MG/GM/	/N62481/001/	/APR/05,/1984/
	∂ PHARMAFAIR	5MG/GM	N62481 001	APR 05, 1984

/POWDER;/FOR/RX/COMPOUNDING/

/ERYTHROMYCIN/

/PADDOCK/	/100%/	/N50610/001/	/NOV/07,/1986/
∂ PADDOCK	100%	N50610 001	NOV 07, 1986

SOLUTION; TOPICAL

ERYTHRA-DERM

AT	PADDOCK	2%	N62687 001 FEB 05, 1988

ERYTHROMYCIN

AT	BARRE	2%	N62957 001	JUL 21, 1988
/AT/	/NASKA/	/2%/	/N62957/001/	/JUL/21,/1988/
AT	PENNEX PHARMS	2%	N62825 001	OCT 23, 1987
/AT/	/PHARM/BASICS/	/2%/	/N62825/001/	/OCT/23,/1987/
/AT/	/PHARMAFAIR/	/1.5%/	/N62485/001/	/JUL/11,/1984/
	∂ PHARMAFAIR	1.5%	N62485 001	JUL 11, 1984

/ETS-2%/

/AT/	/PADDOCK/	/2%/	/N62687/001/	/FEB/05,/1988/

SWAB; TOPICAL

C-SOLVE-2

AT	SYOSSET	2%	N62751 001	JUL 30, 1993

ERYTHROMYCIN

TABLET, COATED PARTICLES; ORAL

PCE

/+//ABBOTT/	/333MG/		/N50611/001/	/SEP/09,/1986/
+ ABBOTT	500MG		N50611 002	AUG 22, 1990
	333MG		N50611 001	SEP 09, 1986
	/500MG/		/N50611/002/	/AUG/22,/1990/

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL

ERYTHROMYCIN ESTOLATE

∂ LIFE LABS	EQ 250MG BASE/5ML	N62362 001 DEC 17, 1982

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

/AB/	/KV/	/EQ 200MG BASE/5ML/	/N62047/001/
/AB/		/EQ 400MG BASE/5ML/	/N62047/002/
	∂ KV	EQ 200MG BASE/5ML	N62047 001
	∂	EQ 400MG BASE/5ML	N62047 002

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROMYCIN LACTOBIONATE

AP	GENSIA	EQ 500MG BASE/VIAL	N63253 001	JUL 30, 1993
AP		EQ 1GM BASE/VIAL	N63253 002	JUL 30, 1993
/AB/	/LYPHOMED/	/EQ 500MG BASE/VIAL/	/N62604/001/	/NOV/24,/1986/
/AB/		/EQ 1GM BASE/VIAL/	/N62604/002/	/NOV/24,/1986/
	∂ LYPHOMED	EQ 500MG BASE/VIAL	N62604 001	NOV 24, 1986
	∂	EQ 1GM BASE/VIAL	N62604 002	NOV 24, 1986

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

	BREVIBLOC		
+	ANAQUEST	10MG/ML	N19386 001 AUG 15, 1988
+		250MG/ML	N19386 002 DEC 31, 1986
	/DUPONT/	/10MG/ML/	/N19386/001/ /AUG/15,/1988/
		/250MG/ML/	/N19386/002/ /DEC/31,/1986/

ESTRADIOL

TABLET; ORAL

	ESTRACE		
	BRISTOL MYERS SQUIBB	0.5MG	N81295 001 JUN 30, 1993

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL

	PREMARIN		
+	AYERST	0.625MG/GM	N20216 001
/+/	/WYETH/AYERST/	/0.625MG/GM/	/N83273/001/

TABLET; ORAL

	CONJUGATED ESTROGENS		
	/3/ZENITH/	/0.3MG/	/N88564/001/ /NOV/29,/1984/
	/3/	/0.625MG/	/N83373/001/
	/3/	/1.25MG/	/N83601/001/
	/3/	/2.5MG/	/N83602/001/
	PREMARIN		
+	WYETH AYERST	1.25MG	N04782 001
/+/		/2.5MG/	/N04782/002/
		/1.25MG/	/N04782/001/
		2.5MG	N04782 002

ESTROPIPATE

TABLET; ORAL

		ESTROPIPATE		
AB		WATSON LABS	0.75MG	N81213 001 SEP 23, 1993
AB			1.5MG	N81214 001 SEP 23, 1993
AB			3MG	N81215 001 SEP 23, 1993
AB			6MG	N81216 001 SEP 23, 1993
		OGEN 1.25		
/AB/	/+/	/ABBOTT/	/1.25MG/	/N83220/002/
AB		ABBOTT	1.5MG	N83220 002
		OGEN 2.5		
AB	+	ABBOTT	3MG	N83220 003
	/+/		/3MG/	/N83220/003/
		OGEN 5		
AB		ABBOTT	6MG	N83220 004

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

	/TABLET;ORAL-28/		
	/NORLESTRIN/FE/1/50/		
/+/	/PARKE/DAVIS/	/0.05MG;75MG;1MG/	/N16766/001/
	∂ PARKE DAVIS	0.05MG;75MG;1MG	N16766 001
	/NORLESTRIN/FE/2.5/50/		
/+/	/PARKE/DAVIS/	/0.05MG;75MG;2.5MG/	/N16854/001/
	∂ PARKE DAVIS	0.05MG;75MG;2.5MG	N16854 001

ETHINYL ESTRADIOL; FLUOXYMESTERONE

	/TABLET;ORAL/		
	/HALODRIN/		
/+/	/UPJOHN/	/0.02MG;1MG/	/N11267/001/
	∂ UPJOHN	0.02MG;1MG	N11267 001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

>ADD>			LEVORA 0.15/30-21		
>ADD>	AB		SYNTEX	0.03MG;0.15MG	N73592 001 DEC 13, 1993
>ADD>					
			NORDETTE-21		
>ADD>	AB	+	WYETH AYERST	0.03MG;0.15MG	N18668 001 MAY 10, 1982
>ADD>					

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

> ADD >
> ADD > **LEVORA 0.15/30-28**
> ADD > AB SYNTEX 0.03MG;0.15MG N73594 001 DEC 13, 1993
> ADD >

NORDETTE-28

> ADD > AB WYETH AYERST 0.03MG;0.15MG N18782 001 JUL 21, 1982
> ADD >

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/35E-21

AB ROBERTS 0.035MG;1MG N71480 001 APR 12, 1988

/AB/ /SCHIAPPARELLI/SEARLE/0.035MG;1MG/ /N71480/001/ /APR/12,/1988/

TABLET; ORAL-28

NORETHIN 1/35E-28

AB ROBERTS 0.035MG;1MG N71481 001 APR 12, 1988

/AB/ /SCHIAPPARELLI/SEARLE/0.035MG;1MG/ /N71481/001/ /APR/12,/1988/

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

/TABLET;/ORAL-21/
/NORLESTRIN/21/1/50/
/+//PARKE/DAVIS/ /0.05MG;1MG/ /N16749/001/
@ PARKE DAVIS 0.05MG;1MG N16749 001

/NORLESTRIN/21/2.5/50/
/+//PARKE/DAVIS/ /0.05MG;2.5MG/ /N16852/001/
@ PARKE DAVIS 0.05MG;2.5MG N16852 001

ETHOSUXIMIDE

SYRUP; ORAL

ETHOSUXIMIDE

AA COPLEY 250MG/5ML N81306 001 JUL 30, 1993

ZARONTIN

AA PARKE DAVIS 250MG/5ML N80258 001

ETHYNODIOL DIACETATE; MESTRANOL

/TABLET;/ORAL-21/
/OVULEN-21/
/+//SEARLE/ /1MG;0.1MG/ /N16029/003/
@ SEARLE 1MG;0.1MG N16029 003

/TABLET;/ORAL-28/
/OVULEN-28/
/SEARLE/ /1MG;0.1MG/ /N16705/001/
@ SEARLE 1MG;0.1MG N16705 001

ETIDRONATE DISODIUM

INJECTABLE; INJECTION
DIDRONEL
+ MGI 50MG/ML N19545 001 APR 20, 1987

/P/AND/S/ /50MG/ML/ /N19545/001/ /APR/20,/1987/

FELBAMATE

SUSPENSION; ORAL
FELBATOL
+ WALLACE 600MG/5ML N20189 003 JUL 29, 1993

TABLET; ORAL
FELBATOL
+ WALLACE 600MG N20189 002 JUL 29, 1993
400MG N20189 001 JUL 29, 1993

> ADD > FENOFIBRATE

> ADD > CAPSULE; ORAL
> ADD > LIPIDIL
> ADD > + FOURNIER 100MG N19304 001 DEC 31, 1993
> ADD >

FENTANYL CITRATE

FLUOCINOLONE ACETONIDE

FENTANYL CITRATE

TROCHE/LOZENGE; ORAL
FENTANYL
+ ANESTA — EQ 0.4MG BASE — N20195 003 OCT 04, 1993
EQ 0.2MG BASE — N20195 001 OCT 04, 1993
EQ 0.3MG BASE — N20195 002 OCT 04, 1993

FIBRINOGEN, I-125

>DLT> /INJECTABLE;INJECTION/
>DLT> /RADIONUCLIDE-LABELED/(125/I)FIBRINOGEN/(HUMAN)/SENSOR/
>DLT> /ABBOTT/ — /140/UCI/ML/ — /N17787/001/
>ADD> ə ABBOTT — 140 UCI/ML — N17787 001

FLUCONAZOLE

>ADD> POWDER FOR RECONSTITUTION; ORAL
>ADD> DIFLUCAN
>ADD> + PFIZER — 200MG/5ML — N20090 002 DEC 23, 1993
>ADD> 50MG/5ML — N20090 001 DEC 23, 1993

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
/AT/ /PHARMADERM/ — /0.01%/ — /N88047/001/DEC/16,/1982/
/AT/ — /0.025%/ — /N88045/001/DEC/16,/1982/
ə PHARMADERM — 0.01% — N88047 001 DEC 16, 1982
ə — 0.025% — N88045 001 DEC 16, 1982
/AT/ /PHARMAFAIR/ — /0.01%/ — /N88499/001/AUG/02,/1984/
/AT/ — /0.025%/ — /N88506/001/AUG/02,/1984/
ə PHARMAFAIR — 0.01% — N88499 001 AUG 02, 1984
ə — 0.025% — N88506 001 AUG 02, 1984

FLUOCINOLONE ACETONIDE

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE
/AT/ /PHARMADERM/ — /0.025%/ — /N88046/001/DEC/16,/1982/
ə PHARMADERM — 0.025% — N88046 001 DEC 16, 1982
/AT/ /PHARMAFAIR/ — /0.025%/ — /N88507/001/FEB/27,/1984/
ə PHARMAFAIR — 0.025% — N88507 001 FEB 27, 1984

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
>ADD> AT BAUSCH AND LOMB — 0.01% — N40059 001 DEC 20, 1993
>ADD> ə PENNEX PHARMS — 0.01% — N88312 001 JAN 27, 1984
/AT/ /PHARM/BASICS/ — /0.01%/ — /N88312/001/JAN/27,/1984/

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL
NEO-SYNALAR
>ADD> + HAMILTON PHARMA CA — 0.025%;EQ 3.5MG BASE/GM — N60700 001
>DLT> /SYNTEX/ — /0.025%;EQ/3.5MG/BASE/GM/ — /N60700/001/

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL
/AP/ /MARCHAR/ — /50MG/ML/ — /N87791/001/JAN/18,/1983/
ə MARCHAR — 50MG/ML — N87791 001 JAN 18, 1983

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
PROZAC
LILLY — EQ 10MG BASE — N18936 006 DEC 23, 1992

FLUOXYMESTERONE

TABLET; ORAL
/ANDROID-F/
/BP/ /ICN/ /10MG/ /N87196/001/
ə ICN 10MG N87196 001

FLUOXYMESTERONE
/BP/ /ICN/ /10MG/ /N88221/001/
/MAY/05,/1983/
ə ICN 10MG N88221 001
MAY 05, 1983

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION
PROLIXIN DECANOATE
AO + APOTHECON 25MG/ML N16727 001
/AO/ /SQUIBB/ /25MG/ML/ /N16727/001/

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION
PROLIXIN ENANTHATE
+ APOTHECON 25MG/ML N16110 001
/SQUIBB/ /25MG/ML/ /N16110/001/

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
PROLIXIN
AA APOTHECON 5MG/ML N70533 001
NOV 07, 1985
/AA/ /SQUIBB/ /5MG/ML/ /N70533/001/
/NOV/07,/1985/

ELIXIR; ORAL
FLUPHENAZINE HCL
AA COPLEY 2.5MG/5ML N81310 001
APR 29, 1993

PROLIXIN
AA APOTHECON 2.5MG/5ML N12145 003
/SQUIBB/ /2.5MG/5ML/ /N12145/003/

INJECTABLE; INJECTION
PROLIXIN
AP + APOTHECON 2.5MG/ML N11751 005
/AP/ /SQUIBB/ /2.5MG/ML/ /N11751/005/

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL
PROLIXIN
AB APOTHECON 1MG N11751 004
AB 2.5MG N11751 001
AB 5MG N11751 003
AB + 10MG N11751 002
/AB/ /SQUIBB/ /1MG/ /N11751/004/
/AB/ /2.5MG/ /N11751/001/
/AB/ /5MG/ /N11751/003/
/AB/ /10MG/ /N11751/002/

/TABLET,/EXTENDED/RELEASE;/ORAL/
/PERMITIL/
/+//SCHERING/ /1MG/ /N12419/004/
ə SCHERING 1MG N12419 004

> ADD > FLUVASTATIN SODIUM

> ADD > CAPSULE; ORAL
> ADD > LESCOL
> ADD > + SANDOZ EQ 40MG BASE N20261 002
> ADD > DEC 31, 1993
> ADD > EQ 20MG BASE N20261 001
> ADD > DEC 31, 1993

FOLIC ACID

INJECTABLE; INJECTION
FOLIC ACID
> ADD > AP LOCH 5MG/ML N81066 001
> ADD > DEC 29, 1993

TABLET; ORAL
FOLIC ACID
/A/BOOTS/ /1MG/ /N84158/001/
ə PHARMERAL 1MG N84158 001
/AA/ /PIONEER/PHARMS/ /1MG/ /N88949/001/
/SEP/13,/1985/
ə PIONEER PHARMS 1MG N88949 001
SEP 13, 1985

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

/AP/	/ASTRA/	/10MG/ML/	/N70014/001/ /SEP/09,/1985/
	∂ ASTRA	10MG/ML	N70014 001 SEP 09, 1985
>DLT >/AP/	/WYETH/AYERST/	/10MG/ML/	/N18670/001/ /JUL/20,/1982/
>DLT >			
>ADD >	∂ WYETH AYERST	10MG/ML	N18670 001 JUL 20, 1982
>ADD >			

SOLUTION; ORAL
FUROSEMIDE

AA	PENNEX PHARMS	10MG/ML	N70655 001 OCT 02, 1987
/AA/	/PHARM/BASICS/	/10MG/ML/	/N70655/001/ /OCT/02,/1987/

TABLET; ORAL
FUROSEMIDE

/AB/	/PARKE/DAVIS/	/20MG/	/N18419/001/ /JAN/31,/1983/
/AB/		/40MG/	/N18419/002/ /JAN/31,/1983/
/AB/		/80MG/	/N18419/003/ /NOV/13,/1984/
	∂ WARNER CHILCOTT	20MG	N18419 001 JAN 31, 1983
	∂	40MG	N18419 002 JAN 31, 1983
	∂	80MG	N18419 003 NOV 13, 1984

>ADD > GABAPENTIN

>ADD > CAPSULE; ORAL
>ADD > NEURONTIN

>ADD >	+ PARKE DAVIS	400MG	N20235 003 DEC 30, 1993
>ADD >		100MG	N20235 001 DEC 30, 1993
>ADD >		300MG	N20235 002 DEC 30, 1993

GADODIAMIDE

INJECTABLE; INJECTION
OMNISCAN

STERLING WINTHROP	287MG/ML	N20123 001 JAN 08, 1993

GEMFIBROZIL

CAPSULE; ORAL
GEMFIBROZIL

AB	MYLAN	300MG	N73466 001 JAN 25, 1993
AB	PUREPAC	300MG	N72929 001 JAN 29, 1993

LOPID

AB	+ PARKE DAVIS	300MG	N18422 002

TABLET; ORAL
GEMFIBROZIL

AB	LEDERLE	600MG	N74270 001 SEP 27, 1993
AB	LEMMON	600MG	N74256 001 OCT 31, 1993

LOPID

AB	+ PARKE DAVIS	600MG	N18422 003 NOV 20, 1986

GENTAMICIN SULFATE

CREAM; TOPICAL
GENTAMICIN SULFATE

/AT/	/PHARMADERM/	/EQ 1MG BASE/GM/	/N62530/001/ /JUL/05,/1984/
	∂ PHARMADERM	EQ 1MG BASE/GM	N62530 001 JUL 05, 1984

INJECTABLE; INJECTION
GENTAMICIN SULFATE

/AP/	/WYETH/AYERST/	/EQ 10MG BASE/ML/	/N62264/001/
/AP/		/EQ 40MG BASE/ML/	/N62264/002/
	∂ WYETH AYERST	EQ 10MG BASE/ML	N62264 001
	∂	EQ 40MG BASE/ML	N62264 002

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

/AP/	/ABBOTT/	/EQ 60MG BASE/100ML/	/N62588/006/
/AP/		/EQ 70MG BASE/100ML/	/JAN/06,/1986/ /N62588/007/
/AP/		/EQ 80MG BASE/100ML/	/JAN/06,/1986/ /N62588/008/
/AP/		/EQ 90MG BASE/100ML/	/JAN/06,/1986/ /N62588/009/
/AP/		/EQ 100MG BASE/100ML/	/JAN/06,/1986/ /N62588/010/
/AP/		/EQ 1.2MG BASE/ML/	/JAN/06,/1986/ /N62588/001/
/AP/		/EQ 1.4MG BASE/ML/	/JAN/06,/1986/ /N62588/002/
/AP/		/EQ 1.6MG BASE/ML/	/JAN/06,/1986/ /N62588/003/
/AP/		/EQ 1.8MG BASE/ML/	/JAN/06,/1986/ /N62588/004/
/AP/		/EQ 2MG BASE/ML/	/JAN/06,/1986/ /N62588/005/

∂ ABBOTT — EQ 60MG BASE/100ML — N62588 006 JAN 06, 1986
∂ — EQ 70MG BASE/100ML — N62588 007 JAN 06, 1986
∂ — EQ 80MG BASE/100ML — N62588 008 JAN 06, 1986
∂ — EQ 90MG BASE/100ML — N62588 009 JAN 06, 1986
∂ — EQ 100MG BASE/100ML — N62588 010 JAN 06, 1986
∂ — EQ 1.2MG BASE/ML — N62588 001 JAN 06, 1986
∂ — EQ 1.4MG BASE/ML — N62588 002 JAN 06, 1986
∂ — EQ 1.6MG BASE/ML — N62588 003 JAN 06, 1986
∂ — EQ 1.8MG BASE/ML — N62588 004 JAN 06, 1986
∂ — EQ 2MG BASE/ML — N62588 005 JAN 06, 1986

OINTMENT; OPHTHALMIC
/GENTAFAIR/

/AT/	/PHARMAFAIR/	/EQ 3MG BASE/GM/	/N62443/001/ /MAY/26,/1983/

∂ PHARMAFAIR — EQ 3MG BASE/GM — N62443 001 MAY 26, 1983

GLIPIZIDE

TABLET; ORAL
GLUCOTROL

+	PFIZER	10MG	N17783 002 MAY 08, 1984
		2.5MG	N17783 003 MAY 11, 1993
		5MG	N17783 001 MAY 08, 1984
/+//ROERIG/		/10MG/	/N17783/002/ /MAY/08,/1984/
		/5MG/	/N17783/001/ /MAY/08,/1984/

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION
GLUCAGON

/AP/	/LILLY/	/EQ 1MG BASE/VIAL/	/N12122/001/
/AP/	/QUAD/	/EQ 1MG BASE/VIAL/	/N71022/001/ /MAR/04,/1987/

LILLY — EQ 1MG BASE/VIAL — N12122 001
∂ QUAD — EQ 1MG BASE/VIAL — N71022 001 MAR 04, 1987

GLUTETHIMIDE

CAPSULE; ORAL
DORIDEN

/∂/RHONE/POULENC/RORER//500MG/			/N09519/008/

GLYBURIDE

TABLET; ORAL
/GLYBATE/

/BX/	/HOECHST/ROUSSEL/	/1.5MG/	/N20055/001/ /APR/17,/1992/
/BX/		/3MG/	/N20055/002/ /APR/17,/1992/

∂ HOECHST ROUSSEL — 1.5MG — N20055 001 APR 17, 1992
∂ — 3MG — N20055 002 APR 17, 1992

GLYBURIDE

TABLET; ORAL
GLYNASE
/BX/ /UPJOHN/ /1.5MG/ /N20051/001/ /MAR/04/1992/
/+/ /3MG/ /N20051/002/ /MAR/04/1992/
+ UPJOHN 6MG N20051 004 SEP 24, 1993
1.5MG N20051 001 MAR 04, 1992
3MG N20051 002 MAR 04, 1992
4.5MG N20051 003 SEP 24, 1993

GONADORELIN ACETATE

INJECTABLE; INJECTION
LUTREPULSE KIT
+ FERRING 0.8MG/VIAL N19687 001 OCT 10, 1989
+ 3.2MG/VIAL N19687 002 OCT 10, 1989
/LUTREPULSE/PUMP/KIT/ /FERRING/ /0.8MG/VIAL/ /N19687/001/ /OCT/10/1989/
/3.2MG/VIAL/ /N19687/002/ /OCT/10/1989/

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION
CHORIONIC GONADOTROPIN
/AP/ /BEL/MAR/ /5,000 UNITS/VIAL/ /N17054/001/
/AP/ /10,000 UNITS/VIAL/ /N17054/002/
∂ BEL MAR 5,000 UNITS/VIAL N17054 001
∂ 10,000 UNITS/VIAL N17054 002
/FOLLUTEIN/
/AP/ /SQUIBB/ /10,000 UNITS/VIAL/ /N17056/001/
∂ SQUIBB 10,000 UNITS/VIAL N17056 001

GOSERELIN ACETATE

IMPLANT; IMPLANTATION
ZOLADEX
/+//IMPERIAL/CHEM/ /EQ/3.6MG/BASE/ /N19726/001/ /DEC/29/1989/

GOSERELIN ACETATE

IMPLANT; IMPLANTATION
ZOLADEX
+ ZENECA EQ 3.6MG BASE N19726 001 DEC 29, 1989

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
/NEO-POLYCIN/
/AT/ /DOW/ /0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML/ /N60427/001/
∂ DOW 0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML N60427 001

>ADD> GRANISETRON HYDROCHLORIDE

>ADD> INJECTABLE; INJECTION
>ADD> KYTRIL
>ADD> + SMITHKLINE BEECHAM EQ 3MG BASE/ML N20239 001 DEC 29, 1993
>ADD>

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE; ORAL
GRISACTIN
/WYETH/AYERST/ /125MG/ /N50051/002/
∂ WYETH AYERST 125MG N50051 002

GUANIDINE HYDROCHLORIDE

TABLET; ORAL
GUANIDINE HCL
>DLT> /KEY/PHARMS/ /125MG/ /N01546/001/
>ADD> SCHERING 125MG N01546 001

HALOFANTRINE HYDROCHLORIDE

/TABLET;ORAL/
/HALFAN/
/+//SMITHKLINE/BEECHAM/ /250MG/ /N20250/001/ /JUL/24/1992/
∂ SMITHKLINE BEECHAM 250MG N20250 001 JUL 24, 1992

HALOPERIDOL

TABLET; ORAL
HALOPERIDOL

/AB/	/LEDERLE/	/0.5MG/	/N72727/001/ /SEP/19,/1989/
/AB/		/1MG/	/N72728/001/ /SEP/19,/1989/
/AB/		/2MG/	/N72729/001/ /SEP/19,/1989/
/AB/		/5MG/	/N72730/001/ /SEP/19,/1989/
/AB/		/10MG/	/N72731/001/ /SEP/19,/1989/
/AB/		/20MG/	/N72732/001/ /SEP/19,/1989/
	∂ LEDERLE	0.5MG	N72727 001 SEP 19, 1989
	∂	1MG	N72728 001 SEP 19, 1989
	∂	2MG	N72729 001 SEP 19, 1989
	∂	5MG	N72730 001 SEP 19, 1989
	∂	10MG	N72731 001 SEP 19, 1989
	∂	20MG	N72732 001 SEP 19, 1989

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
HALOPERIDOL

	∂ PENNEX PHARMS	EQ 2MG BASE/ML	N70710 001 MAR 07, 1986
AA	PHARM ASSOC	EQ 2MG BASE/ML	N73037 001 FEB 26, 1993
/AA/	/PHARM/BASICS/	/EQ 2MG BASE/ML/	/N70710/001/ /MAR/07,/1986/
AA	SILARX	EQ 2MG BASE/ML	N73364 001 SEP 28, 1993

INJECTABLE; INJECTION
HALOPERIDOL

AP	MARSAM	EQ 5MG BASE/ML	N72516 001 FEB 25, 1993
AP		EQ 5MG BASE/ML	N72517 001 FEB 25, 1993

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

/AP/	/SMITH/NEPHEW/SOLOPAK/	/EQ 5MG BASE/ML/	/N70801/001/ /DEC/14,/1987/
/AP/		/EQ 5MG BASE/ML/	/N70864/001/ /DEC/14,/1987/
AP	SOLOPAK	EQ 5MG BASE/ML	N70801 001 DEC 14, 1987
AP		EQ 5MG BASE/ML	N70864 001 DEC 14, 1987

HEPARIN SODIUM

INJECTABLE; INJECTION
LIQUAEMIN SODIUM

/AP/	/ORGANON/	/20,000 UNITS/ML/	/N00552/001/
/AP/		/40,000 UNITS/ML/	/N00552/002/
	∂ ORGANON	20,000 UNITS/ML	N00552 001
	∂	40,000 UNITS/ML	N00552 002

HEXACHLOROPHENE

AEROSOL; TOPICAL
/TURGEX/

	/XTTRIUM/	/3%/	/N18375/001/
	∂ XTTRIUM	3%	N18375 001

EMULSION; TOPICAL
/HEXA-GERM/

/AT/	/HUNTINGTON/	/3%/	/N17411/001/
	∂ HUNTINGTON	3%	N17411 001

PHISOHEX

/AT/	/STERLING/	/3%/	/N08402/001/
	∂ STERLING	3%	N08402 001

/TURGEX/

/AT/	/XTTRIUM/	/3%/	/N19055/001/ /NOV/30,/1984/
	∂ XTTRIUM	3%	N19055 001 NOV 30, 1984

/SOLUTION;/TOPICAL/
/DIAL/

/AT/	/ARMOUR/DIAL/	/0.25%/	/N17421/002/
	∂ DIAL	0.25%	N17421 002

/GERMA-MEDICA/

	/HUNTINGTON/	/1%/	/N17412/001/
	∂ HUNTINGTON	1%	N17412 001

HEXACHLOROPHENE

/SOLUTION;/TOPICAL/
/GERMA-MEDICA/'MG'/
/HUNTINGTON/ /0.25%/ /N17412/002/
@ HUNTINGTON 0.25% N17412 002

SPONGE; TOPICAL
/HEXASCRUB/
/AT/ /PROF/DSPLS/ /3%/ /N18363/001/
@ PROF DSPLS 3% N18363 001
/PHISO-SCRUB/
/AT/ /STERLING/ /3%/ /N17446/001/
@ STERLING 3% N17446 001
/SCRUBTEAN/SURGICAL/SPONGEBRUSH/
/3M/ /330MG/ /N17413/001/
@ 3M 330MG N17413 001

HEXAFLUORENIUM BROMIDE

/INJECTABLE;/INJECTION/
/HYLAXEN/
/WALLACE/ /20MG/ML/ /N09789/003/
@ WALLACE 20MG/ML N09789 003

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION
HISTAMINE PHOSPHATE
/LILLY/ /EQ 0.1MG BASE/ML/ /N00734/003/
@ LILLY EQ 0.1MG BASE/ML N00734 003
@ /EQ 0.2MG BASE/ML/ /N00734/002/
EQ 0.2MG BASE/ML N00734 002
@ /EQ 1MG BASE/ML/ /N00734/001/
EQ 1MG BASE/ML N00734 001

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL
MYCODONE
AA PENNEX PHARMS 1.5MG/5ML;5MG/5ML N88008 001
MAR 03, 1983
/AA/ /PHARM/BASICS/ /1.5MG/5ML;5MG/5ML/ /N88008/001/
/MAR/03,/1983/

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
APRESOLINE
AP + CIBA 20MG/ML N08303 003
/20MG/ML/ /N08303/003/
HYDRALAZINE HCL
/3/SMITH/NEPHEW/SOLOPAK/20MG/ML/ /N88517/001/
/AUG/22,/1985/
AP SOLOPAK 20MG/ML N88517 001
AUG 22, 1985

HYDRALAZINE HYDROCHLORIDE; RESERPINE

/TABLET;/ORAL/
/SERPASIL-APRESOLINE/
/+//CIBA/ /50MG;0.2MG/ /N09296/002/
/25MG;0.1MG/ /N09296/004/
@ CIBA 25MG;0.1MG N09296 004
@ 50MG;0.2MG N09296 002

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL
HYDROCHLOROTHIAZIDE
@ PENNEX PHARMS 50MG/5ML N89661 001
JUN 20, 1988
/AA/ /PHARM/BASICS/ /50MG/5ML/ /N89661/001/
/JUN/20,/1988/
/AA/ /ROXANE/ /50MG/5ML/ /N88587/001/
/JUL/02,/1984/
ROXANE 50MG/5ML N88587 001
JUL 02, 1984

TABLET; ORAL
HYDROCHLOROTHIAZIDE
/AB/ /INWOOD/ /25MG/ /N84776/001/
/AB/ /50MG/ /N84776/002/
@ INWOOD 25MG N84776 001
@ 50MG N84776 002
/AB/ /LEMMON/ /25MG/ /N88924/001/
/FEB/07,/1985/
/AB/ /50MG/ /N88923/001/
/FEB/07,/1985/
@ LEMMON 25MG N88924 001
FEB 07, 1985
@ 50MG N88923 001
FEB 07, 1985
/AB/ /PHARMAFAIR/ /25MG/ /N84325/001/
/AB/ /50MG/ /N84324/001/

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	PHARMERAL	25MG	N84325 001
AB		50MG	N84324 001

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

/AB/	/SCHERING/	/25MG;100MG/	/N19046/001/ /APR/06,/1987/
/AB/		/25MG;200MG/	/N19046/002/ /APR/06,/1987/
/AB//+/		/25MG;300MG/	/N19046/003/ /APR/06,/1987/
	+ SCHERING	25MG;300MG	N19046 003 APR 06, 1987
		25MG;100MG	N19046 001 APR 06, 1987
		25MG;200MG	N19046 002 APR 06, 1987

/TRANDATE HCT/

/AB/	/GLAXO/	/25MG;100MG/	/N19174/001/ /APR/10,/1987/
/AB/		/25MG;200MG/	/N19174/002/ /APR/10,/1987/
/AB/		/25MG;300MG/	/N19174/003/ /APR/10,/1987/
	∂ GLAXO	25MG;100MG	N19174 001 APR 10, 1987
	∂	25MG;200MG	N19174 002 APR 10, 1987
	∂	25MG;300MG	N19174 003 APR 10, 1987

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

PRINZIDE 10-12,5

AB	MERCK	12.5MG;10MG	N19778 003 NOV 18, 1993

/PRINZIDE 12.5/

/AB/	/MERCK/	/12.5MG;20MG/	/N19778/001/ /FEB/16,/1989/

PRINZIDE 20-12,5

AB	MERCK	12.5MG;20MG	N19778 001 FEB 16, 1989

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

PRINZIDE 20-25

AB	+ MERCK	25MG;20MG	N19778 002 FEB 16, 1989

/PRINZIDE 25/

/AB//+/	/MERCK/	/25MG;20MG/	/N19778/002/ /FEB/16,/1989/

ZESTORETIC 10-12,5

AB	ZENECA	12.5MG;10MG	N19888 003 NOV 18, 1993

ZESTORETIC 20-12,5

AB	ZENECA	12.5MG;20MG	N19888 001 SEP 20, 1990

ZESTORETIC 20-25

AB	ZENECA	25MG;20MG	N19888 002 JUL 20, 1989

ZESTORETIC 20/12,5

/AB/	/ZENECA/	/12.5MG;20MG/	/N19888/001/ /SEP/20,/1990/

ZESTORETIC 20/25

/AB/	/ZENECA/	/25MG;20MG/	/N19888/002/ /JUL/20,/1989/

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDROCHLOROTHIAZIDE W/ RESERPINE

/∂/	/PHARMAFAIR/	/25MG;0.125MG/	/N85421/001/
/∂/		/50MG;0.125MG/	/N85420/001/
	∂ PHARMERAL	25MG;0.125MG	N85421 001
	∂	50MG;0.125MG	N85420 001

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

/AB/	/UPSHER/SMITH/	/25MG;25MG/	/N87553/001/
	∂ UPSHER SMITH	25MG;25MG	N87553 001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS	25MG;37.5MG	N73449 001 SEP 23, 1993

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	BARRE	2.5%	N89682 001 MAR 10, 1988
/AT/	/BIOCRAFT/	/0.5%/	/N80400/002/
/AT/		/1%/	/N80400/003/
/AT/		/2.5%/	/N80400/004/
	∂ BIOCRAFT	0.5%	N80400 002
	∂	1%	N80400 003
	∂	2.5%	N80400 004
/AT/	/NASKA/	/2.5%/	/N89682/001/ MAR 10, 1988
/AT/	/PHARMADERM/	/1%/	/N88845/001/ FEB 27, 1986
	∂ PHARMADERM	1%	N88845 001 FEB 27, 1986

/INJECTABLE;/INJECTION/

/CORTEF/

/UPJOHN/	/50MG/ML/	/N09864/001/
∂ UPJOHN	50MG/ML	N09864 001

LOTION; TOPICAL

ACTICORT

AT	BAKER NORTON	1%	N86535 001
/AT/	/KEY/PHARMS/	/1%/	/N86535/001/

/BALNEOL-HC/

/AT/	/SOLVAY/	/1%/	/N88041/001/ DEC 03, 1982
	∂ SOLVAY	1%	N88041 001 DEC 03, 1982

OINTMENT; TOPICAL

HYDROCORTISONE

AT	FOUGERA	2.5%	N81203 001 MAY 28, 1993
/AT/	/PHARMADERM/	/1%/	/N88842/001/ FEB 09, 1987
	∂ PHARMADERM	1%	N88842 001 FEB 09, 1987

TABLET; ORAL

HYDROCORTISONE

∂ FERRANTE	10MG	N80568 001
∂	20MG	N80568 002
/BP/ /MK/	/10MG/	/N80568/001/
/BP/	/20MG/	/N80568/002/

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION; OTIC

/NEOMYCIN SULFATE; POLYMYXIN B SULFATE & HYDROCORTISONE/

/AT/	/PHARMAFAIR/	/1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML/	/N62617/001/ SEP 18, 1985/
	∂ PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62617 001 SEP 18, 1985

SUSPENSION/DROPS; OPHTHALMIC

/NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE/

/AT/	/PHARMAFAIR/	/1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML/	/N62623/001/ SEP 24, 1985/
	∂ PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62623 001 SEP 24, 1985

HYDROCORTISONE ACETATE

INJECTABLE; INJECTION

HYDROCORTISONE ACETATE

/BP/	/BEL/MAR/	/25MG/ML/	/N83739/001/
/BP/		/50MG/ML/	/N83739/002/
	∂ BEL MAR	25MG/ML	N83739 001
	∂	50MG/ML	N83739 002

/OINTMENT;/TOPICAL/

/CORTEF/ACETATE/

/UPJOHN/	/EQ/1%/BASE/	/N08917/002/
	/2.5%/	/N08917/001/
∂ UPJOHN	EQ 1% BASE	N08917 002
∂	2.5%	N08917 001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

OINTMENT; TOPICAL

NEO-CORTEF

/UPJOHN/	/0.5%;EQ/3.5MG/BASE/GM/	/N60751/001/
∂ UPJOHN	0.5%;EQ 3.5MG BASE/GM	N60751 001
	/2.5%;EQ/3.5MG/BASE/GM/	/N60751/003/
∂	2.5%;EQ 3.5MG BASE/GM	N60751 003

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

LOTION; TOPICAL

	PRAMOSONE		
/FERNDALE/	/0.5%;1%/	/N83213/002/	
∂ FERNDALE	0.5%;1%	N83213 002	

HYDROCORTISONE BUTYRATE

/OINTMENT;TOPICAL/

	/LOCOID/		
/+//GALDERMA/	/0.1%/	/N19106/001/	
		/JUL/03/1984/	
∂ GALDERMA	0.1%	N19106 001	
		JUL 03, 1984	

HYDROFLUMETHIAZIDE

TABLET; ORAL

	SALURON		
/AB//+//BRISTOL/	/50MG/	/N11949/001/	
AB + ROBERTS	50MG	N11949 001	

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

	SALUTENSIN		
/BP/+//BRISTOL/	/50MG;0.125MG/	/N12359/003/	
BP + ROBERTS	50MG;0.125MG	N12359 003	
	SALUTENSIN-DEMI		
	/BRISTOL/	/25MG;0.125MG/	/N12359/004/
	ROBERTS	25MG;0.125MG	N12359 004

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

	HYDROXOMIN		
/AP/	/BEL/MAR/	/1MG/ML/	/N84629/001/
	∂ BEL MAR	1MG/ML	N84629 001

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDROXYZINE HCL		
AP	FUJISAWA	25MG/ML	N88184 001
			MAR 31, 1983
AP		50MG/ML	N88185 001
			MAR 31, 1983

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDROXYZINE HCL		
/AP/	/LYPHOMED/	/25MG/ML/	/N88184/001/
			/MAR/31/1983/
/AP/		/50MG/ML/	/N88185/001/
			/MAR/31/1983/
/AP/	/WYETH/AYERST/	/25MG/ML/	/N86258/001/
/AP/		/50MG/ML/	/N86258/002/
	∂ WYETH AYERST	25MG/ML	N86258 001
	∂	50MG/ML	N86258 002

SYRUP; ORAL

	HYDROXYZINE HCL		
AA	BARRE	10MG/5ML	N88785 001
			FEB 03, 1988
/AA/	/NASKA/	/10MG/5ML/	/N88785/001/
			/FEB/03/1988/
AA	PENNEX PHARMS	10MG/5ML	N87294 001
			APR 12, 1982
/AA/	/PHARM/BASICS/	/10MG/5ML/	/N87294/001/
			/APR/12/1982/

TABLET; ORAL

	HYDROXYZINE HCL		
/AA/	/CHELSEA/	/10MG/	/N86827/001/
/AA/		/25MG/	/N86829/001/
/AA/		/50MG/	/N86836/001/
	∂ CHELSEA	10MG	N86827 001
	∂	25MG	N86829 001
	∂	50MG	N86836 001

HYDROXYZINE PAMOATE

CAPSULE; ORAL

		HYDROXYZINE PAMOATE		
>DLT >/AA/	/CHELSEA/	/EQ 25MG HCL/	/N86840/001/
>DLT >			/JUL/01/1982/
>DLT >/AA/		/EQ 50MG HCL/	/N86705/001/
>DLT >			/JUL/01/1982/
>ADD >	∂ CHELSEA	EQ 25MG HCL	N86840 001
>ADD >			JUL 01, 1982
>ADD >	∂	EQ 50MG HCL	N86705 001
>ADD >			JUL 01, 1982

IBUPROFEN

TABLET; ORAL

IBUPROFEN

AB	NORTON HN	400MG	N71145 001 SEP 23, 1986
AB		600MG	N71146 001 SEP 23, 1986
AB		800MG	N71769 001 MAY 08, 1987

IBUPROFEN

/AB/	/PAR/	/400MG/	/N70328/001/ /AUG/06,/1985/
	∂ PAR	300MG	N70328 001 AUG 06, 1985

/IFEN/

/AB/	/LUCHEN/	/400MG/	/N71145/001/ /SEP/23,/1986/
/AB/		/600MG/	/N71146/001/ /SEP/23,/1986/
/AB/		/800MG/	/N71769/001/ /MAY/08,/1987/

IDOXURIDINE

/OINTMENT;/OPHTHALMIC/

/STOXIL/

/+//SMITHKLINE/BEECHAM/	/0.5%/	/N15868/001/
∂ SMITHKLINE BEECHAM	0.5%	N15868 001

SOLUTION/DROPS; OPHTHALMIC

/STOXIL/

/AT/ /SMITHKLINE/BEECHAM/	/0.1%/	/N13934/001/
∂ SMITHKLINE BEECHAM	0.1%	N13934 001

INDAPAMIDE

TABLET; ORAL

LOZOL

RHONE POULENC RORER	1.25MG	N18538 002 APR 29, 1993

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

>DLT >/AB/	/CHELSEA/	/50MG/	/N71635/001/ /MAY/18,/1987/
>DLT >			
>ADD >	∂ CHELSEA	50MG	N71635 001 MAY 18, 1987
>ADD >			

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION

IODOHIPPURATE SODIUM I 131

/AP/	/CIS/	/0.2MCI/ML/	/N17313/001/
AP	SORIN	0.2MCI/ML	N17313 001

IOHEXOL

/INJECTABLE;/INJECTION/

/OMNIPAQUE/180/

/STERLING/	/38.8%/	/N18956/001/ /DEC/26,/1985/

/SOLUTION;/INJECTION,/ORAL/

/OMNIPAQUE/240/

/STERLING/	/51.8%/	/N18956/002/ /DEC/26,/1985/

/OMNIPAQUE/300/

/STERLING/	/64.7%/	/N18956/003/ /DEC/26,/1985/

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 180

+ STERLING	38.8%	N18956 001 DEC 26, 1985

OMNIPAQUE 240

+ STERLING	51.8%	N18956 002 DEC 26, 1985

OMNIPAQUE 300

+ STERLING	64.7%	N18956 003 DEC 26, 1985

IOTROLAN

/INJECTABLE;/INTRATHECAL/
/OSMOVIST/
/BERLEX/ /EQ/190MG/IODINE/ML/ /N19580/001/ /DEC/07,/1989/
/EQ/240MG/IODINE/ML/ /N19580/002/ /DEC/07,/1989/
∂ BERLEX EQ 190MG IODINE/ML N19580 001 DEC 07, 1989
∂ EQ 240MG IODINE/ML N19580 002 DEC 07, 1989

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
ATROVENT
+ BOEHRINGER INGELHEIM 0.02% N20228 001 SEP 29, 1993

IRON DEXTRAN

INJECTABLE; INJECTION
> DLT > /INFERON/
> DLT > /∂/FISONS/ /EQ/50MG/IRON/ML/ /N10787/002/
INFED
BP + SCHEIN PHARM EQ 50MG IRON/ML N17441 001
> ADD > IRON DEXTRAN
> ADD > ∂ FISONS EQ 50MG IRON/ML N10787 002
/IRON/DEXTRAN/
/BP/ /STERIS/ /EQ/50MG/IRON/ML/ /N17441/001/

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL
/AN/ /ASTRA/ /0.125%/ /N87936/001/ /NOV/15,/1982/
/0.062%/ /N87937/001/ /NOV/15,/1982/
∂ ASTRA 0.062% N87937 001 NOV 15, 1982
∂ 0.125% N87938 001 NOV 15, 1982
/AN/ /PARKE/DAVIS/ /1%/ /N85889/001/
/0.5%/ /N85997/001/
∂ PARKE DAVIS 0.5% N85997 001
∂ 1% N85889 001

ISOFLURANE

LIQUID; INHALATION
FORANE
AN + ANAQUEST 99.9% N17624 001
ISOFLURANE
AN ABBOTT 99.9% N74097 001 JAN 25, 1993

ISONIAZID

INJECTABLE; INJECTION
NYDRAZID
+ APOTHECON 100MG/ML N08662 001
/SQUIBB/ /100MG/ML/ /N08662/001/

TABLET; ORAL
ISONIAZID
/AA/ /EON/LABS/ /100MG/ /N08678/002/
AA + EON LABS 100MG N08678 002
/AA/ /300MG/ /N08678/003/
AA + 300MG N08678 003
> DLT >/AA/ /MK/ /100MG/ /N80941/001/
> ADD > ∂ MK 100MG N80941 001
> DLT >/AA/ /PHARMAVITE/ /100MG/ /N85091/001/
> ADD > ∂ PHARMAVITE 100MG N85091 001
/STANDITOE/
/AA/ /EVERYLIFE/ /300MG/ /N80126/002/
∂ EVERYLIFE 300MG N80126 002

ISOPROPAMIDE IODIDE

/TABLET;/ORAL/
/DARBID/
/SMITHKLINE/BEECHAM/ /EQ/5MG/BASE/ /N10744/001/
∂ SMITHKLINE BEECHAM EQ 5MG BASE N10744 001

ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION
AEROLONE
/AN/ /LILLY/ /0.25%/ /N87245/001/
+ LILLY 0.25% N07245 001
/ISOPROTERENOL HCL/
/AN/ /PARKE/DAVIS/ /0.25%/ /N85994/001/
/AN/ /0.5%/ /N85540/001/
∂ PARKE DAVIS 0.25% N85994 001
∂ 0.5% N85540 001

ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

	ISUPREL		
/AN/	/STERLING/	/0.5%/	/N06327/002/
	+ STERLING WINTHROP	0.5%	N06327 002
	/YARD-TSO/		
/AN/	/FISONS/	/0.5%/	/N16813/001/
	∂ FISONS	0.5%	N16813 001

TABLET; RECTAL, SUBLINGUAL

	ISUPREL		
	/STERLING/	/15MG/	/N06328/002/
	∂ STERLING	15MG	N06328 002

ISOSORBIDE DINITRATE

TABLET; ORAL

	SORBITRATE		
/AB/	/ICI/	/10MG/	/N86405/002/ AUG 21, 1990
/AB/		/30MG/	/N88124/001/ AUG 21, 1990
/AB/		/40MG/	/N88125/001/ AUG 21, 1990
AB	ZENECA	20MG	N86405 002 AUG 21, 1990
AB		30MG	N88124 001 AUG 21, 1990
AB		40MG	N88125 001 AUG 21, 1990

ISOSORBIDE MONONITRATE

TABLET; ORAL

	ISMO		
/AB//+//WYETH/		/20MG/	/N19091/001/ DEC 30, 1991
BX +	WYETH	20MG	N19091 001 DEC 30, 1991
	MONOKET		
BX	SCHWARZ PHARMA	20MG	N20215 001 JUN 30, 1993
		10MG	N20215 002 JUN 30, 1993

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

	IMDUR		
	∂ SCHERING PLOUGH	30MG	N20225 001 AUG 12, 1993
		60MG	N20225 002 AUG 12, 1993

KANAMYCIN SULFATE

CAPSULE; ORAL

	KANTREX		
	APOTHECON	EQ 500MG BASE	N62726 001 MAR 06, 1987
	/BRISTOL/	/EQ 500MG BASE/	/N62726/001/ /MAR 06, 1987/

INJECTABLE; INJECTION

	KANTREX		
AP	APOTHECON	EQ 75MG BASE/2ML	N61901 003
AP		EQ 500MG BASE/2ML	N61901 001
AP		EQ 1GM BASE/3ML	N61901 002
/AP/	/BRISTOL/	/EQ 75MG BASE/2ML/	/N61901/003/
/AP/		/EQ 500MG BASE/2ML/	/N61901/001/
/AP/		/EQ 1GM BASE/3ML/	/N61901/002/
	/KLEBCIL/		
/AP/	/SMITHKLINE/BEECHAM/	/EQ 75MG BASE/2ML/	/N62170/001/
/AP/		/EQ 500MG BASE/2ML/	/N62170/002/
/AP/		/EQ 1GM BASE/3ML/	/N62170/003/
	∂ SMITHKLINE BEECHAM	EQ 75MG BASE/2ML	N62170 001
	∂	EQ 500MG BASE/2ML	N62170 002
	∂	EQ 1GM BASE/3ML	N62170 003

KETOPROFEN

CAPSULE; ORAL

	KETOPROFEN		
AB	LEDERLE	25MG	N74014 001 JAN 29, 1993
AB		50MG	N74014 002 JAN 29, 1993
AB		75MG	N74014 003 JAN 29, 1993

CAPSULE, EXTENDED RELEASE; ORAL

	ORUVAIL		
	+ WYETH AYERST	200MG	N19816 001 SEP 24, 1993

LACTULOSE

SOLUTION; ORAL

/CEPHULAC/					
/AA/	/MERRELL/DOW/	/10GM/15ML/	/N17657/001/		
/ENULOSE/					
/AA/	/BARRE/	/10GM/15ML/	/N71548/001/ AUG/15,/1988/		
EVALOSE					
AA	COPLEY	10GM/15ML	N73497 001 MAY 28, 1993		
LACTULOSE					
∂	PENNEX PHARMS	10GM/15ML	N71841 001 SEP 22, 1988	> ADD >	
/AA/	/PHARM/BASICS/	/10GM/15ML/	/N71841/001/ /SEP/22,/1988/	> ADD >	
				> DLT >	
				> DLT >	
/LACTULOSE/					
	/SOLVAY/	/10GM/15ML/	/N17906/001/		
LAXILOSE					
AA	TECHNILAB	10GM/15ML	N73686 001 MAY 28, 1993		

SOLUTION; ORAL, RECTAL

ACILAC			
AA	TECHNILAB	10GM/15ML	N73685 001 MAY 28, 1993
CEPHULAC			
AA	MERRELL DOW	10GM/15ML	N17657 001
ENULOSE			
AA	BARRE	10GM/15ML	N71548 001 AUG 15, 1988
GENERLAC			
/AA/	/PHARM/BASICS/	/10GM/15ML/	/N71842/001/ /SEP/27,/1988/
∂	PENNEX PHARMS	10GM/15ML	N71842 001 SEP 27, 1988
HEPTALAC			
AA	COPLEY	10GM/15ML	N73504 001 MAY 28, 1993
LACTULOSE			
∂	SOLVAY	10GM/15ML	N17906 001
/PORTALAC/			
/AA/	/SOLVAY/	/10GM/15ML/	/N72374/001/ /MAR/22,/1989/
∂	SOLVAY	10GM/15ML	N72374 001 MAR 22, 1989

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

AP	GENSIA	EQ 50MG BASE/VIAL	N81278 001 SEP 28, 1993
AP		EQ 100MG BASE/VIAL	N81277 001 SEP 28, 1993

POWDER FOR RECONSTITUTION; ORAL

LEUCOVORIN CALCIUM

	IMMUNEX	EQ 60MG BASE/VIAL	N08107 003 JAN 30, 1987
	/LEDERLE/	/EQ/60MG/BASE/VIAL/	/N08107/003/ /JAN/30,/1987/

TABLET; ORAL

LEUCOVORIN CALCIUM

AB	IMMUNEX	EQ 10MG BASE	N71962 001 NOV 19, 1987
AB +		EQ 15MG BASE	N71104 001 MAR 04, 1987
BX		EQ 5MG BASE	N18459 001 JAN 30, 1986
/AB/	/LEDERLE/	/EQ 10MG BASE/	/N71962/001/ /NOV/19,/1987/
/AB/+/		/EQ 15MG BASE/	/N71104/001/ /MAR/04,/1987/
/BX/		/EQ/5MG/BASE/	/N18459/001/ /JAN/30,/1986/
AB	ROXANE	EQ 5MG BASE	N72733 001 FEB 22, 1993
AB		EQ 10MG BASE	N72734 001 FEB 22, 1993
AB		EQ 15MG BASE	N72735 001 FEB 22, 1993
AB		EQ 25MG BASE	N72736 001 FEB 22, 1993

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON

/+//TAP/		/1MG/0.2ML/	/N19010/001/ /APR/09,/1985/
+	TAP	5MG/ML	N19010 001 APR 09, 1985
		5MG/ML	N20263 001 APR 16, 1993

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON DEPOT
+ TAP 3.75MG/VIAL N20011 001 OCT 22, 1990
+ 7.5MG/VIAL N19732 001 JAN 26, 1989
/3.75MG/VIAL/ /N20011/001/ /OCT/22,/1990/
/7.5MG/VIAL/ /N19732/001/ /JAN/26,/1989/

LUPRON DEPOT-PED
+ TAP 3.75MG/VIAL&7.5MG/VIAL N20263 003 APR 16, 1993
+ 7.5MG/VIAL&7.5MG/VIAL N20263 004 APR 16, 1993
+ 7.5MG/VIAL N20263 002 APR 16, 1993

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
LIVOSTIN
+ IOLAB EQ 0.05% BASE N20219 001 NOV 10, 1993

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL
ORLAAM
BIODEVELOPMENT 10MG/ML N20315 001 JUL 09, 1993
/BIOMETRICS/RES/ /10MG/ML/ /N20315/001/ /JUL/09,/1993/

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/RAVOCAINE/AND/NOVOCAIN/W/NEO-COBEFRIN/
/COOK/WAITE/ /0.05MG/ML;2%;0.4%/ /N08592/001/
@ STERLING WINTHROP 0.05MG/ML;2%;0.4% N08592 007

LIDOCAINE

/SUPPOSITORY;/RECTAL/
/XYLOCAINE/
/ASTRA/ /100MG/ /N13077/001/

LIDOCAINE

/SUPPOSITORY;/RECTAL/
/XYLOCAINE/
@ ASTRA 100MG N13077 001

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL
/AP/ /ABBOTT/ /10%/ /N87980/001/ /FEB/02,/1983/
@ ABBOTT 10% N87980 001 FEB 02, 1983
/AP/ /BEL/MAR/ /1%/ /N80710/001/
/AP/ /2%/ /N80760/001/
@ BEL MAR 1% N80710 001
@ 2% N80760 001
/AP/ /BRISTOL/ /1%/ /N80390/001/
/AP/ /2%/ /N80390/002/
AP FUJISAWA 1% N80404 002
AP 2% N80404 003
@ 1% N80390 001
@ 2% N80390 002
/AP/ /LYPHOMED/ /1%/ /N80404/002/
/AP/ /1%/ /N86761/001/
/AP/ /2%/ /N80404/003/
/AP/ /2%/ /N86761/002/
@ LYPHOMED 1% N86761 001
@ 2% N86761 002

JELLY; TOPICAL
LIDOCAINE HCL
AT COPLEY 2% N81318 001 APR 29, 1993

SOLUTION; ORAL
MYLOCAINE
AT PENNEX PHARMS 2% N87872 001 NOV 18, 1982
/AT/ /PHARM/BASICS/ /2%/ /N87872/001/ /NOV/18,/1982/

SOLUTION; TOPICAL
/MYLOCAINE/
/AT/ /PHARM/BASICS/ /4%/ /N87881/001/ /NOV/18,/1982/
@ PENNEX PHARMS 4% N87881 001 NOV 18, 1982

LINDANE

LOTION; TOPICAL
LINDANE

AT	PENNEX PHARMS	1%		N88190 001 AUG 16, 1984
/AT/	/PHARM/BASICS/	/1%/		/N88190/001/ /AUG/16,/1984/

SHAMPOO; TOPICAL
LINDANE

AT	PENNEX PHARMS	1%		N88191 001 SEP 18, 1984
/AT/	/PHARM/BASICS/	/1%/		/N88191/001/ /SEP/18,/1984/

LIOTRIX (T4;T3)

TABLET; ORAL
THYROLAR-0.25

	FOREST LABS	0.0125MG;0.0031MG		N16807 001
	/RHONE/POULENC/RORER/	/0.0125MG;0.0031MG/		/N16807/001/

THYROLAR-0.5

	FOREST LABS	0.025MG;0.00625MG		N16807 005
	/RHONE/POULENC/RORER/	/0.025MG;0.00625MG/		/N16807/005/

THYROLAR-1

	FOREST LABS	0.05MG;0.0125MG		N16807 004
	/RHONE/POULENC/RORER/	/0.05MG;0.0125MG/		/N16807/004/

THYROLAR-2

	FOREST LABS	0.1MG;0.025MG		N16807 002
	/RHONE/POULENC/RORER/	/0.1MG;0.025MG/		/N16807/002/

THYROLAR-3

+	FOREST LABS	0.15MG;0.0375MG		N16807 003
/+/	/RHONE/POULENC/RORER/	/0.15MG;0.0375MG/		/N16807/003/

THYROLAR-5

@	FOREST LABS	0.25MG;0.0625MG		N16807 006
/@/	/RHONE/POULENC/RORER/	/0.25MG;0.0625MG/		/N16807/006/

LISINOPRIL

TABLET; ORAL
ZESTRIL

/AB/	/IMPERIAL/CHEM/	/5MG/		/N19777/001/ /MAY/19,/1988/
/AB/		/10MG/		/N19777/002/ /MAY/19,/1988/
/AB/		/20MG/		/N19777/003/ /MAY/19,/1988/
/AB/+/		/40MG/		/N19777/004/ /MAY/19,/1988/

LISINOPRIL

TABLET; ORAL
ZESTRIL

AB	ZENECA	5MG		N19777 001 MAY 19, 1988
AB		10MG		N19777 002 MAY 19, 1988
AB		20MG		N19777 003 MAY 19, 1988
AB	+	40MG		N19777 004 MAY 19, 1988
		2.5MG		N19777 005 APR 29, 1993

LITHIUM CARBONATE

TABLET; ORAL
/ESKALITH/

/AB/	/+//SMITHKLINE/BEECHAM/	/300MG/		/N17971/001/
	@ SMITHKLINE BEECHAM	300MG		N17971 001

LITHANE

/AB/	/MILES/	/300MG/		/N16833/001/ /JUL/18,/1985/
	@ MILES	300MG		N18833 001 JUL 18, 1985
	/@/ROBERIG/	/300MG/		/N16834/001/

LITHIUM CARBONATE

AB	PFIZER	300MG		N16834 001

LITHIUM CITRATE

SYRUP; ORAL
LITHIUM CITRATE

AA	PENNEX PHARMS	EQ 300MG CARBONATE/5ML		N70755 001 MAY 21, 1986
/AA/	/PHARM/BASICS/	/EQ 300MG CARBONATE/5ML/		/N70755/001/ /MAY/21,/1986/

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC
ALOMIDE

+	ALCON	EQ 0.1% BASE		N20191 001 SEP 23, 1993

LORATADINE

TABLET; ORAL
CLARITIN
+ SCHERING 10MG N19658 001
APR 12, 1993

LORAZEPAM

TABLET; ORAL
LORAZEPAM
/AB/ /PAR/ /0.5MG/ /N70675/001/
/DEC/01,/1986/
/AB/ /1MG/ /N70676/001/
/DEC/01,/1986/
/AB/ /2MG/ /N70677/001/
/DEC/01,/1986/
∂ PAR 0.5MG N70675 001
DEC 01, 1986
∂ 1MG N70676 001
DEC 01, 1986
∂ 2MG N70677 001
DEC 01, 1986

MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLON
+ HICKAM EQ 85MG BASE/GM N16763 001
/STERLING/ /EQ/85MG/BASE/GM/ /N16763/001/

MANGANESE SULFATE

INJECTABLE; INJECTION
MANGANESE SULFATE
FUJISAWA EQ 0.1MG MANGANESE/ML N19228 001
MAY 05, 1987
/LYPHOMED/ /EQ/0.1MG/MANGANESE/ML/ /N19228/001/
/MAY/05,/1987/

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10% IN PLASTIC CONTAINER
AP MCGAW 10GM/100ML N20006 002
JUL 26, 1993

MANNITOL 15% IN PLASTIC CONTAINER
AP MCGAW 15GM/100ML N20006 003
JUL 26, 1993

MANNITOL

INJECTABLE; INJECTION
MANNITOL 20% IN PLASTIC CONTAINER
AP MCGAW 20GM/100ML N20006 004
JUL 26, 1993

MANNITOL 5% IN PLASTIC CONTAINER
AP MCGAW 5GM/100ML N20006 001
JUL 26, 1993

MASOPROCOL

CREAM; TOPICAL
ACTINEX
+ BLOCK DRUG 10% N19940 001
SEP 04, 1992
/+//CHEMEX/ /10%/ /N19940/001/
/SEP/04,/1992/

MEGESTROL ACETATE

SUSPENSION; ORAL
MEGACE
+ BRISTOL MYERS SQUIBB 40MG/ML N20264 001
SEP 10, 1993

MENADIOL SODIUM DIPHOSPHATE

/INJECTABLE;/INJECTION/
/SYNKAYVITE/
/ROCHE/ /5MG/ML/ /N03718/004/
/10MG/ML/ /N03718/006/
/37.5MG/ML/ /N03718/008/
∂ ROCHE 5MG/ML N03718 004
∂ 10MG/ML N03718 006
∂ 37.5MG/ML N03718 008

/TABLET;/ORAL/
/SYNKAYVITE/
/ROCHE/ /5MG/ /N03718/010/
∂ ROCHE 5MG N03718 010

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HCL

AP	ASTRA	10MG/ML	N81002 001 JUL 30, 1993
/AP/		/25MG/ML/	/N89781/001/ /MAR/31,/1989/
/AP/		/50MG/ML/	/N89782/001/ /MAR/31,/1989/
/AP/		/50MG/ML/	/N89783/001/ /MAR/31,/1989/
/AP/		/75MG/ML/	/N89785/001/ /MAR/31,/1989/
/AP/		/100MG/ML/	/N89786/001/ /MAR/31,/1989/
/AP/		/100MG/ML/	/N89787/001/ /MAR/31,/1989/
	∂	25MG/ML	N89781 001 MAR 31, 1989
	∂	50MG/ML	N89782 001 MAR 31, 1989
	∂	50MG/ML	N89783 001 MAR 31, 1989
	∂	75MG/ML	N89785 001 MAR 31, 1989
	∂	100MG/ML	N89786 001 MAR 31, 1989
	∂	100MG/ML	N89787 001 MAR 31, 1989
AP	INTL MEDICATION	10MG/ML	N81309 001 AUG 30, 1993

TABLET; ORAL
MEPERIDINE HCL

AA	HALSEY	50MG	N80448 001
AA		100MG	N80448 002
/AA/	/METHADOL/		
/AA/	/HALSEY/	/50MG/	/N80448/001/
/AA/		/100MG/	/N80448/002/

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

/AA/	/LEE/LABS/	/400MG/	/N89538/001/ /NOV/25,/1987/
	∂ LEE LABS	400MG	N89538 001 NOV 25, 1987
	/∂/PHARMAFAIR/	/400MG/	/N84153/001/
	∂ PHARMERAL	400MG	N84153 001

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL
PENTASA

+	MARION MERRELL DOW	250MG	N20049 001 MAY 10, 1993

MESTRANOL; NORETHINDRONE

/TABLET;/ORAL-28/			
/NORINYL/			
/SYNTEX/		/0.1MG;2MG/	/N13625/004/
∂ SYNTEX		0.1MG;2MG	N13625 004

TABLET; ORAL-21
NORETHIN 1/50M-21

AB	ROBERTS	0.05MG;1MG	N71539 001 APR 12, 1988
/AB/	/SCHIAPPARELLI/SEARLE/	0.05MG;1MG/	/N71539/001/ /APR/12,/1988/

TABLET; ORAL-28
NORETHIN 1/50M-28

AB	ROBERTS	0.05MG;1MG	N71540 001 APR 12, 1988
/AB/	/SCHIAPPARELLI/SEARLE/	0.05MG;1MG/	/N71540/001/ /APR/12,/1988/

MESTRANOL; NORETHYNODREL

/TABLET;/ORAL/			
/ENOVID/			
/-//SEARLE/		/0.15MG;9.85MG/	/N10976/005/
		/0.075MG;5MG/	/N10976/008/
	∂ SEARLE	0.075MG;5MG	N10976 008
	∂	0.15MG;9.85MG	N10976 005

METAPROTERENOL SULFATE

SOLUTION; INHALATION
METAPROTERENOL SULFATE

	∂ PENNEX PHARMS	5%	N72190 001 JUN 07, 1988
/AH/	/PHARM/BASICS/	/5%/	/N72190/001/ /JUN/07,/1988/

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE

AA	PENNEX PHARMS	10MG/5ML	N71656 001 OCT 13, 1987
/AA/	/PHARM/BASICS/	/10MG/5ML/	/N71656/001/ /OCT/13,/1987/

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

AP	FUJISAWA	EQ 10MG BASE/ML	N80431 001
AP		EQ 10MG BASE/ML	N80722 001
/AP/	/LYPHOMED/	/EQ 10MG BASE/ML/	/N80431/001/
/AP/		/EQ 10MG BASE/ML/	/N80722/001/

METHADONE HYDROCHLORIDE

TABLET; ORAL

METHADOSE

AA	MALLINCKRODT	5MG	N40050 001 APR 15, 1993
AA		10MG	N40050 002 APR 15, 1993

TABLET, DISPERSIBLE; ORAL

METHADONE HCL

AA	LILLY	40MG	N17058 001

METHADOSE

AA	MALLINCKRODT	40MG	N74184 001 APR 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

/METHAMPEX/

/AA/	/LEMMON/	/10MG/	/N83889/001/
∂	LEMMON	10MG	N83889 001

METHAMPHETAMINE HCL

/AA/	/LEMMON/	/5MG/	/N86359/001/
∂	LEMMON	5MG	N86359 001
/AA/	/REXAR/	/10MG/	/N84931/002/
	REXAR	10MG	N84931 002

METHANTHELINE BROMIDE

TABLET; ORAL

BANTHINE

	ROBERTS	50MG	N07390 001
	/SCHIAPPARELLI/SEARLE/	/50MG/	/N07390/001/

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

AB	COPLEY	25MG	N40001 001 JUN 30, 1993
AB		50MG	N40001 002 JUN 30, 1993
AB	GENEVA	25MG	N40036 001 JUN 30, 1993
AB		50MG	N40036 002 JUN 30, 1993

NEPTAZANE

AB	LEDERLE	25MG	N11721 002 NOV 25, 1991
AB +		50MG	N11721 001

METHICILLIN SODIUM

INJECTABLE; INJECTION

STAPHCILLIN

+	APOTHECON	EQ 900MG BASE/VIAL	N61449 001
+		EQ 3.6GM BASE/VIAL	N61449 002
+		EQ 5.4GM BASE/VIAL	N61449 003
	/BRISTOL/	/EQ/900MG/BASE/VIAL/	/N61449/001/
		/EQ/3.6GM/BASE/VIAL/	/N61449/002/
		/EQ/5.4GM/BASE/VIAL/	/N61449/003/

METHOCARBAMOL

TABLET; ORAL

/DELANIN/

/AA/	/FERNDALE/	/500MG/	/N85454/001/
∂	FERNDALE	500MG	N85454 001

METHOCARBAMOL

AA	NYLOS TRADING	750MG	N85033 001
/∂/	/PHARMAFAIR/	/500MG/	/N84231/002/
/∂/		/750MG/	/N84471/001/
∂	PHARMERAL	500MG	N84231 002
∂		750MG	N84471 001

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

/AA/	/PIONEER/PHARMS/	/500MG/	/N88731/001/ /DEC/13,/1985/
/AA/		/750MG/	/N89082/001/ /DEC/13,/1985/
	∂ PIONEER PHARMS	500MG	N88731 001 DEC 13, 1985
	∂	750MG	N89082 001 DEC 13, 1985
>DLT >/AA/	/SOLVAY/	/500MG/	/N84448/001/
>DLT >/AA/		/750MG/	/N84449/001/
>ADD >	∂ SOLVAY	500MG	N84448 001
>ADD >	∂	750MG	N84449 001
/AA/	/TABLICAPS/	/750MG/	/N85033/001/
/AA/	/UPSHER/SMITH/	/500MG/	/N87453/001/
/AA/		/750MG/	/N87454/001/
	∂ UPSHER SMITH	500MG	N87453 001
	∂	750MG	N87454 001

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM

/AP/	/AKORN/	/EQ 25MG BASE/ML/	/N88648/001/ /MAY/09,/1986/
/AP/	/LYPHOMED/	/EQ 25MG BASE/ML/	/N89263/001/ /JUN/13,/1986/
	∂ LYPHOMED	EQ 25MG BASE/ML	N89263 001 JUN 13, 1986
AP	NORBROOK	EQ 25MG BASE/ML	N88648 001 MAY 09, 1986

METHOXYFLURANE

/SOLUTION;INHALATION/

/PENTHRANE/

/ABBOTT/	/99.9%/	/N13056/003/

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HCL

/AP/	/LYPHOMED/	/50MG/ML/	/N70652/001/ /JUN/03,/1986/
	∂ LYPHOMED	50MG/ML	N70652 001 JUN 03, 1986

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

>DLT > /BX/	/CHELSEA/	/4MG/	/N86161/001/ /FEB/09,/1982/
>DLT >			
>ADD >	∂ CHELSEA	4MG	N86161 001 FEB 09, 1982
>ADD >			

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

M-PREDROL

/BP/	/BEL/MAR/	/40MG/ML/	/N86666/001/
/BP/		/80MG/ML/	/N87135/001/
	∂ BEL MAR	40MG/ML	N86666 001
	∂	80MG/ML	N87135 001

OINTMENT; TOPICAL

MEDROL ACETATE

/UPJOHN/	/1%/	/N12421/002/
∂ UPJOHN	1%	N12421 002

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

/AP/	/ABBOTT/	/EQ 1GM BASE/VIAL/	/N89576/001/ /FEB/22,/1991/
	∂ ABBOTT	EQ 1GM BASE/VIAL	N89576 001 FEB 22, 1991

METHYLPREDNISOLONE SODIUM SUCCINATE

/AP/	/LYPHOMED/	/EQ 40MG BASE/VIAL/	/N89143/001/ /MAR/28,/1986/
/AP/		/EQ 125MG BASE/VIAL/	/N89144/001/ /MAR/28,/1986/
/AP/		/EQ 500MG BASE/VIAL/	/N89187/001/ /MAR/28,/1986/
/AP/		/EQ 1GM BASE/VIAL/	/N89189/001/ /MAR/28,/1986/
	∂ LYPHOMED	EQ 40MG BASE/VIAL	N89143 001 MAR 28, 1986
	∂	EQ 125MG BASE/VIAL	N89144 001 MAR 28, 1986
	∂	EQ 500MG BASE/VIAL	N89187 001 MAR 28, 1986
	∂	EQ 1GM BASE/VIAL	N89189 001 MAR 28, 1986

METHYLTESTOSTERONE

CAPSULE; ORAL

/METHYLTESTOSTERONE/						
/BP/+//HEATHER/	/10MG/	/N84967/001/				
∂ HEATHER	10MG	N84967 001				
TESTRED						
/BP/ /ICN/	/10MG/	/N83976/001/				
BP + ICN	10MG	N83976 001				

TABLET; BUCCAL

/ANDROID/S/						
/ICN/	/5MG/	/N87222/001/				
∂ ICN	5MG	N87222 001				

TABLET; ORAL

METHYLTESTOSTERONE						
/BP/ /INWOOD/	/10MG/	/N80839/001/				
/BP/	/25MG/	/N80973/001/				
∂ INWOOD	10MG	N80839 001				
∂	25MG	N80973 001				

METHYPRYLON

/CAPSULE;ORAL/						
/NOLUDAR/						
/ROCHE/	/300MG/	/N09660/008/				
∂ ROCHE	300MG	N09660 008				
/TABLET;ORAL/						
/NOLUDAR/						
/ROCHE/	/200MG/	/N09660/004/				
∂ ROCHE	200MG	N09660 004				

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

/AP/ /AKORN/	/EQ 10MG BASE/2ML/	/N70892/001/				
		/AUG/26/1988/				
/AP/ /FUJISAWA/	/EQ 10MG BASE/2ML/	/N70293/001/				
		/JAN/24/1986/				
∂ FUJISAWA	EQ 10MG BASE/2ML	N70293 001 JAN 24, 1986				
∂ NORBROOK	EQ 10MG BASE/2ML	N70892 001 AUG 26, 1988				

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE HCL

AA	LEMMON	EQ 5MG BASE/5ML	N71315 001 JUN 30, 1993			
AA	LIQUIPHARM	EQ 5MG BASE/5ML	N71402 001 JUN 25, 1993			
AA	PENNEX PHARMS	EQ 5MG BASE/5ML	N70949 001 MAR 06, 1987			
/AA/	/PHARM/BASICS/	/EQ 5MG BASE/5ML/	/N70949/001/ /MAR/06/1987/			

TABLET; ORAL

METOCLOPRAMIDE HCL

AB	BIOCRAFT	EQ 5MG BASE	N72801 001 JUN 15, 1993			
AB	MUTUAL PHARM	EQ 10MG BASE	N71536 001 APR 28, 1993			
/AB/	/PAR/	/EQ 10MG BASE/	/N70342/001/ /MAR/25/1986/			
∂ PAR		EQ 10MG BASE	N70342 001 MAR 25, 1986			

METOPROLOL TARTRATE

INJECTABLE; INJECTION

LOPRESSOR

>ADD>	AP	+ GEIGY	1MG/ML	N18704 001 MAR 30, 1984		
>ADD>						

METOPROLOL TARTRATE

>ADD>	AP	STERIS	1MG/ML	N74032 001 DEC 21, 1993		
>ADD>						
>ADD>	AP	STERLING WINTHROP	1MG/ML	N74133 001 DEC 21, 1993		
>ADD>						

TABLET; ORAL

LOPRESSOR

>ADD>	AB	+ GEIGY	50MG	N17963 001		
>ADD>	AB	+	100MG	N17963 002		
>ADD>						

METOPROLOL TARTRATE

>ADD>	AB	MUTUAL PHARM	50MG	N73653 001 DEC 21, 1993		
>ADD>						
>ADD>	AB		100MG	N73654 001 DEC 21, 1993		
>ADD>						
>ADD>	AB	MYLAN	50MG	N73666 001 DEC 21, 1993		
>ADD>						
>ADD>	AB		100MG	N73666 002 DEC 21, 1993		
>ADD>						

METRONIDAZOLE

GEL; TOPICAL
METROGEL
/+//CURATEK/ /0.75%/ /N19737/001/ /NOV/22,/1988/
+ GALDERMA 0.75% N19737 001 NOV 22, 1988

TABLET; ORAL
/SATRIC/
/AB/ /SAVAGE/ /250MG/ /N70029/001/ /MAR/19,/1985/
/AB/ /500MG/ /N70731/001/ /JUN/08,/1987/
∂ SAVAGE 250MG N70029 001 MAR 19, 1985
∂ 500MG N70731 001 JUN 08, 1987

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION
MEZLIN
/MILES/ /EQ/1GM/BASE/VIAL/ /N62333/001/
∂ MILES EQ 1GM BASE/VIAL N62333 001
EQ 1GM BASE/VIAL N62372 005 JAN 13, 1983
∂ /EQ/2GM/BASE/VIAL/ /N62333/002/ EQ 2GM BASE/VIAL N62333 002
∂ /EQ/3GM/BASE/VIAL/ /N62333/003/ EQ 3GM BASE/VIAL N62333 003
∂ /EQ/4GM/BASE/VIAL/ /N62333/004/ EQ 4GM BASE/VIAL N62333 004 >DLT> >ADD>

MICONAZOLE NITRATE

/CREAM;/VAGINAL/
/MONISTAT/7/
/JOHNSON/RW/ /2%/ /N17456/001/

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MONISTAT DUAL-PAK
+ JOHNSON RW 2%;200MG N18888 002 OCT 17, 1988

MICONAZOLE NITRATE

/LOTION;/TOPICAL/
/MONISTAT-DERM/
/+//JOHNSON/RW/ /2%/ /N17739/001/
∂ JOHNSON RW 2% N17739 001

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE
AB ABLE 200MG N73508 001 NOV 19, 1993
MONISTAT 3
AB + JOHNSON RW 200MG N18888 001 AUG 15, 1984
/MONISTAT/7/
/JOHNSON/RW/ /100MG/ /N18526/001/ /MAR/15,/1982/

MILRINONE LACTATE

INJECTABLE; INJECTION
MILRINONE LACTATE
+ STERLING EQ 1MG BASE/ML N19436 001 DEC 31, 1987
/+/ /EQ/1MG/BASE/ML/ /N19436/001/ /DEC/31,/1987/

MINOCYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION
MINOCIN
/LEDERLE/ /EQ/100MG/BASE/VIAL/ /N62139/001/
∂ LEDERLE EQ 100MG BASE/VIAL N62139 001

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION
NOVANTRONE
+ IMMUNEX EQ 2MG BASE/ML N19297 001 DEC 23, 1987
/LEDERLE/ /EQ/2MG/BASE/ML/ /N19297/001/ /DEC/23,/1987/

MORICIZINE HYDROCHLORIDE

TABLET; ORAL
ETHMOZINE
/DUPONT/

/200MG/	/N19753/001/ /JUN/19,/1990/
/250MG/	/N19753/002/ /JUN/19,/1990/
/300MG/	/N19753/003/ /JUN/19,/1990/
ROBERTS 200MG	N19753 001 JUN 19, 1990
250MG	N19753 002 JUN 19, 1990
300MG	N19753 003 JUN 19, 1990

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
MS CONTIN
+ PURDUE FREDERICK 200MG N19516 005 NOV 08, 1993

NABILONE

/CAPSULE;/ORAL/
/CESAMET/
/+//LILLY/ /1MG/ /N18677/001/ /DEC/26,/1985/
∂ LILLY 1MG N18677 001 DEC 26, 1985

NADOLOL

TABLET; ORAL
CORGARD

AB	SQUIBB	20MG	N18063 005 OCT 28, 1986
AB		40MG	N18063 001
AB		40MG	N18064 001
AB		80MG	N18063 002
AB		80MG	N18064 002

NADOLOL

AB	MYLAN	20MG	N74172 001 OCT 31, 1993
AB		40MG	N74172 002 OCT 31, 1993
AB		80MG	N74172 003 OCT 31, 1993

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCIL

AP	APOTHECON	EQ 500MG BASE/VIAL	N62527 001 AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N62527 002 AUG 02, 1984
AP		EQ 1GM BASE/VIAL	N62732 001 DEC 23, 1986
AP		EQ 2GM BASE/VIAL	N62527 003 AUG 02, 1984
AP		EQ 2GM BASE/VIAL	N62732 002 DEC 23, 1986
AP		EQ 10GM BASE/VIAL	N62527 004 AUG 02, 1984
/AP/	/BRISTOL/	/EQ 500MG BASE/VIAL/	/N62527/001/ /AUG/02,/1984/
/AP/		/EQ 1GM BASE/VIAL/	/N62527/002/ /AUG/02,/1984/
/AP/		/EQ 1GM BASE/VIAL/	/N62732/001/ /DEC/23,/1986/
/AP/		/EQ 2GM BASE/VIAL/	/N62527/003/ /AUG/02,/1984/
/AP/		/EQ 2GM BASE/VIAL/	/N62732/002/ /DEC/23,/1986/
/AP/		/EQ 10GM BASE/VIAL/	/N62527/004/ /AUG/02,/1984/

/POWDER/FOR/RECONSTITUTION;/ORAL/
/UNIPEN/

/+//WYETH/AYERST/	/EQ/250MG/BASE/5ML/	/N50199/001/
∂ WYETH AYERST	EQ 250MG BASE/5ML	N50199 001

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HCL

/AP/	/ASTRA/	/10MG/ML/	/N72071/001/ /APR/10,/1989/	∂ ASTRA 10MG/ML N72071 001 APR 10, 1989
/AP/		/10MG/ML/	/N72072/001/ /APR/10,/1989/	∂ 10MG/ML N72072 001 APR 10, 1989
/AP/		/20MG/ML/	/N72074/001/ /APR/10,/1989/	∂ 20MG/ML N72074 001 APR 10, 1989
/AP/		/20MG/ML/	/N72075/001/ /APR/10,/1989/	∂ 20MG/ML N72075 001 APR 10, 1989

NALBUPHINE HYDROCHLORIDE

ABBOTT	1.5MG/ML	N20200 001 MAR 12, 1993	

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL

/AP/	/ASTRA/	/0.02MG/ML/	/N72082/001/ /APR/11,/1989/	∂ ASTRA 0.02MG/ML N72082 001 APR 11, 1989
/AP/		/0.02MG/ML/	/N72083/001/ /APR/11,/1989/	∂ 0.02MG/ML N72083 001 APR 11, 1989
/AP/		/0.02MG/ML/	/N72084/001/ /APR/11,/1989/	∂ 0.02MG/ML N72084 001 APR 11, 1989
/AP/		/0.02MG/ML/	/N72085/001/ /APR/11,/1989/	∂ 0.02MG/ML N72085 001 APR 11, 1989
/AP/		/0.4MG/ML/	/N72087/001/ /APR/11,/1989/	∂ 0.4MG/ML N72087 001 APR 11, 1989
/AP/		/0.4MG/ML/	/N72088/001/ /APR/11,/1989/	∂ 0.4MG/ML N72088 001 APR 11, 1989
/AP/		/0.4MG/ML/	/N72089/001/ /APR/11,/1989/	∂ 0.4MG/ML N72089 001 APR 11, 1989
/AP/		/0.4MG/ML/	/N72090/001/ /APR/11,/1989/	∂ 0.4MG/ML N72090 001 APR 11, 1989
/AP/		/1MG/ML/	/N72092/001/ /APR/11,/1989/	∂ 1MG/ML N72092 001 APR 11, 1989
/AP/		/1MG/ML/	/N72093/001/ /APR/11,/1989/	∂ 1MG/ML N72093 001 APR 11, 1989
/AP/	/LYPHOMED/	/0.02MG/ML/	/N70661/001/ /NOV/17,/1986/	∂ LYPHOMED 0.02MG/ML N70661 001 NOV 17, 1986

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

	NARCAN					
/AP/	/DUPONT/	/0.4MG/ML/	/N71083/001/ /JUL/28,/1988/	> ADD > AB > ADD >		
/AP/		/1MG/ML/	/N71084/001/ /JUL/28,/1988/	> ADD > AB > ADD >		
/AP/		/1MG/ML/	/N71311/001/ /JUL/28,/1988/	> ADD > AB > ADD >		
	∂ DUPONT	0.4MG/ML	N71083 001 JUL 28, 1988	> ADD > AB > ADD >		
	∂	1MG/ML	N71084 001 JUL 28, 1988	> ADD > AB > ADD >		
	∂	1MG/ML	N71311 001 JUL 28, 1988	> ADD > AB > ADD >		

NANDROLONE DECANOATE

INJECTABLE; INJECTION

	NANDROLONE DECANOATE					
/AQ/	/LYPHOMED/	/100MG/ML/	/N88290/001/ /OCT/03,/1983/	> ADD > AB > ADD >		
/AQ/		/200MG/ML/	/N88317/001/ /OCT/14,/1983/	> ADD > AB > ADD >		
	∂ LYPHOMED	100MG/ML	N88290 001 OCT 03, 1983	> ADD > AB > ADD >		
	∂	200MG/ML	N88317 001 OCT 14, 1983	> ADD > AB > ADD >		

NAPROXEN

TABLET; ORAL

	NAPROXEN					
> ADD > AB > ADD >	COPLEY	250MG	N74207 001 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >		375MG	N74207 002 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >		500MG	N74207 003 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >	GENEVA	250MG	N74140 001 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >		375MG	N74140 002 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >		500MG	N74140 003 DEC 21, 1993	> ADD > AB > ADD >		

NAPROXEN

TABLET; ORAL

	NAPROXEN					
> ADD > AB > ADD >	LEDERLE	250MG	N74105 001 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >		375MG	N74105 002 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >		500MG	N74105 003 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >	LEMMON	250MG	N74201 001 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >		375MG	N74201 002 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >		500MG	N74201 003 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >	MYLAN	250MG	N74121 001 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >		375MG	N74121 002 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >		500MG	N74121 003 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >	NOVOPHARM	250MG	N74129 001 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >		375MG	N74129 002 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >		500MG	N74129 003 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >	PUREPAC	250MG	N74263 001 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >		375MG	N74263 002 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >		500MG	N74263 003 DEC 21, 1993	> ADD > AB > ADD >		

NAPROXEN SODIUM

TABLET; ORAL

	ANAPROX					
> ADD > AB > DLT >	SYNTEX	EQ 250MG BASE /275MG/	N18164 001 /N18164/001/	> ADD > AB > ADD >		
	ANAPROX DS					
> ADD > AB > ADD >	+ SYNTEX	EQ 500MG BASE	N18164 003 SEP 30, 1987	> DLT > AB > DLT >		
> DLT >	/+/	/550MG/	/N18164/003/ /SEP/30,/1987/			
	NAPROXEN SODIUM					
> ADD > AB > ADD >	DANBURY PHARMA	EQ 250MG BASE	N74195 001 DEC 21, 1993	> ADD > AB > ADD >		
> ADD > AB > ADD >		EQ 500MG BASE	N74195 002 DEC 21, 1993	> ADD > AB > ADD >		

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

> ADD >	AB	GENEVA	EQ 250MG BASE	N74162 001 DEC 21, 1993
> ADD >				
> ADD >	AB		EQ 500MG BASE	N74162 002 DEC 21, 1993
> ADD >				
> ADD >	AB	HAMILTON PHARM	EQ 250MG BASE	N74106 001 AUG 31, 1993
> ADD >				
> DLT >	/AB/		/EQ 250MG BASE/	/N74106/001/ /AUG/31,/1993/
> DLT >				
> ADD >	AB		EQ 500MG BASE	N74106 002 AUG 31, 1993
> ADD >				
> DLT >	/AB/		/EQ 500MG BASE/	/N74106/002/ /AUG/31,/1993/
> DLT >				
> ADD >	AB	LEMMON	EQ 250MG BASE	N74198 001 DEC 21, 1993
> ADD >				
> ADD >	AB		EQ 500MG BASE	N74198 002 DEC 21, 1993
> ADD >				
> ADD >	AB	NOVOPHARM	EQ 250MG BASE	N74142 001 DEC 21, 1993
> ADD >				
> ADD >	AB		EQ 500MG BASE	N74142 002 DEC 21, 1993
> ADD >				
> ADD >	AB	ROXANE	EQ 250MG BASE	N74257 001 DEC 21, 1993
> ADD >				
> ADD >	AB		EQ 500MG BASE	N74257 002 DEC 21, 1993
> ADD >				

NEOMYCIN SULFATE

TABLET; ORAL

> DLT >		/NEOMYCIN/		
> DLT >	/AA/	/UPJOHN/	/EQ 350MG BASE/	/N60520/001/
> ADD >		∂ UPJOHN	EQ 350MG BASE	N60520 001
		NEOMYCIN SULFATE		
	/AA/	/EON LABS/	/EQ 350MG BASE/	/N61586/001/
		∂ EON LABS	EQ 350MG BASE	N61586 001

NIACIN

/CAPSULE; ORAL/

	/NAMPOCAP/		
	/WALLACE/	/500MG/	/N11073/003/
	∂ WALLACE	500MG	N11073 003

NIACIN

TABLET; ORAL

NIACIN

/AA/	/ZENITH/	/500MG/	/N83180/001/
	∂ ZENITH	500MG	N83180 001

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARDENE

> DLT >	/DUPONT/MERCK/	/2.5MG/ML/	/N19734/001/
> DLT >			/JAN/30,/1992/
> ADD >	SYNTEX	2.5MG/ML	N19734 001
> ADD >			JAN 30, 1992

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB	FLEMINGTON	10MG	N72781 001 JUL 30, 1993

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

BC	MILES	30MG	N20198 001 APR 21, 1993
BC		60MG	N20198 002 APR 21, 1993
BC		90MG	N20198 003 APR 21, 1993

PROCARDIA XL

BC +	PFIZER	30MG	N19684 001 SEP 06, 1989
BC +		60MG	N19684 002 SEP 06, 1989
BC +		90MG	N19684 003 SEP 06, 1989
/+/		/30MG/	/N19684/001/ /SEP/06,/1989/
/+/		/60MG/	/N19684/002/ /SEP/06,/1989/
/+/		/90MG/	/N19684/003/ /SEP/06,/1989/

NITROFURANTOIN

TABLET; ORAL
NITROFURANTOIN

AB	ZENITH	50MG	N80078 002
AB		100MG	N80078 001
∂	ZENITH	50MG	N80078 002
∂		100MG	N80078 001

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
MACROBID

+	P AND G	75MG;25MG	N20064 001 DEC 24, 1991

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTOIN

AB	ZENITH	50MG	N73671 001 JAN 28, 1993
AB		100MG	N73652 001 JAN 28, 1993

NITROGLYCERIN

INJECTABLE; INJECTION
NITRO-BID

∂	MARION MERRELL DOW	10MG/ML	N71159 001 FEB 28, 1990

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL

AB	MYLAN	EQ 10MG BASE	N74234 001 JUL 26, 1993
AB		EQ 25MG BASE	N74234 002 JUL 26, 1993
AB		EQ 50MG BASE	N74234 003 JUL 26, 1993
AB		EQ 75MG BASE	N74234 004 JUL 26, 1993

NYSTATIN

CREAM; TOPICAL
NYSTATIN

AT	BARRE	100,000 UNITS/GM	N62949 001 JUN 13, 1988
AT	TARO	100,000 UNITS/GM	N64022 001 JAN 29, 1993

OINTMENT; TOPICAL
NYSTATIN

AT	BARRE	100,000 UNITS/GM	N62840 001 NOV 13, 1987

POWDER; ORAL
NYSTATIN 100

AA	BARLAN	100%	N62489 001 APR 27, 1988
∂	BARLAN	100%	N62489 001 APR 27, 1988

SUSPENSION; ORAL
MYCOSTATIN

AA	APOTHECON	100,000 UNITS/ML	N61533 001

NYSTATIN

AA	BARRE	100,000 UNITS/ML	N62571 001 OCT 29, 1985

NYSTATIN

SUSPENSION; ORAL
NYSTATIN

AA	PENNEX PHARMS	100,000 UNITS/ML	N62512 001	OCT 29, 1984
∂		100,000 UNITS/ML	N62835 001	NOV 19, 1987
/AA/	/PHARM/BASICS/	/100,000 UNITS/ML/	/N62512/001/	/OCT/29,/1984/
/AA/		/100,000 UNITS/ML/	/N62835/001/	/NOV/19,/1987/
/AA/	/PHARMADERM/	/100,000 UNITS/ML/	/N62518/001/	/JUL/06,/1984/
∂	PHARMADERM	100,000 UNITS/ML	N62518 001	JUL 06, 1984

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	BARRE	100,000 UNITS/GM;0.1%	N63010 001	DEC 20, 1988
/AT/	/NASKA/	/100,000 UNITS/GM;0.1%/	/N63010/001/	/DEC/20,/1988/

NYSTATIN-TRIAMCINOLONE ACETONIDE

/AT/	/PHARMADERM/	/100,000 UNITS/GM;0.1%/	/N62596/001/	/OCT/08,/1985/
∂	PHARMADERM	100,000 UNITS/GM;0.1%	N62596 001	OCT 08, 1985

OINTMENT; TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	TARO	100,000 UNITS/GM;0.1%	N63305 001	MAR 29, 1993

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
SANDOSTATIN

/SANDOZ/	/EQ/500UGM/BASE/ML/	/N19667/001/	/OCT/21,/1988/
SANDOZ	EQ 0.05MG BASE/ML	N19667 001	OCT 21, 1988
	/EQ/100UGM/BASE/ML/	/N19667/002/	/OCT/21,/1988/
	EQ 0.1MG BASE/ML	N19667 002	OCT 21, 1988
	EQ 0.2MG BASE/ML	N19667 004	JUN 12, 1991
	/EQ/500UGM/BASE/ML/	/N19667/003/	/OCT/21,/1988/
	EQ 0.5MG BASE/ML	N19667 003	OCT 21, 1988
	EQ 1MG BASE/ML	N19667 005	JUN 12, 1991

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
OCUFLOX

+	ALLERGAN	0.3%	N19921 001	JUL 30, 1993

OXACILLIN SODIUM

CAPSULE; ORAL
PROSTAPHLIN

AB	APOTHECON	EQ 250MG BASE	N61450 002	
>ADD> AB	+	EQ 500MG BASE	N61450 001	
/AB/	/BRISTOL/	/EQ 250MG BASE/	/N61450/002/	
>DLT> /AB/	/;/	/EQ 500MG BASE/	/N50118/002/	
/AB/		/EQ 500MG BASE/	/N61450/001/	
>ADD>	∂ BRISTOL	EQ 500MG BASE	N50118 002	

POWDER FOR RECONSTITUTION; ORAL
PROSTAPHLIN

AA	APOTHECON	EQ 250MG BASE/5ML	N61457 001	
>DLT> /AA/	/BRISTOL/	/EQ 250MG BASE/5ML/	/N50194/001/	
/AA/		/EQ 250MG BASE/5ML/	/N61457/001/	
>ADD>	∂ BRISTOL	EQ 250MG BASE/5ML	N50194 001	

OXANDROLONE

TABLET; ORAL
OXANDRIN
> ADD > + BIO TECH GENERAL 2.5MG N13718 001
> DLT > /+///GYNEX/ /2.5MG/ /N13718/001/

OXPRENOLOL HYDROCHLORIDE

/CAPSULE;/ORAL/
/TRASICOR/
/+///CIBA/ /160MG/ /N18166/004/ /DEC/28,/1983/
/20MG/ /N18166/001/ /DEC/28,/1983/
/40MG/ /N18166/002/ /DEC/28,/1983/
/80MG/ /N18166/003/ /DEC/28,/1983/
@ CIBA 20MG N18166 001 DEC 28, 1983
@ 40MG N18166 002 DEC 28, 1983
@ 80MG N18166 003 DEC 28, 1983
@ 160MG N18166 004 DEC 28, 1983

OXTRIPHYLLINE

SOLUTION; ORAL
CHOLEDYL
/AA/ /PARKE/DAVIS/ /100MG/5ML/ /N09268/012/ /NOV/27,/1984/
PARKE DAVIS 100MG/5ML N09268 012 NOV 27, 1984

/OXTRIPHYLLINE/
/AA/ /PHARM/BASICS/ /100MG/5ML/ /N88243/001/ /DEC/05,/1983/
@ PENNEX PHARMS 100MG/5ML N88243 001 DEC 05, 1983

SYRUP; ORAL
CHOLEDYL
/AA/ /PARKE/DAVIS/ /50MG/5ML/ /N09268/011/
PARKE DAVIS 50MG/5ML N09268 011

OXTRIPHYLLINE

SYRUP; ORAL
/OXTRIPHYLLINE PEDIATRIC/
/AA/ /PHARM/BASICS/ /50MG/5ML/ /N88242/001/ /DEC/05,/1983/
@ PENNEX PHARMS 50MG/5ML N88242 001 DEC 05, 1983

OXYPHENBUTAZONE

TABLET; ORAL
TANDEARIL
@ GEIGY 100MG N12542 004 SEP 03, 1982
/@/RHONE/POULENC/RORER//100MG/ /N12542/004/ /SEP/03,/1982/

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
AREDIA
+ CIBA GEIGY 60MG/VIAL N20036 003 MAY 06, 1993
+ 90MG/VIAL N20036 004 MAY 06, 1993

PANCURONIUM BROMIDE

INJECTABLE; INJECTION
PANCURONIUM BROMIDE
/AP/ /ASTRA/ /2MG/ML/ /N72212/001/ /MAR/31,/1988/
@ ASTRA 2MG/ML N72212 001 MAR 31, 1988

PARAMETHASONE ACETATE

TABLET; ORAL
HALDRONE
/+///LILLY/ /2MG/ /N12772/006/
/1MG/ /N12772/005/
@ LILLY 1MG N12772 005
@ 2MG N12772 006

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAXIL

/+//SMITHKLINE/BEECHAM/	/EQ/10MG/BASE/	/N20031/001/	
/+/	/EQ/30MG/BASE/	/N20031/004/	DEC/29/1992/
@ SMITHKLINE BEECHAM	EQ 10MG BASE	N20031 001	DEC 29, 1992
	/EQ/40MG/BASE/	/N20031/005/	DEC/29/1992/
@	EQ 40MG BASE	N20031 005	DEC 29, 1992
@	EQ 50MG BASE	N20031 004	DEC 29, 1992

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

/+//WYETH/AYERST/	/300,000/UNITS/ML/	/N50131/001/
+ WYETH AYERST	300,000 UNITS/ML	N50141 003
@	300,000 UNITS/ML	N50131 001
	/300,000/UNITS/ML/	/N50141/003/

/TABLET;/ORAL/

/BICILLIN/

/+//WYETH/AYERST/	/200,000/UNITS/	/N50128/001/
@ WYETH AYERST	200,000 UNITS	N50128 001

PENICILLIN G POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

PENICILLIN

/AA/	/BIOCRAFT/	/200,000 UNITS/5ML/	/N60307/002/
	BIOCRAFT	200,000 UNITS/5ML	N60307 002
	/PENTIDS '200'/		
/AA/	/SQUIBB/	/200,000 UNITS/5ML/	/N62149/001/
@ APOTHECON		200,000 UNITS/5ML	N62149 001
	/PENTIDS '400'/		
/AA/	/SQUIBB/	/400,000 UNITS/5ML/	/N62149/002/
@ APOTHECON		400,000 UNITS/5ML	N62149 002

TABLET; ORAL

PENICILLIN G POTASSIUM

@ APOTHECON		250,000 UNITS	
/AB/	/SQUIBB/	/250,000 UNITS/	N60392 003
			/N60392/003/

PENICILLIN G POTASSIUM

TABLET; ORAL

	/PENTIDS '200'/		
/AB/	/SQUIBB/	/200,000 UNITS/	/N62155/001/
@ APOTHECON		200,000 UNITS	N62155 001
	/PENTIDS '250'/		
/AB/	/SQUIBB/	/250,000 UNITS/	/N62155/002/
@ APOTHECON		250,000 UNITS	N62155 002
	/PENTIDS '400'/		
/AB/	/SQUIBB/	/400,000 UNITS/	/N60392/004/
/AB/		/400,000 UNITS/	/N62155/003/
@ APOTHECON		400,000 UNITS	N60392 004
@		400,000 UNITS	N62155 003
	/PENTIDS '800'/		
/AB/	/SQUIBB/	/800,000 UNITS/	/N60392/005/
/AB/		/800,000 UNITS/	/N62155/004/
@ APOTHECON		800,000 UNITS	N60392 005
@		800,000 UNITS	N62155 004

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

	/DUCAETLLIN A.S./		
/AP/	/LILLY/	/300,000 UNITS/ML/	/N60093/001/
@ LILLY		300,000 UNITS/ML	N60093 001

PENICILLIN V

/POWDER/FOR/RECONSTITUTION;/ORAL/

/V-CILLIN/			
/+//LILLY/		/125MG/0.6ML/	/N60002/001/
@ LILLY		125MG/0.6ML	N60002 001

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

	/VEETIDS '125'/		
/AA/	/SQUIBB/	/EQ 125MG BASE/5ML/	/N61206/001/
/AA/		/EQ 125MG BASE/5ML/	/N62153/001/
@ APOTHECON		EQ 125MG BASE/5ML	N61206 001
@		EQ 125MG BASE/5ML	N62153 001
	/VEETIDS '250'/		
/AA/	/SQUIBB/	/EQ 250MG BASE/5ML/	/N61206/002/
/AA/		/EQ 250MG BASE/5ML/	/N62153/002/
@ APOTHECON		EQ 250MG BASE/5ML	N61206 002
@		EQ 250MG BASE/5ML	N62153 002

PENICILLIN V POTASSIUM

TABLET; ORAL
BETAPEN-VK
AB APOTHECON EQ 250MG BASE N61411 001
AB EQ 500MG BASE N61411 002
/AB/ /BRISTOL/ /EQ 250MG BASE/ /N61411/001/
/AB/ /EQ 500MG BASE/ /N61411/002/
/VEETIDS'250/
/AB/ /SQUIBB/ /EQ 250MG BASE/ /N61164/001/
/AB/ /EQ 250MG BASE/ /N62156/002/
∂ APOTHECON EQ 250MG BASE N61164 001
∂ EQ 250MG BASE N62156 002
/VEETIDS'500/
/AB/ /SQUIBB/ /EQ 500MG BASE/ /N61164/002/
/AB/ /EQ 500MG BASE/ /N62156/001/
∂ APOTHECON EQ 500MG BASE N61164 002
∂ EQ 500MG BASE N62156 001

PENTETATE CALCIUM TRISODIUM YB-169

>DLT> /INJECTABLE;INJECTION/
>DLT> /YTTERBIUM/YB-169/DTPA/
>DLT> /3M/ /2MCI/ML/ /N17518/001/
>ADD> ∂ 3M 2MCI/ML N17518 001

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION
/PENTOBARBITAL SODIUM/
/AP/ /ELKINS/SINN/ /50MG/ML/ /N83270/001/
∂ ELKINS SINN 50MG/ML N83270 001

PERFLUBRON

LIQUID; ORAL
IMAGENT
+ ALLIANCE PHARM 100% N20091 001
AUG 13, 1993

>ADD> PERINDOPRIL ERBUMINE

>ADD> TABLET; ORAL
>ADD> ACEON
>ADD> + JOHNSON RW 8MG N20184 003
>ADD> DEC 30, 1993
>ADD> 2MG N20184 001
>ADD> DEC 30, 1993
>ADD> 4MG N20184 002
>ADD> DEC 30, 1993

PERMETHRIN

/LOTION;TOPICAL/
/NIX/
/AT/ /BURROUGHS/WELLCOME/ /1%/ /N19435/001/
/MAR/31/1986/
∂ BURROUGHS WELLCOME 1% N19435 001
MAR 31, 1986

PERPHENAZINE

/TABLET;EXTENDED/RELEASE;ORAL/
/TRILAFON/
/-/SCHERING/ /8MG/ /N11361/002/
∂ SCHERING 8MG N11361 002

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL
/STATOBEX/
/AA/ /LEMMON/ /35MG/ /N85507/001/
∂ LEMMON 35MG N85507 001

TABLET; ORAL
/ADIPEX/
/AA/ /FERNDALE/ /35MG/ /N83655/001/
∂ FERNDALE 35MG N83655 001
/MELFIAT/
/AA/ /SOLVAY/ /35MG/ /N83790/002/
∂ SOLVAY 35MG N83790 002
/METRA/
/AA/ /FOREST/PHARMS/ /35MG/ /N83754/001/
∂ FOREST PHARMS 35MG N83754 001

PHENDIMETRAZINE TARTRATE
/AA/ /ANABOLIC/ /35MG/ /N86020/001/
∂ ANABOLIC 35MG N86020 001

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

/AA/	/FERNDALE/	/35MG/	/N86834/001/
			/SEP/15,/1983/
	∂ FERNDALE	35MG	N86834 001
			SEP 15, 1983
/AA/	/GENEVA/	/35MG/	/N83993/001/
	∂ SOLVAY	35MG	N83993 001

PHENMETRAZINE HYDROCHLORIDE

/TABLET,/EXTENDED/RELEASE;/ORAL/
/PRELUDIN/
/+//BOEHRINGER/INGELHEIM/75MG/ /N11752/003/
∂ BOEHRINGER INGELHEIM 75MG N11752 003

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPEX-P

/AA/	/LEMMON/	/30MG/	/N86911/001/
	/OBESTIN-30/		
/AA/	/FERNDALE/	/30MG/	/N87144/001/
	∂ FERNDALE	30MG	N87144 001

PHENTERMINE HCL

	∂ LEMMON	30MG	N86911 001
/AA/	/PHARM/BASICS/	/30MG/	/N88430/001/
			/MAR/27,/1984/
	∂ PHARM BASICS	30MG	N88430 001
			MAR 27, 1984
/AA/	/ZENITH/	/30MG/	/N86329/001/
	∂ ZENITH	30MG	N86329 001

TABLET; ORAL

/TORA/

/AA/	/SOLVAY/	/8MG/	/N84035/001/
	∂ SOLVAY	8MG	N84035 001

PHENYLBUTAZONE

CAPSULE; ORAL

/BUTAZOLIDIN/

/AB//+//GEIGY/		/100MG/	/N08319/009/
	∂ GEIGY	100MG	N08319 009

PHENYLBUTAZONE

CAPSULE; ORAL

PHENYLBUTAZONE

/AB/	/BARR/	/100MG/	/N88994/001/
			/DEC/04,/1985/
	+ BARR	100MG	N88994 001
			DEC 04, 1985
/AB/	/CHELSEA/	/100MG/	/N87756/001/
			/DEC/17,/1982/
	∂ CHELSEA	100MG	N87756 001
			DEC 17, 1982
/AB/	/GENEVA/	/100MG/	/N87774/001/
			/JUN/16,/1982/
	∂ GENEVA	100MG	N87774 001
			JUN 16, 1982

TABLET; ORAL

/BUTAZOLIDIN/

/AB//+//GEIGY/		/100MG/	/N08319/008/
	∂ GEIGY	100MG	N08319 008

PHENYLBUTAZONE

/AB/	/BARR/	/100MG/	/N88863/001/
			/DEC/04,/1985/
	+ BARR	100MG	N88863 001
			DEC 04, 1985
/AB/	/CHELSEA/	/100MG/	/N86151/001/
	∂ CHELSEA	100MG	N86151 001
/AB/	/DANBURY/PHARMA/	/100MG/	/N87674/001/
			/APR/21,/1982/
	∂ DANBURY PHARMA	100MG	N87674 001
			APR 21, 1982
/AB/	/GENEVA/	/100MG/	/N84339/001/
	∂ GENEVA	100MG	N84339 001

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE VC PLAIN

	∂ PENNEX PHARMS	5MG/5ML;6.25MG/5ML	N88897 001
/AA/	/PHARM/BASICS/	/5MG/5ML;6.25MG/5ML/	JAN 04, 1985 /N88897/001/ /JAN/04,/1985/

PHENYTOIN

SUSPENSION; ORAL

>_DLT_>	/DILANTIN-30/			
>_DLT_>	/PARKE/DAVIS/		/30MG/5ML/	/N08762/002/
>_ADD_>	∂ PARKE DAVIS		30MG/5ML	N08762 002

PHENYTOIN SODIUM, PROMPT

CAPSULE; ORAL
PHENYTOIN SODIUM
/3/PHARMAFAIR/ /100MG/ /N85435/001/
@ PHARMERAL 100MG N85435 001

PHYTONADIONE

INJECTABLE; INJECTION
AQUAMEPHYTON
/BP/ /MSD/ /10MG/ML/ /N12223/001/
BP + MSD 10MG/ML N12223 001
KONAKION
/BP/+//ROCHE/ /10MG/ML/ /N11745/003/
BP ROCHE 10MG/ML N11745 003

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	GENEVA	5MG	N73608 001 MAR 29, 1993
AB		10MG	N73609 001 MAR 29, 1993
AB	NOVOPHARM	5MG	N73661 001 OCT 31, 1993
AB		10MG	N73661 002 OCT 31, 1993
AB	PUREPAC	5MG	N74125 001 APR 28, 1993
AB		10MG	N74125 002 APR 28, 1993
AB	ZENITH	5MG	N73687 001 FEB 26, 1993
AB		10MG	N73687 002 FEB 26, 1993

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION
ZOSYN

+	LEDERLE	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	N50684 001 OCT 22, 1993
+		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	N50684 002 OCT 22, 1993
+		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	N50684 003 OCT 22, 1993
+		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	N50684 004 OCT 22, 1993

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	MEPHA AG	10MG	N74116 001 JUN 15, 1993
AB		20MG	N74118 001 JUN 15, 1993
AB	MUTUAL PHARM	10MG	N73535 001 MAR 12, 1993
AB		20MG	N73536 001 MAR 12, 1993
AB	ROXANE	10MG	N73651 001 FEB 26, 1993
AB		20MG	N73651 002 FEB 26, 1993

PLICAMYCIN

INJECTABLE; INJECTION
MITHRACIN

>ADD> / >DLT>	+	MILES /PFIZER/	2.5MG/VIAL /2.5MG/VIAL/	N50109 001 /N50109/001/

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL
PEG-LYTE

AA	INVAMED	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N73098 001 AUG 31, 1993

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC
POLYTRIM

>ADD<	ALLERGAN	10,000 UNITS/ML; EQ 1MG BASE/ML	N50567 001 OCT 20, 1988	
>ADD<				
>ADD<				
>DLT<	/BURROUGHS/WELLCOME/	/10,000/UNITS/ML;/ /EQ/1MG/BASE/ML/	/N50567/001/ /OCT/20,/1988/	
>DLT<				
>DLT<				

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
K-LEASE

/AB/	/ADRIA/	/8MEQ/	/N73396/001/ /JAN/28,/1992/	
/AB/		/10 MEQ/	/N72427/001/ /MAR/28,/1990/	
AB	SAVAGE	8MEQ	N73398 001 JAN 28, 1992	
AB		10 MEQ	N72427 001 MAR 28, 1990	

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP	FUJISAWA	2MEQ/ML	N84290 001	
AP		2MEQ/ML	N87787 001 APR 20, 1982	
/AP/	/LUITPOLD/	/2MEQ/ML/	/N80221/001/	
/AP/		/2MEQ/ML/	/N80736/001/	
	∂ LUITPOLD	2MEQ/ML	N80221 001	
	∂	2MEQ/ML	N80736 001	
/AP/	/LYPHOMED/	/2MEQ/ML/	/N84290/001/	
/AP/		/2MEQ/ML/	/N87787/001/ /APR/20,/1982/	

TABLET, EXTENDED RELEASE; ORAL
K+8

AB	ALRA	8MEQ	N70998 001 JAN 25, 1993	
	KAON CL			
	/ADRIA/	/6.7MEQ/	/N17046/001/	
	SAVAGE	6.7MEQ	N17046 001	
	KAON CL-10			
/BC/	/ADRIA/	/10MEQ/	/N17046/002/	
BC	SAVAGE	10MEQ	N17046 002	

POTASSIUM CITRATE

	/POWDER/FOR/RECONSTITUTION;/ORAL/ /POTASSIUM/CITRATE/			
	/+//UNIV/TX/	/20MEQ/PACKET/	/N19647/001/ /OCT/13,/1988/	
		/10MEQ/PACKET/	/N19647/002/ /OCT/13,/1988/	
	∂ UNIV TX	10MEQ/PACKET	N19647 002 OCT 13, 1988	
	∂	20MEQ/PACKET	N19647 001 OCT 13, 1988	

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CITRATE

	/+//UNIV/TX/	/5MEQ/	/N19071/001/ /AUG/30,/1985/	
+	UNIV TX	10MEQ	N19071 002 AUG 31, 1992	
		5MEQ	N19071 001 AUG 30, 1985	

PRAVASTATIN SODIUM

TABLET; ORAL
PRAVACHOL

	/+//BRISTOL/MYERS/SQUIBB/20MG/		/N19898/003/ /OCT/31,/1991/	
+	BRISTOL MYERS SQUIBB	40MG	N19898 004 MAR 22, 1993	
		20MG	N19898 003 OCT 31, 1991	

PRAZEPAM

>DLT<	/CAPSULE;/ORAL/ /CENTRAX/			
>DLT<	/+//PARKE/DAVIS/	/10MG/	/N18144/002/	
>DLT<	/+/	/20MG/	/N18144/003/ /MAY/10,/1982/	
>DLT<		/5MG/	/N18144/001/	
>DLT<	∂ PARKE DAVIS	5MG	N18144 001	
>DLT<	∂	10MG	N18144 002	
>DLT<	∂	20MG	N18144 003 MAY 10, 1982	
>ADD<				
>ADD<				
>ADD<				
>ADD<				

	/TABLET;/ORAL/ /CENTRAX/			
	/+//PARKE/DAVIS/	/10MG/	/N17415/001/	

PRAZEPAM

/TABLET;/ORAL/
/CENTRAX/
∂ PARKE DAVIS 10MG N17415 001

PREDNICARBATE

CREAM; TOPICAL
DERMATOP
HOECHST ROUSSEL 0.1% N20279 001
OCT 29, 1993

OINTMENT; TOPICAL
/DERMATOP/
/HOECHST/ROUSSEL/ /0.1%/ /N19568/001/
/SEP/23,/1991/
∂ HOECHST ROUSSEL 0.1% N19568 001
SEP 23, 1991

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE
/BX/ /PRIVATE/FORM/ /5MG/ /N80211/001/
∂ PRIVATE FORM 5MG N80211 001
/BX/ /WEST/WARD/ /5MG/ /N80324/001/
∂ WEST WARD 5MG N80324 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC
CETAPRED
ALCON 0.25%;10% N87771 001
AUG 06, 1993

/PREDSULFAIR/
/AT/ /PHARMAFAIR/ /0.5%;10%/ /N88032/001/
/APR/15,/1983/
∂ PHARMAFAIR 0.5%;10% N88032 001
APR 15, 1983

VASOCIDIN
/AT/ /IOLAB/ /0.5%;10%/ /N88791/001/
/OCT/05,/1984/
+ IOLAB 0.5%;10% N88791 001
OCT 05, 1984

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC
/PREDSULFAIR/
/AT/ /PHARMAFAIR/ /0.5%;10%/ /N88007/001/
/APR/19,/1983/
∂ PHARMAFAIR 0.5%;10% N88007 001
APR 19, 1983

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC
/PREDATE/
/AT/ /PHARMAFAIR/ /EQ 0.11% PHOSPHATE/ /N88415/001/
/FEB/29,/1984/
∂ PHARMAFAIR EQ 0.11% PHOSPHATE N88415 001
FEB 29, 1984

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE
AT STERIS EQ 0.23% PHOSPHATE;10% N73630 001
MAY 27, 1993

VASOCIDIN
AT IOLAB EQ 0.23% PHOSPHATE;10% N18988 001
AUG 26, 1988

PREDNISONE

SOLUTION; ORAL
PREDNISONE
∂ PENNEX PHARMS 5MG/5ML N89726 001
AUG 02, 1988
/AA/ /PHARM/BASICS/ /5MG/5ML/ /N89726/001/
/AUG/02,/1988/
/AA/ /ROXANE/ /5MG/5ML/ /N88703/001/
/NOV/08,/1984/
ROXANE 5MG/5ML N88703 001
NOV 08, 1984

TABLET; ORAL
DELTASONE
AB UPJOHN 2.5MG N09986 005
/BX/ /2.5MG/ /N09986/005/

PREDNISONE

TABLET; ORAL

METICORTEN

>ADD >	AB +	SCHERING	1MG	N09766 002
>DLT >	/BX/	/#/	/1MG/	/N09766/002/
>DLT >	/BX/		/5MG/	/N09766/001/
>ADD >		∂	5MG	N09766 001

PREDNISONE

>DLT >	/AB/	/HEATHER/	/5MG/	/N80320/001/
	/AB/		/10MG/	/N84341/001/
	/AB/		/20MG/	/N84417/001/
	/AB/		/20MG/	/N85543/001/
	/AB/		/50MG/	/N86946/001/
>ADD >		∂ HEATHER	5MG	N80320 001
		∂	10MG	N84341 001
		∂	20MG	N84417 001
		∂	20MG	N85543 001
		∂	50MG	N86946 001
>DLT >	/BX/	/INWOOD/	/5MG/	/N80279/001/
>ADD >		∂ INWOOD	5MG	N80279 001
	/BX/	/KV/	/5MG/	/N84236/001/
		∂ KV	5MG	N84236 001
	BX	NYLOS TRADING	5MG	N85115 001
	/BX/	/TABLICAPS/	/5MG/	/N85115/001/
	/BX/	/UPSHER/SMITH/	/5MG/	/N87471/001/
	/BX/		/20MG/	/N87470/001/
		∂ UPSHER SMITH	5MG	N87471 001
		∂	20MG	N87470 001

PROBENECID

TABLET; ORAL

PROBENECID

>DLT >	/AB/	/CHELSEA/	/500MG/	/N86156/002/
>DLT >				/APR 23, 1982/
>ADD >		∂ CHELSEA	500MG	N86150 002
>ADD >				APR 23, 1982

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HCL

>DLT >	/AB/	/CHELSEA/	/250MG/	/N85167/001/
>DLT >	/AB/		/375MG/	/N87020/001/
>DLT >	/AB/		/500MG/	/N87021/001/
>ADD >		∂ CHELSEA	250MG	N85167 001
>ADD >		∂	375MG	N87020 001
>ADD >		∂	500MG	N87021 001

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PRONESTYL

	AB	APOTHECON	250MG	N07335 001
	AB		375MG	N07335 004
	AB +		500MG	N07335 003
	/AB/	/SQUIBB/	/250MG/	/N07335/001/
	/AB/		/375MG/	/N07335/004/
	/AB/#/		/500MG/	/N07335/003/

INJECTABLE; INJECTION

PROCAINAMIDE HCL

	/AP/	/LYPHOMED/	/100MG/ML/	/N89415/001/
				/NOV 17, 1986/
	/AP/		/500MG/ML/	/N89416/001/
				/NOV 17, 1986/
		∂ LYPHOMED	100MG/ML	N89415 001
				NOV 17, 1986
		∂	500MG/ML	N89416 001
				NOV 17, 1986

PRONESTYL

	AP +	APOTHECON	100MG/ML	N07335 002
	AP +		500MG/ML	N07335 005
	/AP/	/SQUIBB/	/100MG/ML/	/N07335/002/
	/AP/		/500MG/ML/	/N07335/005/

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HCL

	/AP/	/BEL/MAR/	/1%/	/N80711/001/
	/AP/		/2%/	/N80756/001/
		∂ BEL MAR	1%	N80711 001
		∂	2%	N80756 001

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ACHROMYCIN/

>DLT >				
>DLT >	/AP/	/LEDERLE/	/40MG/VIAL;250MG/VIAL/	/N50267/003/
>DLT >			/40MG/VIAL;100MG/VIAL/	/N50267/002/
>DLT >			/40MG/VIAL;100MG/VIAL/	/N50276/001/
>ADD >		∂ LEDERLE	40MG/VIAL;100MG/VIAL	N50276 001
>ADD >		∂	40MG/VIAL;250MG/VIAL	N50276 003

TETRACYN

>DLT >	/AP/	/PFIZER/	/40MG/VIAL;250MG/VIAL/	/N60285/003/
>ADD >		PFIZER	40MG/VIAL;250MG/VIAL	N60285 003

PROCHLORPERAZINE

SUPPOSITORY; RECTAL
COMPAZINE
AB + SMITHKLINE BEECHAM 25MG N11127 002
PROCHLORPERAZINE
AB G AND W 25MG N40058 001
NOV 24, 1993

PROCHLORPERAZINE EDISYLATE

CONCENTRATE; ORAL
PROCHLORPERAZINE EDISYLATE
@ PENNEX PHARMS EQ 10MG BASE/ML N88598 001
OCT 25, 1984
/@/PHARM/BASICS/ /EQ/10MG/BASE/ML/ /N88598/001/
/OCT/25,/1984/

SYRUP; ORAL
PROCHLORPERAZINE EDISYLATE
@ PENNEX PHARMS EQ 5MG BASE/5ML N88597 001
OCT 25, 1984
/@/PHARM/BASICS/ /EQ/5MG/BASE/5ML/ /N88597/001/
/OCT/25,/1984/

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL
KEMADRIN
/BURROUGHS/WELLCOME/ /2MG/ /N09818/005/
@ BURROUGHS WELLCOME 2MG N09818 005

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
SPARINE
/AP/ /WYETH/AYERST/ /25MG/ML/ /N16349/009/

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL
PROMETHACON
/BR/ /ALCON/ /25MG/ /N84901/001/
/BR/ /50MG/ /N84902/001/
BR POLYMEDICA 25MG N84901 001
BR 50MG N84902 001

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE PLAIN
@ PENNEX PHARMS 6.25MG/5ML N87953 001
NOV 15, 1982
/AA/ /PHARM/BASICS/ /6.25MG/5ML/ /N87953/001/
/NOV/15,/1982/

TABLET; ORAL
PROMETHAZINE HCL
/BP/ /CIRCA/ /25MG/ /N83204/001/
@ CIRCA 25MG N83204 001
/BP/ /ZENITH/ /50MG/ /N83613/001/
@ ZENITH 50MG N83613 001

PROPOFOL

INJECTABLE; INJECTION
DIPRIVAN
/ICI/ /10MG/ML/ /N19627/001/
/OCT/02,/1989/
+ ZENECA 10MG/ML N19627 001
OCT 02, 1989

PROPRANOLOL HYDROCHLORIDE

SOLUTION; ORAL
PROPRANOLOL HCL
@ PENNEX PHARMS 20MG/5ML N71984 001
MAR 03, 1989
@ 40MG/5ML N71985 001
MAR 03, 1989
/@/PHARM/BASICS/ /20MG/5ML/ /N71984/001/
/MAR/03,/1989/
/@/ /40MG/5ML/ /N71985/001/
/MAR/03,/1989/

/SUSPENSION;/ORAL/
/INDERAL/
/WYETH/AYERST/ /10MG/ML/ /N19536/001/
/DEC/12,/1986/
@ WYETH AYERST 10MG/ML N19536 001
DEC 12, 1986

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

	PROPRANOLOL HCL			
/AB/	/MYLAN/	/60MG/	/N72275/001/	
			/JUN/09,/1989/	
	∂ MYLAN	60MG	N72275 001	
			JUN 09, 1989	

PROPYLIODONE

/SUSPENSION;/INTRATRACHEAL/

/DIONOSIL/OILY/			
/GLAXO/	/60%/	/N09309/002/	
∂ GLAXO	60%	N09309 002	

PROTAMINE SULFATE

INJECTABLE; INJECTION

	PROTAMINE SULFATE			
/AP/	/QUAD/	/10MG/ML/	/N89306/001/	
			/MAY/30,/1986/	
	∂ QUAD	10MG/ML	N89306 001	
			MAY 30, 1986	

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

	/HISTAFED/			
/AA/	/LIFE/LABS/	/30MG/5ML;1.25MG/5ML/	/N88283/001/	
			/APR/20,/1984/	
	∂ CENCI	30MG/5ML;1.25MG/5ML	N88283 001	
			APR 20, 1984	

PYRANTEL PAMOATE

/SUSPENSION;/ORAL/

/ANTIMINTH/			
/+//ROERIG/	/EQ/250MG/BASE/5ML/	/N16883/001/	

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

	MESTINON			
/AP/	/ICN/	/5MG/ML/	/N09830/001/	
AP	ROCHE	5MG/ML	N09830 001	

PYRIDOSTIGMINE BROMIDE

SYRUP; ORAL

MESTINON			
/ICN/	/60MG/5ML/	/N15193/001/	
ROCHE	60MG/5ML	N15193 001	

TABLET; ORAL

MESTINON			
/+//ICN/	/60MG/	/N09829/002/	
+ ROCHE	60MG	N09829 002	

TABLET, EXTENDED RELEASE; ORAL

MESTINON			
/+//ICN/	/180MG/	/N11665/001/	
+ ROCHE	180MG	N11665 001	

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

	/HEXA-BETALIN/			
/AP/	/LILLY/	/100MG/ML/	/N80854/001/	
	∂ LILLY	100MG/ML	N80854 001	
	PYRIDOXINE HCL			
/AP/	/BEL/MAR/	/100MG/ML/	/N80761/001/	
	∂ BEL MAR	100MG/ML	N80761 001	
AP	FUJISAWA	100MG/ML	N80618 001	
/AP/	/LYPHOMED/	/100MG/ML/	/N80618/001/	

QUAZEPAM

TABLET; ORAL

DORAL			
/+//BAKER/NORTON/	/15MG/	/N18708/001/	
		/DEC/27,/1985/	
	/7.5MG/	/N18708/003/	
		/FEB/26,/1987/	
+ WALLACE	15MG	N18708 001	
		DEC 27, 1985	
	7.5MG	N18708 003	
		FEB 26, 1987	

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

/DURAQUIN/			
/PARKE/DAVIS/	/330MG/	/N17917/001/	

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL
/DURAQUIN/
∂ WARNER CHILCOTT 330MG N17917 001

QUINIDINE GLUCONATE
>DLT >/AA/ /CHELSEA/ /324MG/ /N87785/001/
>DLT > /JAN/24/1983/
>ADD > ∂ CHELSEA 324MG N87785 001
>ADD > JAN 24, 1983

QUINIDINE SULFATE

TABLET; ORAL
/CIN-QUIN/
/AA/ /SOLVAY/ /100MG/ /N85299/001/
/AA/ /200MG/ /N84932/001/
/AA/ /300MG/ /N85298/001/
∂ SOLVAY 100MG N85299 001
∂ 200MG N84932 001
∂ 300MG N85298 001

QUINIDINE SULFATE
/AA/ /PARKE/DAVIS/ /200MG/ /N83879/001/
∂ WARNER CHILCOTT 200MG N83879 001

RAUWOLFIA SERPENTINA

TABLET; ORAL
RAUDIXIN
BP APOTHECON 50MG N08842 001
BP + 100MG N08842 002
/BP/ /SQUIBB/ /50MG/ /N088442/001/
/BP/+/ /100MG/ /N08842/002/

RESERPINE

TABLET; ORAL
RESERPINE
/BP/ /LEMMON/ /0.1MG/ /N89020/001/
/MAR/07/1985/
/BP/ /0.25MG/ /N89019/001/
/MAR/07/1985/
∂ LEMMON 0.1MG N89020 001
MAR 07, 1985
∂ 0.25MG N89019 001
MAR 07, 1985

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL
/NAQUIVAL/
/BP/+//SCHERING/ /0.1MG;4MG/ /N12265/003/
∂ SCHERING 0.1MG;4MG N12265 003

RIMANTADINE HYDROCHLORIDE

SYRUP; ORAL
FLUMADINE
+ FOREST LABS 50MG/5ML N19650 001
SEP 17, 1993

TABLET; ORAL
FLUMADINE
+ FOREST LABS 100MG N19649 001
SEP 17, 1993

>ADD > RISPERIDONE

>ADD > TABLET; ORAL
>ADD > RISPERDAL
>ADD > + JANSSEN 4MG N20272 004
>ADD > DEC 29, 1993
>ADD > 1MG N20272 001
>ADD > DEC 29, 1993
>ADD > 2MG N20272 002
>ADD > DEC 29, 1993
>ADD > 3MG N20272 003
>ADD > DEC 29, 1993
>ADD > ∂ 5MG N20272 005
>ADD > DEC 29, 1993

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL
/AP/ /QUAD/ /10MG/ML/ /N70700/001/
/OCT/06/1986/
∂ QUAD 10MG/ML N70700 001
OCT 06, 1986

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE
∂ PENNEX PHARMS 2.5% N88228 001 SEP 01, 1983
/AT/ /PHARM/BASICS/ /2.5%/ /N88228/001/ /SEP/01,/1983/

SERACTIDE ACETATE

/INJECTABLE;/INJECTION/
/ACTHAR/GEL-SYNTHETIC/
/ARMOUR/ /40/UNITS/ML/ /N17861/001/
/80/UNITS/ML/ /N17861/002/
∂ ARMOUR 40 UNITS/ML N17861 001
∂ 80 UNITS/ML N17861 002

SILVER SULFADIAZINE

/DRESSING;/TOPICAL/
/SILVADENE/
∂ BIOPLASTY 1% N19608 001 NOV 30, 1989
/SILVADENE/
/ENDAY/ /1%/ /N19608/001/ /NOV/30,/1989/

SODIUM BICARBONATE

/INJECTABLE;/INJECTION/
/SODIUM/BICARBONATE/IN/PLASTIC/CONTAINER/
/ABBOTT/ /0.9MEQ/ML/ /N19443/001/ /JUN/03,/1986/
/1MEQ/ML/ /N19443/002/ /JUN/03,/1986/
∂ ABBOTT 0.9MEQ/ML N19443 001 JUN 03, 1986
∂ 1MEQ/ML N19443 002 JUN 03, 1986

SODIUM CHLORIDE

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP FUJISAWA 9MG/ML N88911 001 FEB 07, 1985

SODIUM CHLORIDE

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
/AP/ /LYPHOMED/ /9MG/ML/ /N88911/001/ /FEB/07,/1985/

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER
∂ FUJISAWA 234MG/ML N19329 001 APR 22, 1987
/∂/LYPHOMED/ /234MG/ML/ /N19329/001/ /APR/22,/1987/

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION
CHROMITOPE SODIUM
/SQUIBB/ /2MCI/VIAL/ /N13993/002/
∂ SQUIBB 2MCI/VIAL N13993 002

SODIUM IODIDE, I-131

CAPSULE; ORAL
SODIUM IODIDE I 131
/∂/CIS/ /50/UCI/ /N17316/001/
∂ CIS 50 UCI N17316 001
/100/UCI/ /N17316/002/
100 UCI N17316 002

SOLUTION; ORAL
SODIUM IODIDE I 131
/CIS/ /50MCI/ML/ /N17315/001/
CIS 50MCI/ML N17315 001

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
∂ PENNEX PHARMS 453.6GM/BOT N88786 001 SEP 11, 1984
/AA/ /PHARM/BASICS/ /453.6GM/BOT/ /N88786/001/ /SEP/11,/1984/

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
∂ PENNEX PHARMS 15GM/60ML N88717 001 SEP 11, 1984
/AA/ /PHARM/BASICS/ /15GM/60ML/ /N88717/001/ /SEP/11,/1984/

SOMATROPIN, BIOSYNTHETIC

INJECTABLE; INJECTION
HUMATROPE
BX + LILLY — 5MG/VIAL — N19640 004 MAR 08, 1987

NUTROPIN
BX GENENTECH — 5MG/VIAL — N20168 001 NOV 17, 1993
+ — 10MG/VIAL — N20168 002 NOV 17, 1993

SOYBEAN OIL

INJECTABLE; INJECTION
INTRALIPID 30%
>ADD> KABI — 30% — N19942 001 DEC 30, 1993
>ADD>

NUTRILIPID 10%
AP MCGAW — 10% — N19531 001 MAY 28, 1993

NUTRILIPID 20%
AP MCGAW — 20% — N19531 002 MAY 28, 1993

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE
>DLT> /B*/ /CHELSEA/ — /25MG/ — /N87078/001/
>ADD> @ CHELSEA — 25MG — N87078 001
/AB/ /UPSHER/SMITH/ — /25MG/ — /N87554/001/
@ UPSHER SMITH — 25MG — N87554 001

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION
METASTRON
MEDI PHYSICS — 1MCI/ML — N20134 001 JUN 18, 1993

SUCRALFATE

>ADD> SUSPENSION; ORAL
>ADD> CARAFATE
>ADD> + MARION MERRELL DOW — 1GM/10ML — N19183 001 DEC 16, 1993
>ADD>

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC
/SULFAIR 10/
/AT/ /PHARMAFAIR/ — /10%/ — /N88000/001/ /DEC/22/1982/
@ PHARMAFAIR — 10% — N88000 001 DEC 22, 1982

SULFADIAZINE

TABLET; ORAL
SULFADIAZINE
/ABBOTT/ — /300MG/ — /N04125/005/
@ ABBOTT — 300MG — N04125 005

SULFADIAZINE SODIUM

>DLT> /INJECTABLE;/INJECTION/
>DLT> /SULFADIAZINE/SODIUM/
>DLT> /LEDERLE/ — /250MG/ML/ — /N04054/002/
>ADD> @ LEDERLE — 250MG/ML — N04054 002

SULFAMETHIZOLE

TABLET; ORAL
THIOSULFIL
/WYETH/AYERST/ — /250MG/ — /N08565/001/
@ WYETH AYERST — 250MG — N08565 001

SULFAMETHOXAZOLE

TABLET; ORAL
/GANTANOL-DS/
/ROCHE/ — /1GM/ — /N12715/003/
@ ROCHE — 1GM — N12715 003

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
TRIMETH/SULFA
AB BARRE — 200MG/5ML;40MG/5ML — N72289 001 MAY 23, 1988
AB — 200MG/5ML;40MG/5ML — N72398 001 MAY 23, 1988

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
TRIMETH/SULFA

/AB/	/NASKA/	/200MG/5ML;40MG/5ML/	/N72269/001/	/MAY/23,/1988/
/AB/		/200MG/5ML;40MG/5ML/	/N72396/001/	/MAY/23,/1988/

TABLET; ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM

> DLT >	/AB/	/CHELSEA/	/400MG;80MG/	/N70002/001/	/NOV/07,/1984/
> DLT >					
> DLT >	/AB/		/800MG;160MG/	/N70000/001/	/NOV/07,/1984/
> DLT >					
> ADD >		∂ CHELSEA	400MG;80MG	N70002 001	NOV 07, 1984
> ADD >					
> ADD >		∂	800MG;160MG	N70000 001	NOV 07, 1984
> ADD >					
	/BN/	/INTERPHARM/	/400MG;80MG/	/N71299/001/	/OCT/27,/1987/
	/BN/		/800MG;160MG/	/N71300/001/	/OCT/27,/1987/
		∂ INTERPHARM	400MG;80MG	N71299 001	OCT 27, 1987
		∂	800MG;160MG	N71300 001	OCT 27, 1987

SULFISOXAZOLE

TABLET; ORAL
SULFISOXAZOLE

/AB/	/HEATHER/	/500MG/	/N80189/001/	
	∂ HEATHER	500MG	N80189 001	
	/S/PHARMAFAIR/	/500MG/	/N84385/001/	
	∂ PHARMERAL	500MG	N84385 001	

SULFISOXAZOLE ACETYL

/EMULSION;/ORAL/
/LIPO/GANTRISIN/

/ROCHE/	/EQ/1GM/BASE/5ML/	/N09182/009/	
∂ ROCHE	EQ 1GM BASE/5ML	N09182 009	

SULFISOXAZOLE DIOLAMINE

/OINTMENT;/OPHTHALMIC/
/GANTRISIN/

/ROCHE/	/EQ/4%/BASE/	/N08414/002/	
∂ ROCHE	EQ 4% BASE	N08414 002	

SULINDAC

TABLET; ORAL
SULINDAC

AB	MYLAN	150MG	N73038 001 JUN 22, 1993
AB		200MG	N73039 001 JUN 22, 1993

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX

+	PARKE DAVIS	EQ 40MG BASE	N20070 004 SEP 09, 1993
		EQ 10MG BASE	N20070 001 SEP 09, 1993
		EQ 20MG BASE	N20070 002 SEP 09, 1993
		EQ 30MG BASE	N20070 003 SEP 09, 1993

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX

/#/STUART/	/EQ/10MG/BASE/	/N17976/001/	
+ ZENECA	EQ 10MG BASE	N17970 001	

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
/A-N/STANNOUS/AGGREGATED/ALBUMIN/

/BS/	/NORTH/AM/CHEM/	/N/A/	/N17916/001/
	∂ NORTH AM CHEM	N/A	N17916 001

AN-MAA

BS	SORIN	N/A	N17792 001
		/N/A/	/N17792/001/

/TECHNETIUM/TC/99M/MAA/

/BS/	/MEDI/PHYSICS/	/N/A/	/N17773/001/
	∂ MEDI PHYSICS	N/A	N17773 001

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT

>DLT>	/INJECTABLE;/INJECTION/			
>DLT>	/INSTANT/MICROSPHERES/			
>DLT>	/3M/	/N/A/	/N17832/001/	
>ADD>	@ 3M	N/A	N17832 001	

TECHNETIUM TC-99M MEDRONATE KIT

	INJECTABLE; INJECTION			
	/AMERSCAN MDP KIT/			
/AP/	/AMERSHAM/	/N/A/	/N18335/001/ /AUG/05,/1982/	
	@ AMERSHAM	N/A	N18335 001 AUG 05, 1982	

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

	SOLUTION; INJECTION, ORAL			
	/MINITEC/			
	/SQUIBB/	/0.22-2.22CI/GENERATOR/	/N17339/001/	
	@ SQUIBB	0.22-2.22CI/GENERATOR	N17339 001	

TEMAZEPAM

	CAPSULE; ORAL			
	TEMAZEPAM			
AB	DANBURY PHARMA	15MG	N71446 001 MAY 21, 1993	
AB		30MG	N71447 001 MAY 21, 1993	

TERAZOSIN HYDROCHLORIDE

	TABLET; ORAL			
	HYTRIN			
	/-///ABBOTT/	/2MG/	/N19057/002/ /AUG/07,/1987/	
	+ ABBOTT	EQ 2MG BASE	N19057 002 AUG 07, 1987	
	+	EQ 2MG BASE	N20223 002 SEP 29, 1993	
		/1MG/	/N19057/001/ /AUG/07,/1987/	
		EQ 1MG BASE	N19057 001 AUG 07, 1987	
		EQ 1MG BASE	N20223 001 SEP 29, 1993	
		/5MG/	/N19057/003/ /AUG/07,/1987/	
		EQ 5MG BASE	N19057 003 AUG 07, 1987	
		EQ 5MG BASE	N20223 003 SEP 29, 1993	
		/10MG/	/N19057/004/ /AUG/07,/1987/	
		EQ 10MG BASE	N19057 004 AUG 07, 1987	
		EQ 10MG BASE	N20223 004 SEP 29, 1993	

TESTOSTERONE

	FILM, EXTENDED RELEASE; TRANSDERMAL			
	TESTODERM			
	+ ALZA	4MG/24HR	N19762 001 OCT 12, 1993	
	+	6MG/24HR	N19762 002 OCT 12, 1993	

	INJECTABLE; INJECTION			
	TESTOSTERONE			
>DLT>	/STERIS/	/25MG/ML/	/N86420/001/ /MAY/10,/1983/	
>DLT>				
>ADD>	@ STERIS	25MG/ML	N86420 001 MAY 10, 1983	
>ADD>				
>DLT>		/50MG/ML/	/N86419/001/ /AUG/23,/1983/	
>DLT>				
>ADD>	@	50MG/ML	N86419 001 AUG 23, 1983	
>ADD>				

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTOSTERONE

>DLT >		/UPJOHN/	/50MG/ML/	/N85635/001/
>ADD >	ə	UPJOHN	50MG/ML	N85635 001

TESTOSTERONE CYPIONATE

>DLT >/AO/		/STERIS/	/100MG/ML/	/N84401/001/
>DLT >/AO/			/200MG/ML/	/N84401/002/
>ADD >	ə	STERIS	100MG/ML	N84401 001
>ADD >	ə		200MG/ML	N84401 002

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

TESTOSTERONE ENANTHATE

>DLT >/AO/		/STERIS/	/200MG/ML/	/N83667/002/
>DLT >			/100MG/ML/	/N83667/001/
>ADD >	ə	STERIS	100MG/ML	N83667 001
>ADD >	ə		200MG/ML	N83667 002

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

TESTOSTERONE PROPIONATE

/AO/		/BEL/MAR/	/25MG/ML/	/N80741/001/
/AO/			/50MG/ML/	/N80742/001/
/AO/			/100MG/ML/	/N80743/001/
	ə	BEL MAR	25MG/ML	N80741 001
	ə		50MG/ML	N80742 001
	ə		100MG/ML	N80743 001
>DLT >/AO/		/LILLY/	/50MG/ML/	/N80254/002/
>ADD >	ə	LILLY	50MG/ML	N80254 002
/AO/		/STERIS/	/25MG/ML/	/N80188/001/
>DLT >/AO/			/50MG/ML/	/N80188/002/
>DLT >/AO/			/50MG/ML/	/N85490/002/
/AO/			/100MG/ML/	/N80188/003/
	+	STERIS	25MG/ML	N80188 001
	+		100MG/ML	N80188 003
>DLT >			/25MG/ML/	/N85490/001/
>ADD >	ə		25MG/ML	N85490 001
>ADD >			50MG/ML	N80188 002
>ADD >	ə		50MG/ML	N85490 002
>DLT >			/100MG/ML/	/N83595/003/
>ADD >	ə		100MG/ML	N83595 003

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

/TETRACHEL/

/AB/		/RACHELLE/	/250MG/	/N60343/001/
/AB/			/500MG/	/N60343/003/
	ə	ANGUS	250MG	N60343 001
	ə		500MG	N60343 003

TETRACYCLINE HCL

/AB/		/ICN/	/250MG/	/N60471/001/
	ə	ICN	250MG	N60471 001

TABLET; ORAL

SUMYCIN

AB		APOTHECON	50MG	N61147 003
AB			100MG	N61147 002
AB			250MG	N61147 001
AB	+		500MG	N61147 004
/AB/		/SQUIBB/	/50MG/	/N61147/003/
/AB/			/100MG/	/N61147/002/
/AB/			/250MG/	/N61147/001/
/AB/	/S/		/500MG/	/N61147/004/

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

/AP/		/SQUIBB/	/1MCI/ML/	/N18548/001/ /DEC/30,/1982/
	ə	SQUIBB	1MCI/ML	N18548 001 DEC 30, 1982

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

/THEOBID/

/BC/	/S/	/GLAXO/	/260MG/	/N85983/001/ /MAR/20,/1985/
	ə	WHITBY	260MG	N85983 001 MAR 20, 1985

/THEOBID/JR./

/BC/	/S/	/GLAXO/	/130MG/	/N87854/001/ /MAR/20,/1985/
	ə	WHITBY	130MG	N87854 001 MAR 20, 1985

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEOCLEAR L.A.-130

/BC/	/CENTRAL/PHARMS/	/130MG/	/N86569/001/ /MAY/27,/1982/
BC +	CENTRAL PHARMS	130MG	N86569 001 MAY 27, 1982

THEOCLEAR L.A.-260

/BC/	/CENTRAL/PHARMS/	/260MG/	/N86569/002/ /MAY/27,/1982/
BC +	CENTRAL PHARMS	260MG	N86569 002 MAY 27, 1982

ELIXIR; ORAL

	/THEOPHYL-225/ /JOHNSON/RW/	/112.5MG/15ML/	/N86485/001/
	@ JOHNSON RW	112.5MG/15ML	N86485 001

THEOPHYLLINE

AA	BARRE	80MG/15ML	N89223 001 MAY 27, 1988
/AA/	/NASKA/	/80MG/15ML/	/N89223/001/ /MAY/27,/1988/
AA /AA/	PENNEX PHARMS /PHARM/BASICS/	80MG/15ML /80MG/15ML/	N86748 001 /N86748/001/

TABLET; ORAL

QUIBRON-T

	/+//BRISTOL/MYERS/	/300MG/	/N88656/001/ /AUG/22,/1985/
	+ ROBERTS	300MG	N88656 001 AUG 22, 1985

	/THEOPHYL-225/ /JOHNSON/RW/	/225MG/	/N84726/001/
	@ JOHNSON RW	225MG	N84726 001

	/TABLET,/CHEWABLE;/ORAL/ /THEOPHYL/ /JOHNSON/RW/	/100MG/	/N86506/001/ /SEP/12,/1985/
	@ JOHNSON RW	100MG	N86506 001 SEP 12, 1985

TABLET, EXTENDED RELEASE; ORAL

QUIBRON-T/SR

/BC/	/BRISTOL/MYERS/	/300MG/	/N87563/001/ /JUN/21,/1983/
BC	ROBERTS	300MG	N87563 001 JUN 21, 1983

THEOPHYLLINE SODIUM GLYCINATE

	/ELIXIR;/ORAL/ /SYNOPHYLATE/ /CENTRAL/PHARMS/	/EQ/165MG/BASE/15ML/	/N06333/008/
	@ CENTRAL PHARMS	EQ 165MG BASE/15ML	N06333 008

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

/AP/	/BEL/MAR/	/100MG/ML/	/N80718/001/
/AP/		/200MG/ML/	/N80712/001/
	@ BEL MAR	100MG/ML	N80718 001
	@	200MG/ML	N80712 001
AP	FUJISAWA	100MG/ML	N80556 001
/AP/	/LYPHOMED/	/100MG/ML/	/N80556/001/
/AP/	/STERIS/	/200MG/ML/	/N80571/002/
/AP/		/200MG/ML/	/N83534/002/
	+ STERIS	200MG/ML	N80571 002
		200MG/ML	N83534 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

THIORIDAZINE HCL

	@ PENNEX PHARMS	30MG/ML	N88258 001 JUL 25, 1983
	@	100MG/ML	N88227 001 JUL 05, 1983
/AA/	/PHARM/BASICS/	/30MG/ML/	/N88258/001/ /JUL/25,/1983/
/AA/		/100MG/ML/	/N88227/001/ /JUL/05,/1983/

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL
THIORIDAZINE HCL

/AB/	/PAR/	/10MG/	/N88351/001/ /DEC/05,/1983/	
/AB/		/15MG/	/N88352/001/ /DEC/05,/1983/	
/AB/		/25MG/	/N88336/001/ /DEC/05,/1983/	
/AB/		/50MG/	/N88322/001/ /DEC/05,/1983/	
/AB/		/100MG/	/N88480/001/ /DEC/29,/1983/	
	∂ PAR	10MG	N88351 001 DEC 05, 1983	
	∂	15MG	N88352 001 DEC 05, 1983	
	∂	25MG	N88336 001 DEC 05, 1983	
	∂	50MG	N88322 001 DEC 05, 1983	
	∂	100MG	N88480 001 DEC 29, 1983	
/AB/	/ZENITH/	/100MG/	/N88273/001/ /OCT/03,/1983/	
	∂ ZENITH	100MG	N88273 001 OCT 03, 1983	

THIOTEPA

INJECTABLE; INJECTION
THIOTEPA

>ADD>	+ IMMUNEX	15MG/VIAL	N11683 001	
>DLT>	/+//LEDERLE/	/15MG/VIAL/	/N11683/001/	

TICARCILLIN DISODIUM

INJECTABLE; INJECTION
TICAR

	+ SMITHKLINE BEECHAM	EQ 20GM BASE/VIAL	N50497 004	
	+	EQ 30GM BASE/VIAL	N50497 005 APR 04, 1984	

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID

+ SYNTEX	250MG	N19979 002 OCT 31, 1991	
∂	125MG	N19979 001 MAR 24, 1993	
	/250MG/	/N19979/002/ /OCT/31,/1991/	

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOPTIC-XE

+ MERCK	EQ 0.25% BASE	N20330 001 NOV 04, 1993	
+	EQ 0.5% BASE	N20330 002 NOV 04, 1993	

TABLET; ORAL
TIMOLOL MALEATE

AB	NOVOPHARM	5MG	N72648 001 JUN 16, 1993
AB		10MG	N72649 001 JUN 16, 1993
AB		20MG	N72650 001 JUN 16, 1993

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC
TOBRAMYCIN

AT	BAUSCH AND LOMB	0.3%	N64052 001 NOV 29, 1993

TOBREX

AT	+ ALCON	0.3%	N50541 001
AT		0.3%	N62535 001 DEC 13, 1984

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

/B*/	/INTERPHARM/	/250MG/	/N71270/001/ /SEP/23,/1986/
/B*/		/500MG/	/N71271/001/ /SEP/23,/1986/
	∂ INTERPHARM	250MG	N71270 001 SEP 23, 1986
	∂	500MG	N71271 001 SEP 23, 1986

TOLMETIN SODIUM

CAPSULE; ORAL
TOLMETIN SODIUM

AB	MYLAN	EQ 400MG BASE	N73393 001 MAY 27, 1993

TABLET; ORAL
TOLMETIN SODIUM

AB	GENEVA	EQ 600MG BASE	N74002 001 SEP 27, 1993

TORSEMIDE

INJECTABLE; INJECTION
DEMADEX

+	BOEHRINGER MANNHEIM	10MG/ML	N20137 002 AUG 23, 1993

TABLET; ORAL
DEMADEX

+	BOEHRINGER MANNHEIM	100MG	N20136 004 AUG 23, 1993
		5MG	N20136 001 AUG 23, 1993
		10MG	N20136 002 AUG 23, 1993
		20MG	N20136 003 AUG 23, 1993

TRANYLCYPROMINE SULFATE

TABLET; ORAL
PARNATE

+	SKF	EQ 10MG BASE	N12342 003 AUG 16, 1985

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
DESYREL

AB	APOTHECON	50MG	N18207 001
AB	+	100MG	N18207 002
AB		150MG	N18207 003 MAR 25, 1985
		300MG	N18207 004 NOV 07, 1988
/AB/	/BRISTOL/MYERS/	/50MG/	/N18207/001/
/AB/	/+/	/100MG/	/N18207/002/
/AB/		/150MG/	/N18207/003/ /MAR/25,/1985/
		/300MG/	/N18207/004/ /NOV/07,/1988/

TRAZODONE HCL

AB	MUTUAL PHARM	50MG	N73136 001 MAR 24, 1993
AB		100MG	N73137 001 MAR 24, 1993

TRETINOIN

/SWAB;/TOPICAL/
/RETIN-A/

/+//JOHNSON/RW/	/0.05%/	/N16921/002/
∂ JOHNSON RW	0.05%	N16921 002

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION
AZMACORT

+	RHONE POULENC RORER	0.1MG/INH	N18117 001 APR 23, 1982
/+/		/0.225MG/INH/	/N18117/001/ /APR/23,/1982/

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	TRIAMCINOLONE ACETONIDE		
	@ PENNEX PHARMS	0.025%	N88094 001 SEP 01, 1983
	@	0.1%	N88095 001 SEP 01, 1983
	@	0.5%	N88096 001 SEP 01, 1983
	/@/PHARM/BASICS/	/0.025%/	/N88094/001/ /SEP/01,/1983/
	/@/	/0.1%/	/N88095/001/ /SEP/01,/1983/
	/@/	/0.5%/	/N88096/001/ /SEP/01,/1983/
/AT/	/PHARMADERM/	/0.025%/	/N87990/001/ /JUL/07,/1983/
/AT/		/0.1%/	/N87991/001/ /JUL/07,/1983/
/AT/		/0.5%/	/N87992/001/ /JUL/07,/1983/
	@ PHARMADERM	0.025%	N87990 001 JUL 07, 1983
	@	0.1%	N87991 001 JUL 07, 1983
	@	0.5%	N87992 001 JUL 07, 1983
/AT/	/PHARMAFAIR/	/0.025%/	/N87921/001/ /AUG/10,/1982/
/AT/		/0.1%/	/N87912/001/ /AUG/10,/1982/
/AT/		/0.5%/	/N87922/001/ /AUG/10,/1982/
	@ PHARMAFAIR	0.025%	N87921 001 AUG 10, 1982
	@	0.1%	N87912 001 AUG 10, 1982
	@	0.5%	N87922 001 AUG 10, 1982

LOTION; TOPICAL

	TRIAMCINOLONE ACETONIDE		
AT	PENNEX PHARMS	0.025%	N88450 001 APR 01, 1985
AT		0.1%	N88451 001 APR 03, 1985
/AT/	/PHARM/BASICS/	/0.025%/	/N88450/001/ /APR/01,/1985/
/AT/		/0.1%/	/N88451/001/ /APR/03,/1985/

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

	TRIAMCINOLONE ACETONIDE		
AT	BARRE	0.5%	N89913 001 DEC 23, 1988
/AT/	/NASKA/	/0.5%/	/N89913/001/ /DEC/23,/1988/
	@ PENNEX PHARMS	0.025%	N88090 001 SEP 01, 1983
	@	0.1%	N88091 001 SEP 01, 1983
	@	0.5%	N88092 001 SEP 01, 1983
	/@/PHARM/BASICS/	/0.025%/	/N88090/001/ /SEP/01,/1983/
	/@/	/0.1%/	/N88091/001/ /SEP/01,/1983/
	/@/	/0.5%/	/N88092/001/ /SEP/01,/1983/
/AT/	/PHARMADERM/	/0.025%/	/N88692/001/ /AUG/02,/1984/
/AT/		/0.1%/	/N88690/001/ /AUG/02,/1984/
	@ PHARMADERM	0.025%	N88692 001 AUG 02, 1984
	@	0.1%	N88690 001 AUG 02, 1984

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

/I*P/			
/AA/	/GENEVA/	/EQ 10MG BASE/ML/	/N85787/001/ /APR/15,/1982/
	TRIFLUOPERAZINE HCL		
AA	GENEVA	EQ 10MG BASE/ML	N85787 001 APR 15, 1982
	TRIFLUOPERAZINE HCL		
	@ PENNEX PHARMS	EQ 10MG BASE/ML	N88143 001 JUL 26, 1983
/AA/	/PHARM/BASICS/	/EQ 10MG BASE/ML/	/N88143/001/ /JUL/26,/1983/

TABLET; ORAL

/I*P/			
/AB/	/GENEVA/	/EQ 1MG BASE/	/N85785/001/
/AB/		/EQ 2MG BASE/	/N85786/001/
/AB/		/EQ 5MG BASE/	/N85789/001/
/AB/		/EQ 10MG BASE/	/N85788/001/

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL

AB	GENEVA	EQ 1MG BASE	N85785 001
AB		EQ 2MG BASE	N85786 001
AB		EQ 5MG BASE	N85789 001
AB		EQ 10MG BASE	N85788 001

TRIFLUPROMAZINE

/SUSPENSION;ORAL/
/VESPRIN/
/SQUIBB/ /EQ/50MG/HCL/5ML/ /N11491/004/
ə APOTHECON EQ 50MG HCL/5ML N11491 004

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
VESPRIN

AP	+ APOTHECON	10MG/ML	N11325 004
AP	+	20MG/ML	N11325 001
/AP/	/SQUIBB/	/10MG/ML/	/N11325/004/
/AP/		/20MG/ML/	/N11325/001/

/TABLET;ORAL/
/VESPRIN/

/SQUIBB/	/50MG/	/N11123/003/
	/10MG/	/N11123/001/
	/25MG/	/N11123/002/
ə SQUIBB	10MG	N11123 001
ə	25MG	N11123 002
ə	50MG	N11123 003

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL
TRIHEXYPHENIDYL HCL

AA	NYLOS TRADING	5MG	N85622 001
/AA/	/TABLICAPS/	/5MG/	/N85622/001/

TRIMEPRAZINE TARTRATE

SYRUP; ORAL
TRIMEPRAZINE TARTRATE
ə PENNEX PHARMS EQ 2.5MG BASE/5ML N88285 001
APR 11, 1985

TRIMEPRAZINE TARTRATE

SYRUP; ORAL
TRIMEPRAZINE TARTRATE
/ə/PHARM/BASICS/ /EQ/2.5MG/BASE/5ML/ /N88285/001/
/APR/11,/1985/

> ADD > **TRIMETREXATE GLUCURONATE**

> ADD > INJECTABLE; INJECTION
> ADD > NEUTREXIN
> ADD > + US BIOSCIENCE EQ 25MG BASE/VIAL N20326 001
> ADD > DEC 17, 1993

TRIOXSALEN

TABLET; ORAL
TRISORALEN
/ELDER/ /5MG/ /N12697/001/
ICN 5MG N12697 001

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL
TRIPELENNAMINE HCL

/AA/	/HEATHER/	/50MG/	/N83989/001/
	ə HEATHER	50MG	N83989 001
AA	NYLOS TRADING	50MG	N85412 001
/AA/	/TABLICAPS/	/50MG/	/N85412/001/

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC
MYDRIACYL

> DLT >	/AT/	/ALCON/	/0.5%/	/N12111/002/
> DLT >	/AT/		/1%/	/N84305/001/
> ADD >	AT	+ ALCON	0.5%	N84305 001
> DLT >	/AT/		/1%/	/N12111/004/
> DLT >	/AT/		/2%/	/N84306/001/
> ADD >	AT	+	1%	N84306 001
> ADD >		ə	0.5%	N12111 002
> ADD >		ə	1%	N12111 004

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE

/AP/	/QUAD/	/3MG/ML/	/N89442/001/ /AUG/12,/1988/
	∂ QUAD	3MG/ML	N89442 001 AUG 12, 1988

VALPROIC ACID

CAPSULE; ORAL
VALPROIC ACID

AB	PHARMACAPS	250MG	N73484 001 JUN 29, 1993

SYRUP; ORAL
MYPROIC ACID

AA	PENNEX PHARMS	250MG/5ML	N70868 001 JUL 01, 1986
/AA/	/PHARM/BASICS/	/250MG/5ML/	/N70868/001/ /JUL/01,/1986/

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOCIN HCL IN PLASTIC CONTAINER

	+ LILLY	EQ 500MG BASE/100ML	N50671 001 APR 29, 1993

POWDER FOR RECONSTITUTION; ORAL
VANCOCIN HCL

AB	LILLY	EQ 250MG BASE/5ML	N61667 002 JUL 13, 1983
AB		EQ 500MG BASE/6ML	N61667 001

VANCOLED

AB	LEDERLE	EQ 250MG BASE/5ML	N63321 001 OCT 15, 1993
AB		EQ 500MG BASE/6ML	N63321 003 OCT 15, 1993

VASOPRESSIN TANNATE

>DLT>	/INJECTABLE;/INJECTION/		
>DLT>	/PITRESSIN/TANNATE/		
>DLT>	/PARKE/DAVIS/	/5/PRESSOR/UNITS/ML/	/N03402/001/
>ADD>	∂ PARKE DAVIS	5 PRESSOR UNITS/ML	N03402 001

>ADD> VENLAFAXINE HYDROCHLORIDE

>ADD> TABLET; ORAL
>ADD> EFFEXOR

>ADD>	+ WYETH AYERST	EQ 25MG BASE	N20151 002 DEC 28, 1993
>ADD>	+	EQ 100MG BASE	N20151 005 DEC 28, 1993
>ADD>	∂	EQ 12.5MG BASE	N20151 001 DEC 28, 1993
>ADD>		EQ 37.5MG BASE	N20151 006 DEC 28, 1993
>ADD>		EQ 50MG BASE	N20151 003 DEC 28, 1993
>ADD>		EQ 75MG BASE	N20151 004 DEC 28, 1993

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
ISOPTIN

/AP/	/KNOLL/	/2.5MG/ML/	/N18485/001/
AP	+ KNOLL	2.5MG/ML	N18485 001

VERAPAMIL HCL

AP	MARSAM	2.5MG/ML	N72233 001 FEB 26, 1993
AP		2.5MG/ML	N73485 001 SEP 27, 1993

TABLET; ORAL
VERAPAMIL HCL

AB	WATSON LABS	40MG	N72923 001 JUN 29, 1993
AB		40MG	N72924 001 JUN 29, 1993

VINBLASTINE SULFATE

INJECTABLE; INJECTION
VINBLASTINE SULFATE

	FUJISAWA	1MG/ML	N89515 001 APR 29, 1987
	/LYPHOMED/	/1MG/ML/	/N89515/001/ /APR/29,/1987/

VITAMIN A PALMITATE

CAPSULE; ORAL

	AFAXIN		
ə	STERLING	EQ 50,000 UNITS BASE	N83187 001
	VITAMIN A		
/AA/	/WHARTON/	/EQ 50,000 UNITS BASE/	/N83665/001/
ə	WHARTON	EQ 50,000 UNITS BASE	N83665 001
/AA/	/ZENITH/	/EQ 50,000 UNITS BASE/	/N83035/001/
/AA/		/EQ 50,000 UNITS BASE/	/N83190/001/
ə	ZENITH	EQ 50,000 UNITS BASE	N83035 001
ə		EQ 50,000 UNITS BASE	N83190 001

INJECTABLE; INJECTION

	AQUASOL A		
/AP/	/ASTRA/	/EQ 50,000 UNITS BASE/ML	/N06823/001/
	ASTRA	EQ 50,000 UNITS BASE/ML	N06823 001
	/VITAMIN A PALMITATE/		
/AP/	/BEL/MAR/	/EQ 50,000 UNITS BASE/ML	/N80819/001/
ə	BEL MAR	EQ 50,000 UNITS BASE/ML	N80819 001

WARFARIN SODIUM

TABLET; ORAL

	COUMADIN		
/BX/	/DUPONT/	/2MG/	/N09218/013/
/BX/		/2.5MG/	/N09218/018/
/BX/		/5MG/	/N09218/007/
/BX/		/10MG/	/N09218/005/
+	DUPONT	2MG	N09218 013
+		10MG	N09218 005
		2.5MG	N09218 018
		4MG	N09218 023
			AUG 24, 1993
		5MG	N09218 007
	/PANWARFIN/		
/BX/	/ABBOTT/	/2MG/	/N17020/001/
/BX/		/2.5MG/	/N17020/002/
/BX/		/5MG/	/N17020/003/
/BX/		/7.5MG/	/N17020/004/
/BX/		/10MG/	/N17020/005/
ə	ABBOTT	2MG	N17020 001
ə		2.5MG	N17020 002
ə		5MG	N17020 003
ə		7.5MG	N17020 004
ə		10MG	N17020 005

XENON, XE-133

GAS; INHALATION

	XENON XE 133		
/AA/	/DUPONT/	/30MCI/VIAL/	/N17284/004/
/AA/		/40MCI/VIAL/	/N17284/005/
/AA/		/50MCI/VIAL/	/N17284/006/
/AA/		/60MCI/VIAL/	/N17284/007/
/AA/		/100MCI/VIAL/	/N17284/003/
AA	MEDI PHYSICS	10MCI/VIAL	N17687 002
AA		20MCI/VIAL	N17687 003

XYLOSE

POWDER; ORAL

	XYLO-PFAN		
/AA/	/ADRIA/	/25GM/BOT/	/N17605/001/
AA	SAVAGE	25GM/BOT	N17605 001

ZINC SULFATE

	/INJECTABLE;/INJECTION/		
	/ZINC SULFATE/		
	/LYPHOMED/	/EQ 1MG ZINC/ML/	/N19229/002/
			/MAY 05, 1987/
ə	LYPHOMED	EQ 1MG ZINC/ML	N19229 002
			MAY 05, 1987

ACETAMINOPHEN

SUPPOSITORY; RECTAL

NEOPAP		
/ALCON/	/120MG/	/N16401/001/
POLYMEDICA	120MG	N16401 001

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DRIXORAL PLUS		
/SCHERING/	/500MG;3MG;60MG/	/N19453/001/ /MAY/22,/1987/
+ SCHERING PLOUGH	500MG;3MG;60MG	N19453 001 MAY 22, 1987

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

/ALUMINUM/HYDROXIDE/AND/MAGNESIUM/TRISILICATE/		
/PENNEX/	/80MG;20MG/	/N89449/001/ /NOV/27,/1987/
∂ PENNEX	80MG;20MG	N89449 001 NOV 27, 1987

BACITRACIN; POLYMYXIN B SULFATE

/AEROSOL;/TOPICAL/		
/ANABIOTIC/		
/COMBE/	/500/UNITS/GM;/ /5,000/UNITS/GM/	/N50598/001/ /SEP/22,/1986/
∂ COMBE	500 UNITS/GM; 5,000 UNITS/GM	N50598 001 SEP 22, 1986

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

HIBISTAT		
/STUART/	/0.5%/	/N18300/001/
+ ZENECA	0.5%	N18300 001

TINCTURE; TOPICAL

HIBITANE		
/∂/STUART/	/0.5%/	/N18049/001/
∂ ZENECA	0.5%	N18049 001

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON		
/SCHERING/	/8MG/ /12MG/	/N07638/001/ /N07638/002/
+ SCHERING PLOUGH	8MG	N07638 001
+	12MG	N07638 002

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DEMAZIN		
/SCHERING/	/4MG;25MG/	/N18556/001/ /MAY/14,/1984/
+ SCHERING PLOUGH	4MG;25MG	N18556 001 MAY 14, 1984

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

/VSOLVON/		
/CIBA/	/8MG;120MG/	/N18747/001/ /MAR/06,/1986/
∂ FISONS	8MG;120MG	N18747 001 MAR 06, 1986

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON		
/SCHERING/	/8MG;120MG/	/N18397/001/
+ SCHERING PLOUGH	8MG;120MG	N18397 001

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

/SUSPENSION;/EXTENDED/RELEASE;/ORAL/		
/PENNTUSS/		
/FISONS/	/EQ/4MG/MALEATE/5ML;/ /EQ/10MG/BASE/5ML/	/N18928/001/ /AUG/14,/1985/
∂ FISONS	EQ 4MG MALEATE/5ML; EQ 10MG BASE/5ML	N18928 001 AUG 14, 1985

CHLORPHENIRAMINE POLISTIREX; PHENYLPROPANOLAMINE POLISTIREX

/SUSPENSION;/EXTENDED/RELEASE;/ORAL/

/CORSYM/		
/FISONS/	/EQ/4MG/MALEATE/5ML;/ /EQ/37.5MG/HCL/5ML/	/N18050/001/ /JAN/04,/1984/
ə FISONS	EQ 4MG MALEATE/5ML; EQ 37.5MG HCL/5ML	N18050 001 JAN 04, 1984

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE		
GENEVA	1.34MG	N73458 001 OCT 31, 1993

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE		
TARO	1%	N72640 002 AUG 31, 1993
LOTRIMIN AF		
/SCHERING/	/1%/	/N17619/002/ /OCT/27,/1989/
+ SCHERING PLOUGH	1%	N17619 002 OCT 27, 1989

CREAM; VAGINAL

CLOTRIMAZOLE		
NMC	1%	N74165 001 JUL 16, 1993
GYNE-LOTRIMIN		
/SCHERING/	/1%/	/N18052/002/ /NOV/30,/1990/
+ SCHERING PLOUGH	1%	N18052 002 NOV 30, 1990

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

GYNE-LOTRIMIN COMBINATION PACK		
+ SCHERING PLOUGH	1%;100MG	N20289 002 APR 26, 1993

> DLT >
> DLT >
> ADD >
> ADD >

CLOTRIMAZOLE

LOTION; TOPICAL

LOTRIMIN AF		
+ SCHERING	1%	N18813 002 OCT 27, 1989
	/1%/	/N18813/002/ /OCT/27,/1989/

SOLUTION; TOPICAL

LOTRIMIN AF		
/SCHERING/	/1%/	/N17613/002/ /OCT/27,/1989/
+ SCHERING PLOUGH	1%	N17613 002 OCT 27, 1989

TABLET; VAGINAL

GYNE-LOTRIMIN		
/SCHERING/	/100MG/	/N17717/002/ /NOV/30,/1990/
+ SCHERING PLOUGH	100MG	N17717 002 NOV 30, 1990

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DISOPHROL		
/SCHERING/	/6MG;120MG/	/N13483/004/ /SEP/13,/1982/
SCHERING PLOUGH	6MG;120MG	N13483 004 SEP 13, 1982
DRIXORAL		
/SCHERING/	/6MG;120MG/	/N13483/003/ /SEP/13,/1982/
+ SCHERING PLOUGH	6MG;120MG	N13483 003 SEP 13, 1982

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL

DIPHEN		
PENNEX PHARMS	12.5MG/5ML	N70118 001 OCT 01, 1985
/PHARM/BASICS/	/12.5MG/5ML/	/N70118/001/ /OCT/01,/1985/
DIPHENHYDRAMINE HCL		
BARRE	12.5MG/5ML	N70497 001 APR 25, 1989

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL
DIPHENHYDRAMINE HCL
/NASKA/ /12.5MG/5ML/ /N70497/001/ /APR/25,/1989/

IBUPROFEN

TABLET; ORAL
IBUPROFEN
/LUCHEN/ /200MG/ /N72901/001/ /DEC/19,/1991/
/200MG/ /N72903/001/ /DEC/19,/1991/

IBUPROFEN
NORTON HN 200MG N71144 001 JAN 20, 1987
200MG N72901 001 DEC 19, 1991
200MG N72903 001 DEC 19, 1991

/IBUPROFEN/
/OHM/ /200MG/ /N71214/001/ /DEC/01,/1986/

IBUPROFEN
/ZENITH/ /200MG/ /N71154/001/ /OCT/27,/1987/
@ ZENITH 200MG N71154 001 OCT 27, 1987

IBUPROHM
OHM 200MG N71214 001 DEC 01, 1986

/NEUVIL/
/LUCHEN/ /200MG/ /N71144/001/ /JAN/20,/1987/

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

/INJECTABLE;/INJECTION/
/PROTAMINE,/ZINC/&/ILETIN/I/(BEEF-PORK)/
/LILLY/ /40/UNITS/ML/ /N17932/001/
/100/UNITS/ML/ /N17932/002/
@ LILLY 40 UNITS/ML N17932 001
@ 100 UNITS/ML N17932 002

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
LOPERAMIDE HCL
WATSON LABS 1MG/5ML N73062 001 MAY 28, 1993

TABLET; ORAL
LOPERAMIDE HCL
ABLE 2MG N73528 001 NOV 30, 1993
NOVOPHARM 2MG N73254 001 JUL 30, 1993

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MONISTAT 7 COMBINATION PACK
+ ADVANCED CARE 2%;100MG N20288 002 APR 26, 1993

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE
ABLE 100MG N73507 001 NOV 19, 1993

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OCUCLEAR
/SCHERING/ /0.025%/ /N18471/001/ /MAY/30,/1986/
SCHERING PLOUGH 0.025% N18471 001 MAY 30, 1986

PSEUDOEPHEDRINE HYDROCHLORIDE

/CAPSULE,/EXTENDED/RELEASE;/ORAL/
/SUDAFED/12/HOUR/
/BURROUGHS/WELLCOME/ /120MG/ /N17941/002/
@ BURROUGHS WELLCOME 120MG N17941 002

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

/CAPSULE;/ORAL/
/ACTIFED/
/BURROUGHS/WELLCOME/ /60MG;2.5MG/ /N19268/001/
/JAN/15,/1985/

CAPSULE, EXTENDED RELEASE; ORAL
/ACTIFED/
/BURROUGHS/WELLCOME/ /120MG;5MG/ /N18996/001/
/JUN/17,/1985/
a BURROUGHS WELLCOME 120MG;5MG N18996 001
JUN 17, 1985

/SYRUP;/ORAL/
/ACTIFED/
/BURROUGHS/WELLCOME/ /30MG/5ML;1.25MG/5ML/ /N11935/003/
/NOV/26,/1982/

/TRIOFED/
/BARRE/ /30MG/5ML;1.25MG/5ML/ /N88115/001/
/MAR/04,/1983/

/TRIPOSED/
/HALSEY/ /30MG/5ML;1.25MG/5ML/ /N88213/002/
/MAR/30,/1984/

/TABLET;/ORAL/
/ACTIFED/
/BURROUGHS/WELLCOME/ /60MG;2.5MG/ /N11936/002/
/NOV/26,/1982/

/TRI-SUDO/
/MD/PHARM/ /60MG;2.5MG/ /N85624/002/
/JAN/10,/1984/

/TRIPODRINE/
/DANBURY/PHARMA/ /60MG;2.5MG/ /N88112/001/
/JAN/20,/1983/

/TRIPOSED/
/HALSEY/ /60MG;2.5MG/ /N88192/002/
/MAY/01,/1984/

/TRIPROLIDINE/HCL/AND/PSEUDOEPHEDRINE/HCL/
/CHELSEA/ /60MG;2.5MG/ /N88118/002/
/JAN/26,/1984/

TABLET, EXTENDED RELEASE; ORAL
> DLT > /TRIPROLIDINE/AND/PSEUDOEPHEDRINE/HCL/
> DLT > /KV/ /120MG;5MG/ /N72758/001/
> DLT > /NOV/25,/1991/
> ADD > TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES
> ADD > + KV 120MG;5MG N72758 001
> ADD > NOV 25, 1991

PSEUDOEPHEDRINE POLISTIREX

/SUSPENSION,/EXTENDED/RELEASE;/ORAL/
/PSEUDO-12/
/FISONS/ /EQ/60MG/HCL/5ML/ /N19401/001/
/JUN/19,/1987/
a FISONS EQ 60MG HCL/5ML N19401 001
JUN 19, 1987

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
AFRINOL
/SCHERING/ /120MG/ /N18191/001/
+ SCHERING PLOUGH 120MG N18191 001

TRIPROLIDINE HYDROCHLORIDE

/SYRUP;/ORAL/
/ACTIDIL/
/BURROUGHS/WELLCOME/ /1.25MG/5ML/ /N11496/002/
/JUL/01,/1983/
a BURROUGHS WELLCOME 1.25MG/5ML N11496 002
JUL 01, 1983

/TABLET;/ORAL/
/ACTIDIL/
/BURROUGHS/WELLCOME/ /2.5MG/ /N11110/002/
/JUL/01,/1983/
a BURROUGHS WELLCOME 2.5MG N11110 002
JUL 01, 1983

INDIUM^{111} CHLORIDE

SOLUTION; INJECTION
INDICLOR
AMERSHAM N/A N19862
DEC 29, 1992

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January thru November 1993]

NAME Generic/Chemical Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
-DESULFATED HEPARIN AEROPIN	TREATMENT OF CYSTIC FIBROSIS.	KENNEDY & HOIDAL, MDs. 7702 PARHAM ROAD RICHMOND VA 23294 DD 09/17/93 MA / /
MONOCLONAL ANTIBODY TO CD4	FOR USE IN POST-EXPOSURE PROPHYLAXIS FOR OCCUPATIONAL EXPOSURE TO HUMAN IMMUNODEFICIENCY VIRUS.	BIOGEN, INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 DD 12/20/93 MA / /
METHOXSALEN UVADEX	FOR USE IN CONJUNCTION WITH THE UVAR PHOTOPHERESIS TO TREAT DIFFUSE SYSTEMIC SCLEROSIS.	THERAKOS, INCORPORATED 201 BRANDYWINE PARKWAY WEST CHESTER PA 19380 DD 06/22/93 MA / /
3-PYRIDYLMETHYL]-9-DEAZAGUANI	TREATMENT OF CUTANEOUS T-CELL LYMPHOMA.	BIOCRYST PHARMACEUTICALS, INCORPORATED 2190 PARKWAY LAKE DRIVE BIRMINGHAM AL 35244 DD 10/05/93 MA / /
OSALICYLATE SODIUM	TREATMENT OF CROHN'S DISEASE.	SYNCOM PHARMACEUTICALS, INC. 155 PASSAIC AVENUE FAIRFIELD NJ 07004 DD 04/06/93 MA / /
OSIDINE GABBROMICINA	TREATMENT OF TUBERCULOSIS.	KANYOK, THOMAS P. PHARM.D. UNIVERSITY OF RHODE ISLAND PROVIDENCE RI 02908-4735 DD 05/14/93 MA / /
OSIDINE GABBROMICINA	TREATMENT OF MYCOBACTERIUM AVIUM COMPLEX.	KANYOK, THOMAS P. PHARM.D. UNIVERSITY OF RHODE ISLAND PROVIDENCE RI 02908-4735 DD 11/15/93 MA / /
IODARONE AMIO-AQUEOUS	TREATMENT OF INCESSANT VENTRICULAR TACHYCARDIA.	ACADEMIC PHARMACEUTICALS, INC. 25720 SAUNDERS ROAD NORTH LAKE FOREST IL 60045 DD 08/17/93 MA / /
T-THYMOCYTE SERUM NASHVILLE RABBIT T-THYMOCYTE SERUM	TREATMENT OF ALLOGRAFT REJECTION, INCLUDING SOLID ORGAN (KIDNEY, LIVER, HEART, LUNG, AND PANCREAS) AND BONE MARROW TRANSPLANTATION.	APPLIED MEDICAL RESEARCH 1600 HAYES STREET NASHVILLE TN 37203 DD 06/02/93 MA / /
MORPHINE HCL INJECTION	TREATMENT OF THE ON-OFF FLUCTUATIONS ASSOCIATED WITH LATE-STAGE PARKINSON'S DISEASE.	BRITANNIA PHARMACEUTICALS LTD FORUM HOUSE, BRIGHTON ROAD REDHILL, SURREY UK DD 04/22/93 MA / /
AVAQUONE MEPRON	TREATMENT AND SUPPRESSION OF TOXOPLASMA GONDII ENCEPHALITIS.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 03/16/93 MA / /
AVAQUONE MEPRON	PRIMARY PROPHYLAXIS OF HIV-INFECTED PERSONS AT HIGH RISK FOR DEVELOPING TOXOPLASMA GONDII ENCEPHALITIS.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 03/16/93 MA / /
FACTANT SURVANTA INTRATHECAL PENSION	TREATMENT OF FULL-TERM NEWBORN INFANTS WITH RESPIRATORY FAILURE CAUSED BY MECONIUM ASPIRATION SYNDROME, PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN, OR PNEUMONIA AND SEPSIS.	ROSS LABORATORIES 625 CLEVELAND AVENUE COLUMBUS OH 43215 DD 12/20/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN- Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD- Date Designated MA- Marketing Approval
BISPECIFIC ANTIBODY 520C9x22 TN=	IN VIVO SEROTHERAPY OF PATIENTS WITH OVARIAN CANCER.	MEDAREX 12 COMMERCE AVENUE WEST LEBANON NH 03784 DD 10/05/93 MA / /
BLEOMYCIN SULFATE TN= BLENOXANE	TREATMENT OF MALIGNANT PLEURAL EFFUSION.	BRISTOL-MYERS SQUIBB PO BOX 4000 PRINCETON NJ 08543-4000 DD 09/17/93 MA / /
BOVINE WHEY PROTEIN CONCENTRATE TN= IMMUNO-C	TREATMENT OF CRYPTOSPORIDIOSIS CAUSED BY THE PRESENCE OF CRYPTOSPORIDIUM PARVUM IN THE GASTROINTESTINAL TRACT OF PATIENTS WHO ARE IMMUNODEFICIENT/IMMUNOCOMPROMISED OR IMMUNOCOMPETENT.	BIOMUNE SYSTEMS, INCORPORATED 40 EAST SOUTH TEMPLE SUITE 31 SALT LAKE CITY UT 84111 DD 09/30/93 MA / /
CLADRIBINE TN= LEUSTATIN INJECTION	TREATMENT OF NON-HODGKIN'S LYMPHOMA.	R.W.JOHNSON RESEARCH INSTITUT ROUTE 202 SOUTH, P.O. BOX 300 RARITAN NJ 08869-0602 DD 04/19/93 MA / /
COLFOSCERIL PALMITATE, CETYL ALCOHOL, TYLOXAPOL TN= EXOSURF	TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 01/11/93 MA / /
CY-1503 TN=	TREATMENT OF POST-ISCHEMIC REPERFUSION EDEMA FOLLOWING SURGICAL TREATMENT FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION.	CYTEL CORPORATION 3525 JOHN HOPKINS COURT SAN DIEGO CA 92121 DD 12/22/93 MA / /
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE TN=	TREATMENT OF CYSTIC FIBROSIS.	GENETIC THERAPY, INC. 19 FIRSTFIELD ROAD GAITHERSBURG MD 20878 DD 01/08/93 MA / /
DEPOFOAM ENCAPSULATED CYTARABINE TN=	TREATMENT OF NEOPLASTIC MENINGITIS.	DEPOTECH CORPORATION 11025 NORTH TORREY PINES ROAD SUITE 100 LA JOLLA CA 92037 DD 06/02/93 MA / /
DISODIUM CLODRONATE TN=	TREATMENT OF HYPERCALCEMIA OF MALIGNANCY.	DISCOVERY EXPERIMENTAL & DEVELOPMENT,INC 29949 S.R. 54 WEST WESLEY CHAPEL FL 33543 DD 06/16/93 MA / /
EPOETIN ALFA TN=	TREATMENT OF MYELODYSPLASTIC SYNDROME.	R.W. JOHNSON RESEARCH INSTITU ROUTE 202 SOUTH, BOX 300 RARITAN NJ 08869-0602 DD 12/20/93 MA / /
FACTOR XIII, RECOMBINANT TN=	TREATMENT OF CONGENITAL FACTOR XIII DEFICIENCY.	ZYMOGENETICS, INC. 4225 ROOSEVELT WAY SEATTLE WA 98105 DD 04/22/93 MA / /
HEMIN AND ZINC MESOPORPHYRIN TN= HEMEX	TREATMENT OF ACUTE PORPHYRIC SYNDROMES.	BONKOVSKY, HERBERT L. M.D. UNIVERSITY OF MASSACHUSETTS MEDICAL CTR WORCESTER MA 01655 DD 12/20/93 MA / /
HUMANIZED ANTI-TAC TN=	PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION.	HOFFMANN-LA ROCHE, INC. 340 KINGSLAND STREET NUTLEY NJ 07110 DD 03/05/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

ME eric/Chemical = Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD = Date Designated MA = Marketing Approval
ANIZED ANTI-TAC	PREVENTION OF ACUTE GRAFT-VS-HOST DISEASE FOLLOWING BONE MARROW TRANSPLANTATION.	HOFFMANN-LA ROCHE, INC. 340 KINGSLAND STREET NUTLEY NJ 07110 DD 03/05/93 MA / /
MUNE GLOBULIN INTRAVENOUS UMAN) = GAMIMUNE N	INFECTION PROPHYLAXIS IN PEDIATRIC PATIENTS AFFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS.	MILES, INC. 4TH & PARKER STREETS BERKELEY CA 94710 DD 02/18/93 MA / /
MUNE GLOBULIN INTRAVENOUS UMAN) = IMMUNE GLOBULIN INTRAVENOUS UMAN) IMMUNO, IVEEGAM	TREATMENT OF PATIENTS WITH ACUTE MYOCARDITIS.	IMMUNO CLINICAL RESEARCH CORPORATION 750 LEXINGTON AVENUE NEW YORK NY 10022 DD 11/22/93 MA / /
TERFERON BETA (RECOMBINANT MAN) =	TREATMENT OF PRIMARY BRAIN TUMORS.	BIOGEN, INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 DD 01/13/93 MA / /
TERLEUKIN-3, HUMAN, OMBINANT =	FOR SEQUENTIAL ADMINISTRATION WITH SARGRAMOSTIM TO ACCELERATE NEUTROPHIL AND PLATELET RECOVERY IN PATIENTS UNDERGOING AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF HODGKIN'S DISEASE OR NON-HODGKIN'S LYMPHOMA.	SANDOZ PHARMACEUTICALS CORP. 59 ROUTE 10 EAST HANOVER NJ 07936-1080 DD 09/30/93 MA / /
OCARNITINE = CARNITOR	TREATMENT OF PEDIATRIC CARDIOMYOPATHY.	SIGMA-TAU PHARMACEUTICALS, INC. 200 ORCHARD RIDGE DRIVE, SUITE 300 GAITHERSBURG MD 20878 DD 11/17/93 MA / /
POSOMAL DAUNORUBICIN = DAUNOXOME	TREATMENT OF PATIENTS WITH ADVANCED HIV-ASSOCIATED KAPOSI'S SARCOMA.	VESTAR, INC. 650 CLIFFSIDE DRIVE SAN DIMAS CA 91773 DD 05/14/93 MA / /
LATONIN =	TREATMENT OF CIRCADIAN RHYTHM SLEEP DISORDERS IN BLIND PEOPLE WITH NO LIGHT PERCEPTION.	SACK, ROBERT, M.D. 3181 S.W. SAM JACKSON PARK ROAD PORTLAND OR 97201-3098 DD 11/15/93 MA / /
THOTREXATE = RHEUMATREX	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	LEDERLE LABORATORIES 401 N. MIDDLETOWN ROAD PEARL RIVER NY 10965-1299 DD 08/23/93 MA / /
DAFINIL =	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN NARCOLEPSY.	CEPHALON, INC. 145 BRANDYWINE PARKWAY WEST CHESTER PA 19380-4245 DD 03/15/93 MA / /
NOCLONAL ANTIBODY FOR MUNIZATION AGAINST LUPUS PHRITIS =	TREATMENT OF LUPUS NEPHRITIS.	MEDCLONE, INC. 2435 MILITARY AVENUE LOS ANGELES CA 90064 DD 01/07/93 MA / /
ROLAURIN = GLYLORIN	TREATMENT OF CONGENITAL PRIMARY ICHTHYOSIS.	CELLEGY PHARMACEUTICALS, INC. 371 BEL MARIN KEYS, SUITE 210 NOVATO CA 94949 DD 04/29/93 MA / /
TOMYCIN-C =	TREATMENT OF REFRACTORY GLAUCOMA AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY.	IOP INCORPORATED 3100 AIRWAY AVENUE COSTA MESA CA 92626 DD 08/20/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
NITRIC OXIDE TN=	TREATMENT OF PERSISTENT PULMONARY HYPERTENSION IN THE NEWBORN.	OHMEDA PHARMACEUTICAL PRODU DIVISION 110 ALLEN ROAD, PO BOX 804 LIBERTY CORNER NJ 07938-080 DD 06/22/93 MA / /
POLY I: POLY C12U TN= AMPLIGEN	TREATMENT OF CHRONIC FATIGUE SYNDROME.	HEM PHARMACEUTICALS CORP. ONE PENN CENTER, SUITE 660 PHILADELPHIA PA 19103 DD 12/09/93 MA / /
PRIMAQUINE PHOSPHATE TN=	FOR USE IN COMBINATION WITH CLINDAMYCIN HYDROCHLORIDE IN THE TREATMENT OF PNEUMOCYSTIS CARINII PNEUMONIA ASSOCIATED WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.	STERLING WINTHROP INC. 90 PARK AVENUE NEW YORK NY 10016 DD 07/23/93 MA / /
PROSTAGLANDIN E1 ALPHA-CYCLODEXTRIN TN= VASOPROST	TREATMENT OF SEVERE PERIPHERAL ARTERIAL OCCLUSIVE DISEASE (CRITICAL LIMB ISCHEMIA) IN PATIENTS WHERE OTHER PROCEDURES, GRAFTS OR ANGIOPLASTY, ARE NOT INDICATED.	SCHWARZ PHARMA 5600 WEST COUNTY LINE ROAD MEQUON WI 53092 DD 10/20/93 MA / /
PROTEIN C CONCENTRATE TN= PROTEIN C CONCENTRATE (HUMAN) VAPOR HEATED, IMMUNO	FOR USE IN THE PREVENTION AND TREATMENT OF PURPURA FULMINANS IN MENINGOCOCCEMIA.	IMMUNO CLINICAL RESEARCH COR 750 LEXINGTON AVENUE, 19TH F NEW YORK NY 10022 DD 04/22/93 MA / /
PROTIRELIN TN=	PREVENTION OF INFANT RESPIRATORY DISTRESS SYNDROME ASSOCIATED WITH PREMATURITY.	UCB PHARMACEUTICALS, INC. 5505-A ROBIN HOOD ROAD NORFOLK VA 23513 DD 08/24/93 MA / /
PULMONARY SURFACTANT REPLACEMENT, PORCINE TN= CUROSURF	FOR THE TREATMENT AND PREVENTION OF RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS.	CHIESI PHARMACEUTICALS, INC. 150 DANBURY ROAD RIDGEFIELD CT 06877 DD 08/02/93 MA / /
RECOMBINANT RETROVIRAL VECTOR - GLUCOCEREBROSIDASE TN=	FOR USE AS ENZYME REPLACEMENT THERAPY FOR PATIENTS WITH TYPES I, II, OR III GAUCHER DISEASE.	GENETIC THERAPY, INC. 19 FIRSTFIELD ROAD GAITHERSBURG MD 20878 DD 11/15/93 MA / /
RHo(D) IMMUNE GLOBULIN (HUMAN) TN= WINPHO SD	TREATMENT OF IMMUNE THROMBOCYTOPENIC PURPURA.	RH PHARMACEUTICALS, INC. 104 CHANCELLOR MATHESON ROAD WINNIPEG, MANITOBA DD 11/09/93 MA / /
RII RETINAMIDE TN=	TREATMENT OF MYELODYSPLASTIC SYNDROMES.	SPARTA PHARMACEUTICALS, INCORPORATED PO BOX 13288 RESEARCH TRIANGLE PK NC 2770 DD 05/06/93 MA / /
RILUZOLE TN=	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	RHONE-POULENC RORER PHARM. 500 ARCOLA ROAD, PO BOX 1200 COLLEGEVILLE PA 19426-0107 DD 03/16/93 MA / /
ROQUINIMEX TN= LINOMIDE	TO PROLONG TIME TO RELAPSE IN LEUKEMIA PATIENTS WHO HAVE UNDERGONE AUTOLOGOUS BONE MARROW TRANSPLANTATION.	KABI PHARMACIA, INC. 800 CENTENNIAL AVENUE PISCATAWAY NJ 08855-1327 DD 07/01/93 MA / /
SECALCIFEROL TN= OSTEO-D	TREATMENT OF FAMILIAL HYPOPHOSPHATEMIC RICKETS.	LEMMON COMPANY 650 CATHILL ROAD SELLERSVILLE PA 18960 DD 07/26/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical & Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
UM BENZOATE/SODIUM YLACETATE	TREATMENT OF UREA CYCLE DISORDERS: CARBAMYLPHOSPHATE SYNTHETASE DEFICIENCY, ORNITHINE TRANSCARBAMYLASE DEFICIENCY, AND ARGININOSUCCINIC ACID SYNTHETASE DEFICIENCY.	BRUSILOW, SAUL W. M.D. JOHNS HOPKINS MEDICAL INSTITUTIONS BALTIMORE MD 21205 DD 11/17/93 MA / /
IUM PHENYLBUTYRATE	TREATMENT OF UREA CYCLE DISORDERS: CARBAMYLPHOSPHATE SYNTHETASE DEFICIENCY, ORNITHINE TRANSCARBAMYLASE DEFICIENCY, AND ARGINIOSUCCINIC ACID SYNTHETASE DEFICIENCY.	BRUSILOW, SAUL W. M.D. JOHNS HOPKINS MEDICAL INSTITUTIONS BALTIMORE MD 21205 DD 11/17/93 MA / /
ATROPIN BIOTROPIN	TREATMENT OF CACHEXIA ASSOCIATED WITH AIDS.	BIO-TECHNOLOGY GENERAL CORPORATION 1250 BROADWAY, 20th FLOOR NEW YORK NY 10001 DD 02/12/93 MA / /
ALFATE	TREATMENT OF ORAL MUCOSITIS AND STOMATITIS FOLLOWING RADIATION THERAPY FOR HEAD AND NECK CANCER.	FUISZ TECHNOLOGIES, LTD. 3810 CONCORDE PARKWAY, SUITE 100 CHANTILLY VA 22021 DD 07/15/93 MA / /
ASE (YEAST-DERIVED) SACARASA	TREATMENT OF CONGENITAL SUCRASE-ISOMALTASE DEFICIENCY.	TREEM, WILLIAM R. M.D. HARTFORD HOSPITAL HARTFORD CT 06115 DD 12/10/93 MA / /
IDOMIDE	TREATMENT OF THE CLINICAL MANIFESTATIONS OF MYCOBACTERIAL INFECTION CAUSED BY MYCOBACTERIUM TUBERCULOSIS AND NON-TUBERCULOUS MYCOBACTERIA.	CELGENE CORPORATION 7 POWDER HORN DRIVE WARREN NJ 07059 DD 01/12/93 MA / /
XIFENE ESTRINEX	TREATMENT OF DESMOID TUMORS.	ADRIA LABORATORIES P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 08/17/93 MA / /
TINOIN TRETINOIN LF, IV	TREATMENT OF ACUTE AND CHRONIC LEUKEMIA.	ARGUS PHARMACEUTICALS, INC. 3400 RESEARCH FOREST DRIVE THE WOODLANDS TX 77381 DD 01/14/93 MA / /
OR NECROSIS FACTOR-BINDING TEIN 1	TREATMENT OF SYMPTOMATIC PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME INCLUDING ALL PATIENTS WITH CD4 COUNTS LESS THAN 200 CELLS PER MM3.	SERONO LABORATORIES, INC. 100 LONGWATER CIRCLE NORWELL MA 02061 DD 01/06/93 MA / /
OR NECROSIS FACTOR-BINDING TEIN II	TREATMENT OF SYMPTOMATIC PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME INCLUDING ALL PATIENTS WITH CD4 T-CELL COUNTS LESS THAN 200 CELLS PER MM3.	SERONO LABORATORIES, INC. 100 LONGWATER CIRCLE NORWELL MA 02061 DD 01/06/93 MA / /
ACTIVE INTESTINAL PEPTIDE	TREATMENT OF ACUTE ESOPHAGEAL FOOD IMPACTION.	RESEARCH TRIANGLE PHARMACEUTICALS 200 WESTPARK CORPORATE CENTER DURHAM NC 27713 DD 06/23/93 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval

Orphan Drug Approvals

ANTIHEMOPHILIC FACTOR (RECOMBINANT) TN= KOGENATE	PROPHYLAXIS AND TREATMENT OF BLEEDING IN INDIVIDUALS WITH HEMOPHILIA A OR FOR PROPHYLAXIS WHEN SURGERY IS REQUIRED IN INDIVIDUALS WITH HEMOPHILIA A.	MILES, INC. 4TH & PARKER STREETS BERKELEY CA 94701 DD 09/25/89 MA 02/25/93
APROTININ TN= TRASYLOL	FOR PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE HOMOLOGOUS BLOOD TRANSFUSION REQUIREMENT IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS SURGERY IN THE COURSE OF REPEAT CORONARY ARTERY BYPASS GRAFT SURGERY, AND IN SELECTED CASES OF PRIMARY CORONARY ARTERY BYPASS GRAFT SURGERY WHERE THE RISK OF BLEEDING IS ESPECIALLY HIGH (IMPAIRED HEMOSTASIS, E.G. PRESENCE OF ASPIRIN OR OTHER COAGULOPATHY) OR WHERE TRANSFUSION IS UNAVAILABLE OR UNACCEPTABLE.	MILES, INC. 400 MORGAN LANE WEST HAVEN CT 06516 DD 11/17/93 MA 12/29/93
CLADRIBINE TN= LEUSTATIN INJECTION	TREATMENT OF HAIRY CELL LEUKEMIA.	R.W.JOHNSON RESEARCH INSTITUTE ROUTE 202, PO BOX 300 RARITAN NJ 08869-0602 DD 11/15/90 MA 02/26/93
DORNASE ALFA TN= PULMOZYME	TO REDUCE MUCOUS VISCOSITY AND ENABLE THE CLEARANCE OF AIRWAY SECRETIONS IN PATIENTS WITH CYSTIC FIBROSIS.	GENENTECH, INC. 460 POINT SAN BRUNO BOULEVARD SOUTH SAN FRANCISCO CA 94080 DD 01/16/91 MA 12/30/93
FELBAMATE TN= FELBATOL	TREATMENT OF LENNOX-GASTAUT SYNDROME.	WALLACE LABORATORIES 301B COLLEGE ROAD EAST PRINCETON NJ 08540 DD 01/24/89 MA 07/29/93
IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TN= GAMIMUNE N	INFECTION PROPHYLAXIS IN PEDIATRIC PATIENTS AFFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS.	MILES, INC. 4TH & PARKER STREETS BERKELEY CA 94710 DD 02/18/93 MA 12/27/93
INTERFERON BETA, RECOMBINANT HUMAN TN=BETASERON	TREATMENT OF MULTIPLE SCLEROSIS.	CHIRON CORPORATION 4560 HORTON STREET EMERYVILLE CA 94608 DD 11/17/88 MA 07/23/93
LEUPROLIDE ACETATE TN= LUPRON INJECTION	TREATMENT OF CENTRAL PRECOCIOUS PUBERTY.	TAP PHARMACEUTICALS, INC. 2355 WAUKEGAN ROAD DEERFIELD IL 60015 DD 07/25/88 MA 04/16/93
LEVOMETHADYL ACETATE HYDROCHLORIDE TN=ORLAAM	TREATMENT OF HEROIN ADDICTS SUITABLE FOR MAINTENANCE ON OPIATE AGONISTS.	BIODEVELOPMENT CORPORATION 1300 NORTH 17TH STREET, SUITE 300 ARLINGTON VA 22209-2306 DD 01/24/84 MA 07/09/93
LODOXAMIDE TROMETHAMINE TN= ALOMIDE OPHTHALMIC SOLUTION	TREATMENT OF VERNAL KERATOCONJUNCTIVITIS.	ALCON LABORATORIES, INC. 6201 SOUTH FREEWAY FORT WORTH TX 76134 DD 10/16/91 MA 09/23/93
MEGESTROL ACETATE TN= MEGACE	TREATMENT OF PATIENTS WITH ANOREXIA, CACHEXIA, OR SIGNIFICANT WEIGHT LOSS (=/>10% OF BASELINE BODY WEIGHT) AND CONFIRMED DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS).	BRISTOL-MYERS SQUIBB 2400 WEST LLOYD EXPRESSWAY EVANSVILLE IN 47721-0001 DD 04/13/88 MA 09/10/93

NE ric/Chemical Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD = Date Designated MA = Marketing Approval
Orphan Drug Approvals		
ATROPIN FOR INJECTION NUTROPIN	TREATMENT OF GROWTH RETARDATION ASSOCIATED WITH CHRONIC RENAL FAILURE.	GENENTECH, INC. 460 POINT SAN BRUNO BOULEVARD SOUTH SAN FRANCISCO CA 94080 DD 08/04/89 MA 11/17/93
METREXATE GLUCURONATE NEUTREXIN	TREATMENT OF PNEUMOCYSTIS CARINII PNEUMONIA IN AIDS PATIENTS.	U.S. BIOSCIENCE, INC. ONE TOWER BRIDGE, 100 FRONT STREET WEST CONSHOHOCKEN PA 19428 DD 05/15/86 MA 12/17/93

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO DECMEBER 1993 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
BUMETANIDE (TABLET)	APR 23, 1993	
BUSIPRONE HYDROCHLORIDE (TABLET)	AUG 13, 1993	
CAPTOPRIL (TABLET)	MAY 13, 1993	
CEFACLOR (CAPSULE AND SUSPENSION)	APR 23, 1993	
CHOLESTRYRAMINE (POWDER)	JUL 15, 1993	
DICLOFENAC SODIUM (TABLET)	DEC 24, 1992	DEC 02, 1993
GLIPIZIDE (TABLET)	APR 23, 1993	
GLYBURIDE (TABLET)	APR 23, 1993	
GUANABENZ ACETATE (TABLET)	APR 23, 1993	
INDAPAMIDE (TABLET)	APR 23, 1993	
KETOPROFEN (CAPSULE)	APR 23, 1993	
ORAL EXTENDED (CONTROLLED RELEASE)	SEP 09, 1993	
PINDOLOL (TABLET)	APR 23, 1993	
RANITIDINE HYDROCHLORIDE (TABLET)	APR 23, 1993	
TRIAZOLAM (TABLET)	DEC 24, 1992	

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ACETAMINOPHEN; ASPIRIN; HYRDOCODONE BITARTRATE CAPSULE; ORAL	150MG 180MG 2.5MG	92 P-0282/ CP3	MIKART	NEW COMBINATION	APPROVED NOV 10, 1993
ACETAMINOPHEN; ASPIRIN; HYRDOCODONE BITARTRATE CAPSULE; ORAL	150MG 180MG 5MG	92 P-0282/ CP1	MIKART	NEW COMBINATION	APPROVED NOV 10, 1993
ACETAMINOPHEN; ASPIRIN; HYRDOCODONE BITARTRATE CAPSULE; ORAL	150MG 180MG 7.5MG	92 P-0282/ CP2	MIKART	NEW COMBINATION NEW STRENGTH	APPROVED NOV 10, 1993
ACETAMINOPHEN; ASPIRIN; HYRDOCODONE BITARTRATE CAPSULE; ORAL	150MG 180MG 10MG	92 P-0282/ CP4	MIKART	NEW COMBINATION	APPROVED NOV 10, 1993
ACETAMINOPHEN; ASPIRIN; HYRDOCODONE BITARTRATE TABLET; ORAL	150MG 180MG 2.5MG	92 P-0282/ CP3	MIKART	NEW COMBINATION NEW DOSAGE FORM	APPROVED NOV 10, 1993
ACETAMINOPHEN; ASPIRIN; HYRDOCODONE BITARTRATE TABLET; ORAL	150MG 180MG 5MG	92 P-0282/ CP1	MIKART	NEW COMBINATION NEW DOSAGE FORM	APPROVED NOV 10, 1993
ACETAMINOPHEN; ASPIRIN; HYRDOCODONE BITARTRATE TABLET; ORAL	150MG 180MG 7.5MG	92 P-0282/ CP2	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED NOV 10, 1993
ACETAMINOPHEN; ASPIRIN; HYRDOCODONE BITARTRATE TABLET; ORAL	150MG 180MG 10MG	92 P-0282/ CP4	MIKART	NEW COMBINATION NEW DOSAGE FORM	APPROVED NOV 10, 1993
ACETAMINOPHEN; CODEINE PHOSPHATE CAPSULE; ORAL	500MG 45MG	93 P-0314/ CP1	MIKART	NEW DOSAGE FORM NEW STRENGTH	APPROVED NOV 10, 1993
ACETAMINOPHEN; CODEINE PHOSPHATE TABLET; ORAL	500MG 45MG	93 P-0314/ CP1	MIKART	NEW STRENGTH	APPROVED NOV 10, 1993
ACYCLOVIR SODIUM INJECTABLE; INJECTION	EQ 50MG BASE/ML (10ML/VIAL) (20ML/VIAL)	92 P-0468/ CP1	BULL	NEW DOSAGE FORM	APPROVED SEP 01, 1993
AMINOSALICYLIC ACID GRANULES, ENTERIC-COATED; ORAL	4GM/PACKET	92 P-0356/ CP1	JACOBUS	NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 03, 1993

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
CARBOPLATIN INJECTABLE; INJECTION	10MG/ML (5ML/VIAL) (15ML/VIAL) (45ML/VIAL)	92 P-0467/ CP1	BULL	NEW DOSAGE FORM	APPROVED MAY 20, 1993
CHLORPROMAZINE HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML	92 P-0284/ CP1	UDL	NEW STRENGTH	APPROVED JAN 07, 1993
CISPLATIN INJECTABLE; INJECTION	1MG/ML (200ML/VIAL)	93 P-0084/ CP1	FUJISAWA	NEW STRENGTH	APPROVED NOV 10, 1993
CYTARABINE INJECTABLE; INJECTION	20MG/ML (12.5ML/VIAL)	92 P-0381/ CP1	BRISTOL MYERS SQUIBB	NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 18, 1993
DOBUTAMINE HYDROCHLORIDE INJECTABLE; INJECTION	EQ 12.5MG BASE/ML (40ML/VIAL)	92 P-0365/ CP1	LYPHOMED	NEW STRENGTH	APPROVED FEB 11, 1993
DOBUTAMINE HYDROCHLORIDE INJECTABLE; INJECTION	EQ 12.5MG BASE/ML (100ML/CONTAINER)	93 P-0045/ CP1	MARSAM	NEW STRENGTH	APPROVED SEP 10, 1993
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (12.5MG/VIAL)	92 P-0355/ CP1	LEDERLE	NEW STRENGTH	APPROVED JAN 07, 1993
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (50ML/CONTAINER)	91 P-0460/ CP1	ABBOTT	NEW STRENGTH	APPROVED FEB 11, 1993
LACTULOSE CRYSTAL; ORAL	10GM/PACKET	92 P-0370/ CP1	BENNETT AND COMPANY	NEW DOSAGE FORM	APPROVED JAN 07, 1993
METHYLPHENIDATE HYDROCHLORIDE; TABLET, EXTENDED RELEASE; ORAL	10MG	92 P-0400/ CP1	MD PHARM	NEW STRENGTH	APPROVED MAR 22, 1993
PREDNISOLONE SYRUP; ORAL	10MG/5ML	92 P-0439/ CP1	WE PHARMS	NEW STRENGTH	APPROVED MAY 20, 1993
PREDNISONE TABLET, CHEWABLE; ORAL	5MG 10MG	92 P-0336/ CP1	WE PHARMS	NEW DOSAGE FORM	APPROVED NOV 10, 1993
PROPRANOLOL HYDROCHLORIDE TABLET, EFFERVESCENT; ORAL	10MG 20MG 60MG 80MG 90MG	93 P-0049/ CP1	FLEMINGTON PHARM	NEW DOSAGE FORM NEW STRENGTH	APPROVED SEP 01, 1993
TERBUTALINE SULFATE INJECTABLE; INJECTION	1MG/ML (0.25ML/CONTAINER)	92 P-0430/ CP1	STERLING WINTHROP	NEW STRENGTH	APPROVED MAR 18, 1993
TRIMETHOPRIM SOLUTION; ORAL	25MG/5ML	92 P-0500/ CP1	ASCENT PHARMS	NEW DOSAGE FORM	APPROVED MAY 20, 1993

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
CROTAMITON GEL; TOPICAL	10%	92 P-0249/ CP1	HAMER	NEW DOSAGE FORM	DENIED NOV 10, 1993

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW DOSING SCHEDULE

D-20	SINGLE 32MG DOSE

REFERENCES
NEW INDICATION

I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY

REFERENCES
PATENT USE CODE

U-74	METHOD OF PROVIDING HYPNOTIC EFFECT
U-75	RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76	USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77	TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78	ULCERATIVE COLITIS
U-79	SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD
U-80	METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
U-81	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
U-82	TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
U-83	TREATMENT OF SEIZURES
U-84	A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-85	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-86	METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
U-87	METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS
U-88	TREATMENT OF MODERATE PLAQUE PSORIASIS
U-89	TREATMENT OR PROPHYLAXIS OF EMESIS
U-90	TREATMENT OF PSYCHOTIC DISORDERS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18473 001	ALBUTEROL; VENTOLIN				I-93	JUL 20, 1996
	19489 001	ALBUTEROL SULFATE; VENTOLIN ROTACAPS				I-93	JUL 20, 1996
	19604 001	ALBUTEROL SULFATE; VOLMAX	4851229	JUN 14, 2005			
			4777049	OCT 11, 2005			
			4751071	JUN 14, 2005			
	19604 002	ALBUTEROL SULFATE; VOLMAX	4851229	JUN 14, 2005			
			4777049	OCT 11, 2005			
			4751071	JUN 14, 2005		NS	DEC 23, 1995
	18276 004	ALPRAZOLAM; XANAX	5061494	OCT 29, 2008			
>ADD>	19787 001	AMLODIPINE BESYLATE; NORVASC	4572909	AUG 01, 2006		NCE	JUL 31, 1997
>DLT>	~~19787 001~~	~~AMLODIPINE BESYLATE; NORVASC~~	~~4572909~~	~~FEB 25, 2003~~		~~NCE~~	~~JUL 31, 1997~~
>ADD>	19787 002	AMLODIPINE BESYLATE; NORVASC	4572909	AUG 01, 2006		NCE	JUL 31, 1997
>DLT>	~~19787 002~~	~~AMLODIPINE BESYLATE; NORVASC~~	~~4572909~~	~~FEB 25, 2003~~		~~NCE~~	~~JUL 31, 1997~~
>ADD>	19787 003	AMLODIPINE BESYLATE; NORVASC	4572909	AUG 01, 2006		NCE	JUL 31, 1997
>DLT>	~~19787 003~~	~~AMLODIPINE BESYLATE; NORVASC~~	~~4572909~~	~~FEB 25, 2003~~		~~NCE~~	~~JUL 31, 1997~~
	20258 001	APRACLONIDINE HYDROCHLORIDE; IOPIDINE	4517199	MAY 14, 2002	U-15	NS	JUL 30, 1996
>ADD>	20304 001	APROTININ BOVINE; TRASYLOL				NCE	DEC 29, 1998
	19402 001	ASTEMIZOLE; HISMANAL	4219559	AUG 26, 1999		NCE	DEC 29, 1993
	20045 001	AVOBENZONE; SHADE UVAGUARD	4522807	JUN 11, 2002		NC	DEC 07, 1995
			4387089	JUN 07, 2002			
	19807 001	BETAXOLOL HYDROCHLORIDE; KERLEDEX	4252984	AUG 30, 1999			
	19807 002	BETAXOLOL HYDROCHLORIDE; KERLEDEX	4252984	AUG 30, 1999			
>ADD>	19982 001	BISOPROLOL FUMARATE; ZEBETA	4258062	MAR 24, 2000	U-63	NCE	JUL 31, 1997
>DLT>	~~19982 001~~	~~BISOPROLOL FUMARATE; ZEBETA~~	~~4258062~~	~~MAR 24, 1998~~	~~U-63~~	~~NCE~~	~~JUL 31, 1997~~
>ADD>	19982 002	BISOPROLOL FUMARATE; ZEBETA	4258062	MAR 24, 2000	U-63	NCE	JUL 31, 1997
>DLT>	~~19982 002~~	~~BISOPROLOL FUMARATE; ZEBETA~~	~~4258062~~	~~MAR 24, 1998~~	~~U-63~~	~~NCE~~	~~JUL 31, 1997~~
>ADD>	20186 001	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 2000	U-63	NCE	JUL 31, 1997
>DLT>	~~20186 001~~	~~BISOPROLOL FUMARATE; ZIAC~~	~~4258062~~	~~MAR 24, 1998~~	~~U-63~~	~~NCE~~	~~JUL 31, 1997~~
						NC	FEB 26, 1996
>ADD>	20186 002	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 2000	U-63	NCE	JUL 31, 1997
>DLT>	~~20186 002~~	~~BISOPROLOL FUMARATE; ZIAC~~	~~4258062~~	~~MAR 24, 1998~~	~~U-63~~	~~NCE~~	~~JUL 31, 1997~~
						NC	FEB 26, 1996
>ADD>	20186 003	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 2000	U-63	NCE	JUL 31, 1997
>DLT>	~~20186 003~~	~~BISOPROLOL FUMARATE; ZIAC~~	~~4258062~~	~~MAR 24, 1998~~	~~U-63~~	~~NCE~~	~~JUL 31, 1997~~
						NC	FEB 26, 1996
>ADD>	20273 001	CALCIPOTRIENE; DOVONEX	4866048	SEP 12, 2006	U-88	NCE	DEC 29, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18343 001	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-95	SEP 23, 1996
	18343 002	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-95	SEP 23, 1996
	18343 003	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-95	SEP 23, 1996
	18343 005	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-95	SEP 23, 1996
	20210 001	CISAPRIDE MONOHYDRATE; PROPULSID	4962115	OCT 09, 2007	U-79	NCE	JUL 29, 1998
	20210 002	CISAPRIDE MONOHYDRATE; PROPULSID	4962115	OCT 09, 2007	U-79	NCE	JUL 29, 1998
	20229 001	CLADRIBINE; LEUSTATIN				NCE	FEB 26, 1998
						ODE	FEB 26, 2000
>ADD>	20118 001	DESFLURANE; SUPRANE	4762856	SEP 18, 2006	U-67	NCE	SEP 18, 1997
>DLT>	~~20118 001~~	~~DESFLURANE; SUPRANE~~	~~4762856~~	~~AUG 09, 2005~~	~~U-67~~	~~NCE~~	~~SEP 18, 1997~~
>ADD>	20071 001	DESOGESTREL; DESOGEN	3927046	NOV 19, 1995		NC	DEC 10, 1995
>ADD>	20071 002	DESOGESTREL; DESOGEN	3927046	NOV 19, 1995		NC	DEC 10, 1995
>ADD>	20301 001	DESOGESTREL; ORTHO-CEPT	3927046	NOV 19, 1995		NC	DEC 10, 1995
>ADD>	20301 002	DESOGESTREL; ORTHO-CEPT	3927046	NOV 19, 1995		NC	DEC 10, 1995
	19287 001	DIAZEPAM; DIZAC	RE32393	SEP 18, 1996		NDF	JUN 18, 1996
>ADD>	20142 001	DICLOFENAC POTASSIUM; CATAFLAM				NDF	NOV 24, 1996
>ADD>	20142 002	DICLOFENAC POTASSIUM; CATAFLAM				NDF	NOV 24, 1996
	18723 001	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	18723 002	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	18723 003	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	19680 001	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	19794 001	DIVALPROEX SODIUM; DEPAKOTE CP	5212326	JAN 29, 2008			
	19794 002	DIVALPROEX SODIUM; DEPAKOTE CP	5212326	JAN 29, 2008			
	18651 001	DRONABINOL; MARINOL				ODE	DEC 22, 1999
	18651 002	DRONABINOL; MARINOL				ODE	DEC 22, 1999
	18651 003	DRONABINOL; MARINOL				ODE	DEC 22, 1999
	19879 002	EFLORNITHINE HYDROCHLORIDE; ORNIDYL	4399151	AUG 16, 2000		NCE	NOV 28, 1995
	19616 004	ENOXACIN; PENETREX	4359578	NOV 16, 2001		NCE	DEC 31, 1996
	19616 005	ENOXACIN; PENETREX	4359578	NOV 16, 2001		NCE	DEC 31, 1996
	20164 001	ENOXAPARIN SODIUM; LOVENOX				NCE	MAR 29, 1998
	20189 001	FELBAMATE; FELBATOL	5082861	JAN 21, 2009	U-83	ODE	JUL 29, 2000
			4978680	DEC 18, 2007	U-83	NCE	JUL 29, 1998
	20189 002	FELBAMATE; FELBATOL	5082861	JAN 21, 2009	U-83	ODE	JUL 29, 2000
			4978680	DEC 18, 2007	U-83	NCE	JUL 29, 1998
	20189 003	FELBAMATE; FELBATOL	5082861	JAN 21, 2009	U-83	ODE	JUL 29, 2000
			4978680	DEC 18, 2007	U-83	NCE	JUL 29, 1998
>ADD>	19304 001	FENOFIBRATE; LIPIDIL				NCE	DEC 31, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20195 001	FENTANYL CITRATE; FENTANYL	4671953	JUN 09, 2004	U-87	NDF	OCT 04, 1996
>ADD>	20195 002	FENTANYL CITRATE; FENTANYL	4671953	JUN 09, 2004	U-87	NDF	OCT 04, 1996
>ADD>	20195 003	FENTANYL CITRATE; FENTANYL	4671953	JUN 09, 2004	U-87	NDF	OCT 04, 1996
>ADD>	20090 001	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000			
>ADD>			4404216	OCT 16, 2003		NCE	JAN 29, 1995
>ADD>	20090 002	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000			
>ADD>			4404216	OCT 16, 2003		NCE	JAN 29, 1995
	20073 001	FLUMAZENIL; MAZICON	4316839	MAR 03, 2003		NCE	DEC 20, 1996
	18936 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4626549	DEC 02, 2003	U-84		
	18936 006	FLUOXETINE HYDROCHLORIDE; PROZAC	4626549	DEC 02, 2003	U-84		
			4314081	FEB 02, 2001			
			4194009	APR 19, 1994			
	20101 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4018895	APR 19, 1994	U-12		
>ADD>	20261 001	FLUVASTATIN SODIUM; LESCOL	4626549	DEC 02, 2003	U-84		
>ADD>	20261 002	FLUVASTATIN SODIUM; LESCOL				NCE	DEC 31, 1998
	20068 001	FOSCARNET SODIUM; FOSCAVIR				NCE	DEC 31, 1998
>ADD>	20235 001	GABAPENTIN; NEURONTIN	4215113	JUN 06, 2000	U-64	NCE	SEP 27, 1996
>ADD>			4087544	MAY 02, 1995	U-86		
>ADD>	20235 002	GABAPENTIN; NEURONTIN	4024175	MAY 17, 1994		NCE	DEC 30, 1998
>ADD>			4087544	MAY 02, 1995	U-86		
>ADD>	20235 003	GABAPENTIN; NEURONTIN	4024175	MAY 17, 1994		NCE	DEC 30, 1998
>ADD>			4087544	MAY 02, 1995	U-86		
			4024175	MAY 17, 1994		NCE	DEC 30, 1998
	20123 001	GADODIAMIDE; OMNISCAN	4687659	AUG 18, 2004	U-76	NCE	JAN 08, 1998
	19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	4957939	MAR 03, 2004		I-94	AUG 17, 1996
	17783 003	GLIPIZIDE; GLUCOTROL				NCE	MAY 08, 1994
	20051 003	GLYBURIDE; GLYNASE	4916163	APR 10, 2007		NP	MAR 04, 1995
			4735805	APR 05, 2005		NCE	MAY 01, 1994
	20051 004	GLYBURIDE; GLYNASE	4916163	APR 10, 2007		NP	MAR 04, 1995
			4735805	APR 05, 2005		NCE	MAY 01, 1994
	19726 001	GOSERELIN ACETATE; ZOLADEX				I-88	FEB 02, 1996
>ADD>	20239 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 12, 2006	U-89	NCE	DEC 29, 1998
	19032 001	GUANFACINE HYDROCHLORIDE; TENEX				I-91	MAY 11, 1996
	19032 002	GUANFACINE HYDROCHLORIDE; TENEX				I-91	MAY 11, 1996
>ADD>	19778 003	HYDROCHLOROTHIAZIDE; PRINZIDE 10-12.5				NS	NOV 18, 1996
	19888 003	HYDROCHLOROTHIAZIDE; ZESTORETIC 10-12.5				NS	NOV 18, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19891 001	HYDROMORPHONE HYDROCHLORIDE; DILAUDID				NCE	JAN 11, 1994
					NDF	DEC 07, 1995
19892 001	HYDROMORPHONE HYDROCHLORIDE; DILAUDID				NCE	JAN 11, 1994
					NDF	DEC 07, 1995
18538 002	INDAPAMIDE; LOZOL				NS	APR 29, 1996
18956 001	IOHEXOL; OMNIPAQUE 180				NCE	JUL 06, 1993
		4250113	DEC 26, 1999		I-97	JUL 13, 1996
19710 005	IOVERSOL; OPTIRAY 350	4021481	MAY 03, 1994		NR	JUL 13, 1996
20228 001	IPRATROPIUM BROMIDE; ATROVENT				I-48	JUL 27, 1996
20215 001	ISOSORBIDE MONONITRATE; MONOKET				NDF	SEP 29, 1996
20215 002	ISOSORBIDE MONONITRATE; MONOKET				NCE	DEC 30, 1996
					NCE	DEC 30, 1996
20225 001	ISOSORBIDE MONONITRATE; IMDUR				NS	JUN 30, 1996
					NCE	DEC 30, 1996
20225 002	ISOSORBIDE MONONITRATE; IMDUR				NDF	AUG 12, 1996
					NCE	DEC 30, 1996
19084 001	KETOCONAZOLE; NIZORAL				NDF	AUG 12, 1996
19700 001	KETOROLAC TROMETHAMINE; ACULAR	4335125	JUN 15, 1999		I-30	JAN 27, 1996
		5110493	MAY 05, 2009	U-75	NCE	NOV 30, 1994
		4454151	JUN 12, 2001	U-75	NDF	NOV 09, 1995
20263 001	LEUPROLIDE ACETATE; LUPRON	4089969	MAY 16, 1997	U-75		
		4917893	MAR 24, 2004			
		4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
		4005063	JAN 25, 1996		ODE	APR 16, 2000
20263 002	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4917893	MAR 24, 2004			
		4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
		4005063	JAN 25, 1996		ODE	APR 16, 2000

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20263 003	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4917893	MAR 24, 2004			
			4849228	JUL 18, 2006		NP	APR 16, 1996
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			
			4005063	JAN 25, 1996		ODE	APR 16, 2000
	20263 004	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4917893	MAR 24, 2004			
			4849228	JUL 18, 2006		NP	APR 16, 1996
			4728721	MAR 01, 2005			
			4677191	JUN 30, 2004			
			4652441	MAR 24, 2004			
			4005063	JAN 25, 1996		ODE	APR 16, 2000
>ADD>	20219 001	LEVOCABASTINE HYDROCHLORIDE; LIVOSTIN				NCE	NOV 10, 1998
	18948 001	LEVOCARNITINE; CARNITOR				I-86	DEC 16, 1995
						ODE	DEC 16, 1999
	18948 002	LEVOCARNITINE; CARNITOR				I-86	DEC 16, 1995
						ODE	DEC 16, 1999
	20315 001	LEVOMETHADYL ACETATE HYDROCHLORIDE; ORLAAM				NCE	JUL 09, 1998
						ODE	JUL 09, 2000
	19558 001	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19558 002	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19558 003	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19558 004	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 001	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 002	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 003	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 004	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 005	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	20191 001	LODOXAMIDE TROMETHAMINE; ALOMIDE				NCE	SEP 23, 1998
						ODE	SEP 23, 2000
	20013 001	LOMEFLOXACIN HYDROCHLORIDE; MAXAQUIN	4528287	MAY 05, 2005	U-36	NCE	FEB 21, 1997
	19658 001	LORATADINE; CLARITIN	4282233	AUG 04, 1998	U-77	NCE	APR 12, 1998
>ADD>	19940 001	MASOPROCOL; ACTINEX	4695590	SEP 05, 2006		NCE	SEP 04, 1997
>DLT>	~~19940 001~~	~~MASOPROCOL; ACTINEX~~	~~4695590~~	~~SEP 22, 2004~~		~~NCE~~	~~SEP 04, 1997~~
						ODE	SEP 10, 2000
	20264 001	MEGESTROL ACETATE; MEGACE	4980173	DEC 25, 2007	U-78		
	20049 001	MESALAMINE; PENTASA	4496553	JAN 29, 2002	U-78	NP	MAY 10, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20098 001	MIVACURIUM CHLORIDE; MIVACRON	4761418	JAN 22, 2006		NCE	JAN 22, 1997
	20098 002	MIVACURIUM CHLORIDE; MIVACRON IN DEXTROSE 5%	4761418	JAN 22, 2006		NCE	JAN 22, 1997
	19583 001	NABUMETONE; RELAFEN	4420639	DEC 13, 2002		NCE	DEC 24, 1996
	19583 002	NABUMETONE; RELAFEN	4420639	DEC 13, 2002		NCE	DEC 24, 1996
	20109 001	NAFARELIN ACETATE; SYNAREL	4234571	NOV 18, 1999		NCE	FEB 13, 1995
	19356 001	NAFTIFINE HYDROCHLORIDE; NAFTIN	4282251	AUG 04, 2000		NCE	MAR 01, 1993
	20150 001	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
	20150 002	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
	20150 003	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
	20066 001	NICOTINE POLACRILEX; NICORETTE DS				NCE	JAN 13, 1994
	20198 001	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
	20198 002	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
	20198 003	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
	19921 001	OFLOXACIN; OCUFLOX	4551456	NOV 05, 2002	U-80	NDF	JUL 30, 1996
			4382892	MAY 10, 2000			
	20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 03, 2005		D-20	FEB 02, 1996
						I-9	AUG 13, 1996
	20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 03, 2005		NCE	JAN 04, 1996
	20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 03, 2005		NCE	JAN 04, 1996
	20036 001	PAMIDRONATE DISODIUM; AREDIA	3962432	JUL 16, 1996	U-53		
	20036 003	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004			
			3962432	JUL 16, 1996	U-53	NCE	OCT 31, 1996
	20036 004	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004			
			3962432	JUL 16, 1996	U-53	NCE	OCT 31, 1996
	20091 001	PERFLUBRON; IMAGENT				NCE	AUG 13, 1998
>ADD>	20184 001	PERINDOPRIL ERBUMINE; ACEON				NCE	DEC 30, 1998
>ADD>	20184 002	PERINDOPRIL ERBUMINE; ACEON				NCE	DEC 30, 1998
>ADD>	20184 003	PERINDOPRIL ERBUMINE; ACEON				NCE	DEC 30, 1998
	20014 001	PIRBUTEROL ACETATE; MAXAIR	4664107	MAY 12, 2004			
	19795 001	PODOFILOX; CONDYLOX				NCE	DEC 13, 1995
	19898 004	PRAVASTATIN SODIUM; PRAVACHOL	4346227	AUG 24, 1999		NCE	OCT 31, 1996
	19568 001	PREDNICARBATE; DERMATOP	4242334	DEC 30, 1999	U-50	NE	SEP 23, 1994
	20279 001	PREDNICARBATE; DERMATOP	4242334	DEC 30, 1999	U-50	NE	SEP 23, 1994
	19627 001	PROPOFOL; DIPRIVAN				I-90	MAR 08, 1996
	19664 001	PSEUDOEPHEDRINE HYDROCHLORIDE; SELDANE-D	4996061	FEB 26, 2008			
			4929605	MAY 29, 2007	U-81		
			4254129	MAR 03, 1998	U-81		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19885 001	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005		I-92	OCT 29, 1996
	19885 002	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005		I-92	OCT 29, 1996
	19885 003	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005		I-92	OCT 29, 1996
	19885 004	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4743450	MAY 10, 2005		I-92	OCT 29, 1996
	50689 001	RIFABUTIN; MYCOBUTIN				ODE	DEC 23, 1999
	19649 001	RIMANTADINE HYDROCHLORIDE; FLUMADINE				NCE	SEP 17, 1998
	19650 001	RIMANTADINE HYDROCHLORIDE; FLUMADINE				NCE	SEP 17, 1998
>ADD>	20272 001	RISPERIDONE; RISPERDAL	4804663	FEB 14, 2006	U-90	NCE	DEC 29, 1998
>ADD>	20272 002	RISPERIDONE; RISPERDAL	4804663	FEB 14, 2006	U-90	NCE	DEC 29, 1998
>ADD>	20272 003	RISPERIDONE; RISPERDAL	4804663	FEB 14, 2006	U-90	NCE	DEC 29, 1998
>ADD>	20272 004	RISPERIDONE; RISPERDAL	4804663	FEB 14, 2006	U-90	NCE	DEC 29, 1998
>ADD>	20272 005	RISPERIDONE; RISPERDAL	4804663	FEB 14, 2006	U-90	NCE	DEC 29, 1998
>ADD>	19839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	SEP 28, 2010	U-12		
>ADD>			4962128	OCT 09, 2007			
			4536518	DEC 31, 2005		NCE	DEC 30, 1996
>ADD>	19839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	SEP 28, 2010	U-12		
>ADD>			4962128	OCT 09, 2007			
			4536518	DEC 31, 2005		NCE	DEC 30, 1996
>ADD>	19839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	SEP 28, 2010	U-12		
>ADD>			4962128	OCT 09, 2007			
			4536518	DEC 31, 2005		NCE	DEC 30, 1996
>ADD>	19839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	SEP 28, 2010	U-12		
>ADD>			4962128	OCT 09, 2007			
			4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19766 001	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 002	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 003	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 004	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	20168 001	SOMATROPIN, BIOSYNTHETIC; NUTROPIN				I-98	NOV 17, 1996
>ADD>						ODE	NOV 17, 2000
	20168 002	SOMATROPIN, BIOSYNTHETIC; NUTROPIN				I-98	NOV 17, 1996
>ADD>						ODE	NOV 17, 2000
	20134 001	STRONTIUM CHLORIDE, SR-89; METASTRON				NCE	JUN 18, 1998
>ADD>	19183 001	SUCRALFATE; CARAFATE				NDF	DEC 16, 1996
	19050 001	SUFENTANIL CITRATE; SUFENTA				NR	MAR 19, 1996
						I-89	MAR 19, 1996
	20080 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	MAR 28, 2006	U-72		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20070 001	TACRINE HYDROCHLORIDE; COGNEX	4816456	MAR 28, 2006	U-82	NCE	SEP 09, 1998
20070 002	TACRINE HYDROCHLORIDE; COGNEX	4816456	MAR 28, 2006	U-82	NCE	SEP 09, 1998
20070 003	TACRINE HYDROCHLORIDE; COGNEX	4816456	MAR 28, 2006	U-82	NCE	SEP 09, 1998
20070 004	TACRINE HYDROCHLORIDE; COGNEX	4816456	MAR 28, 2006	U-82	NCE	SEP 09, 1998
19882 001	TECHNETIUM TC-99M MERTIATIDE KIT; TECHNESCAN MAG3				I-87	NOV 27, 1995
20043 003	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	JAN 30, 2006	U-36	NCE	JAN 30, 1997
20043 004	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	JAN 30, 2006	U-36	NCE	JAN 30, 1997
18163 003	TEMAZEPAM; RESTORIL	5211954	MAY 18, 2010			
		5030632	JUL 09, 2008	U-70	NS	OCT 25, 1994
19057 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000	U-3	I-96	SEP 29, 1996
19057 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000	U-3	I-96	SEP 29, 1996
19057 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000	U-3	I-96	SEP 29, 1996
19057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000	U-3	I-96	SEP 29, 1996
20223 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000			
		4112097	SEP 05, 1995			
		4026894	MAY 31, 1994		I-96	SEP 29, 1996
20223 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000			
		4112097	SEP 05, 1995			
		4026894	MAY 31, 1994		I-96	SEP 29, 1996
20223 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000			
		4112097	SEP 05, 1995			
		4026894	MAY 31, 1994		I-96	SEP 29, 1996
20223 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000			
		4112097	SEP 05, 1995			
		4026894	MAY 31, 1994		I-96	SEP 29, 1996
18949 001	TERFENADINE; SELDANE	4254129	MAR 03, 1998	U-81		
19762 001	TESTOSTERONE; TESTODERM				NDF	OCT 12, 1996
19762 002	TESTOSTERONE; TESTODERM				NDF	OCT 12, 1996
19979 001	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	NOV 01, 2005			
		4051141	SEP 27, 1996		NCE	OCT 31, 1996
19979 002	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	NOV 01, 2005			
		4051141	SEP 27, 1996		NCE	OCT 31, 1996
20330 001	TIMOLOL MALEATE; TIMOPTIC-XE				NP	NOV 04, 1996
20330 002	TIMOLOL MALEATE; TIMOPTIC-XE				NP	NOV 04, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20136 001	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
			4018929	APR 19, 1994		NCE	AUG 23, 1998
			RE30633	APR 19, 1994			
	20136 002	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
			4018929	APR 19, 1994		NCE	AUG 23, 1998
			RE30633	APR 19, 1994			
	20136 003	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
			4018929	APR 19, 1994		NCE	AUG 23, 1998
			RE30633	APR 19, 1994			
	20136 004	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
			4018929	APR 19, 1994		NCE	AUG 23, 1998
			RE30633	APR 19, 1994			
	20137 002	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
			4018929	APR 19, 1994		NCE	AUG 23, 1998
			RE30633	APR 19, 1994			
	18207 004	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 24, 1998			
			4215104	JUL 29, 1997			
>ADD>	19798 001	TRIAMCINOLONE ACETONIDE; NASACORT	4767612	AUG 30, 2005	U-85	NR	JUL 11, 1994
>ADD>	20326 001	TRIMETREXATE GLUCURONATE; NEUTREXIN	4376858	MAR 15, 2000		NCE	DEC 17, 1998
	18776 003	VECURONIUM BROMIDE; NORCURON	4297351	OCT 27, 1998			
			4237126	DEC 02, 1997		NCE	APR 30, 1994
>ADD>	20151 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	AUG 13, 2002		NCE	DEC 28, 1998
>ADD>	20151 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	AUG 13, 2002		NCE	DEC 28, 1998
>ADD>	20151 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	AUG 13, 2002		NCE	DEC 28, 1998
>ADD>	20151 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	AUG 13, 2002		NCE	DEC 28, 1998
>ADD>	20151 005	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	AUG 13, 2002		NCE	DEC 28, 1998
>ADD>	20151 006	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	AUG 13, 2002		NCE	DEC 28, 1998
	19908 001	ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2000	U-74	NCE	DEC 16, 1997
	19908 002	ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2000	U-74	NCE	DEC 16, 1997

*U.S. Government Printing Office: 1994 — 301-037/80006

*U.S. Government Printing Office: 1994 — 301-037/80006

New 14th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7229

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** please send me the following indicated subscriptions:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $55.00 per year.

The total cost of my order is $_____. Prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Company or personal name)

_____
(Additional address/attention line)

_____
(Street address)

_____
(City, State, ZIP Code)

(_____) _____
(Daytime phone including area code)

_____
(Purchase Order No.)

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature) (04/93)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2233.
To charge your subscription call (202) 783-3238.

ST. LOUIS COLLEGE OF PHARMACY
3 2201 90036 5111

RM301.45 .A66 1993 Dec Suppl

Approved drug products with therapeutic equivalence
C:355661 M:174736 O:12937927

Library Use Only

Library Use Only